EQAS CATALOG 2027

INSTAND

# EXCELLENCE IN QUALITY

RIDACOM

We promote quality in medical laboratories by offering a wide range of external quality controls and continuous education.

www.instand-international.com

INSTAND

INSTAND International GMBH

Ubierstr. 20, 40223 Duesseldorf, Germany

T +49 [0] 211 876 3529 0

E info@instand-international.com

**Represented by:**

Chief Executive Officer: Prof. Dr. rer. nat. Ingo Schellenberg

**Register:**

Registered in the Registry of Associations

Register Court: Amtsgericht Düsseldorf Register

Number: HRB 95353

Sales tax identification number according to § 27a Sales Tax Act:

DE351329066

**Version: 09/07/2026**

## Dear Colleagues,

INSTAND celebrates its 60th anniversary in 2026. We want to take this opportunity to thank you for your ongoing collaboration. Our success is based, among other things, on our close collaboration with the scientific community, our valued EQAS/PT experts, and laboratory teams worldwide, who ensure the high quality of our EQAS/PT and processes. To mark this special occasion, we have given our catalog a modern layout and optimized its individual sections.

INSTAND e.V., the Society for promoting Quality Assurance in Medical Laboratories e.V., has been conducting EQAS/PT in all areas of in-vitro diagnostics as a reference institution of the German Medical Association since 1970.

As an External Quality Assessment organization, we are **accredited according to DIN EN ISO/IEC 17043**. We offer **over 400 External Quality Assessment (EQA) schemes/Proficiency Tests (PT)** for external quality control in laboratory diagnostics, in accordance with the current version of the German Medical Association (Rili-BÄK) guidelines. For this purpose, we ship around 165,000 sample sets annually to approximately 12,000 participating laboratories in nearly 80 countries.

We have optimized our **2027 INSTAND EQA Scheme Program** to meet the highest quality standards. Our new features at a glance (see pages 11 and 12 for detailed information):

- **Molecular Genetics:** New EQAS/PT and EQAS/PT with new parameters
- **Immunology**: New EQAS/PT and EQAS/PT with new parameters
- **Clinical Chemistry**: EQAS/PT with new parameters
- **Virus Diagnostics:** New EQAS/PT
- Participation will have access to our EQAS/PT the **2027 Pricelist,** including shipping costs, on the INSTAND RV-Online.

The current EQAS/PT program is available on the **RV-Online System** and on our **Website**.

We are excited to continue our excellent and pleasant cooperation with you.

Your INSTAND Team

**Prof. Dr. med.**
**Michael Spannagl**
President of the Board

**Prof. Dr. rer. nat.**
**Ingo Schellenberg**
Vice President of the Board

**Prof. Dr. med.**
**Klaus-Peter Hunfeld**
Vice President of the Board

# INSTAND ACADEMY

As a medical-scientific society, we offer an extensive program of continued education on various advanced topics. While the majority of our training programs are currently in German, our English program is growing continuously. New information will be posted on our website and on LinkedIn.

**All courses are available on our website**

SCAN ME

# CALIBRATION LABORATORY

Head: Dr. Patricia Kaiser
**kaiser@instand-ev.de**

Our calibration laboratory is accredited according to DIN EN ISO/IEC 17025 and DIN EN ISO 15195. We use internationally recognized calibration methods for the metrological traceability of measurement results for measurands in the field of laboratory medicine to SI units. In line with the requirements of the Rili-BÄK, target values in serum, plasma, whole blood, urine, and cerebrospinal fluid are determined in our laboratory as an evaluation standard in EQAS at the level of accuracy. In addition, we also offer our expertise in determining target values as a calibration service for the certification of control and calibration materials for external customers. Our calibration procedures and services are listed in the Joint Committee for Traceability in Laboratory Medicine (**JCTLM**) database.

| Measurand | Sample Type | Range | | Measuring Method | U[a] |
|---|---|---|---|---|---|
| **Substrates/Metabolites:** | | | | | |
| Cholesterol | Serum/Plasma | 1-10 | mmol/l | GC-IDMS | 1.0% |
| Glucose | Serum/Plasma | 1-60 | mmol/l | GC-IDMS | 1.0% |
| | Urine/Liquor | 0.5-60 | mmol/l | | 1.0% |
| Uric acid | Serum/Plasma | 50-1000 | µmol/l | GC-IDMS | 1.0% |
| | Urine | 20-2500 | µmol/l | | 1.0% |
| Urea | Serum/Plasma | 0.5-50 | mmol/l | GC-IDMS | 1.0% |
| | Urine | 0.5-500 | mmol/l | | 1.0% |
| Creatinine | Serum/Plasma | 25-2000 | µmol/l | GC-IDMS | 1.0% |
| | Urine | 0.05-40 | mmol/l | | 1.0% |
| Total Bilirubin[b] | Serum/Plasma | 7-600 | µmol/l | Photometric Absorbance Measurement | 2.5% |
| Total glycerol | Serum/Plasma | 0.5-6 | mmol/l | GC-IDMS | 1.0% |
| **Hormones:** | | | | | |
| Cortisol | Serum/Plasma | 30-2000 | nmol/l | GC-IDMS | 1.0% |
| Estradiol-17ß | Serum/Plasma | 37-2500 | pmol/l | GC-IDMS | 1.0% |
| Progesterone | Serum/Plasma | 0.5-150 | nmol/l | GC-IDMS | 1.0% |
| Testosterone | Serum/Plasma | 0.7-69 | nmol/l | GC-IDMS | 1.5% |
| Thyroxine | Serum/Plasma | 6.4-283 | nmol/l | GC-IDMS | 1.0% |
| **Ions:** | | | | | |
| Calcium | Serum/Plasma | 0.5-8 | mmol/l | ICP-IDMS | 1.0% |
| Chloride | Serum/Plasma | 50-150 | mmol/l | ICP-IDMS | 1.0% |
| Potassium | Serum/Plasma | 1-10 | mmol/l | ICP-IDMS | 1.0% |
| | Urine | 1-200 | mmol/l | | 1.0% |
| Lithium | Serum/Plasma | 0.1-5 | mmol/l | ICP-IDMS | 1.0% |
| Magnesium | Serum/Plasma | 0.1-5 | mmol/l | ICP-IDMS | 1.0% |
| Sodium | Serum/Plasma | 70-200 | mmol/l | ICP-MS | 1.0% |
| | Urine | 20-300 | mmol/l | | 1.0% |
| **Enzymes:** | | | | | |
| Alanine aminotransferase (ALAT) | Serum/Plasma | 0.33-6.67 | µkat/l | Kinetic spectrophotometry | 2.5% |
| Aspartate aminotransferase (ASAT) | Serum/Plasma | 0.33-6.67 | µkat/l | | 2.5% |
| Creatine kinase (CK) | Serum/Plasma | 0.8-24 | µkat/l | | 2.5% |
| γ-Glutamyl transferase (GGT) | Serum/Plasma | 0.33-5 | µkat/l | | 2.5% |
| Lactate dehydrogenase (LDH) | Serum/Plasma | 1-12 | µkat/l | | 2.5% |
| **Glycated Proteins:** | | | | | |
| HbA1c | Blood/Hemolysate | 29-150 | mmol/mol Hb | LC-MS | 1.5% |
| **Proteins:** | | | | | |
| Total hemoglobin | Blood/Hemolysate | 20-200 | g/l | Spectrophotometry | 1.1% |
| Total protein | Serum/Plasma | 25-130 | g/l | | 1.5% |
| **Drugs:** | | | | | |
| Digitoxin | Serum/Plasma | 1-100 | nmol/l | LC-IDMS | 2.5% |
| Digoxin | Serum Plasma | 0.2-20 | nmol/l | LC-IDMS | 2.5% |
| Theophylline | Serum/Plasma | 5-500 | µmol/l | GC-IDMS | 1.0% |

[a] best measurement capability

[b] applied to be listed as a calibration service by the JCTLM

For more details about our calibration procedures, please visit our **website**.

## Service Information

### INSTAND e.V.'s Mission and Vision

We promote quality in medical laboratories by offering a wide range of external quality control and continuous education. Our vision is to improve the reliability of measurement results in medical laboratories worldwide. In the Federal Republic of Germany, INSTAND e.V. is listed by the German Medical Association as a reference institution for external quality assurance.

### Accreditation

INSTAND e.V.'s versatile EQA program is accredited in all represented disciplines of laboratory diagnostics by the German Accreditation Body (DAkkS) according to DIN EN ISO/IEC 17043.

### Terms and Conditions, FAQ

Our "General Terms and Conditions for Participation in INSTAND e.V. EQA Schemes" shall apply to all participants of the INSTAND e.V. EQA schemes. These terms and conditions can be found at:

https://www.instand-ev.de/en/terms-conditions/

We would also be happy to send them to you upon request. We have compiled answers to frequently asked questions in our FAQ: https://www.instand-ev.de/en/faq/

Costumers of the INSTAND International GMBH, please find the terms and conditions here:

https://www.instand-international.com/terms-conditions/

The INSTAND International GMBH FAQ can be found at:

https://www.instand-international.com/faq-1/

### Information about the RV-Online Portal

A user account for our RV-Online system is required to participate in INSTAND e.V. EQA schemes:

https://rv-online.instandev.de/index.shtml?lang=en

After signing into RV-Online, you will be able to manage your master data and orders, as well as enter your EQAS results, view reports and retrieve your certificates. On our YouTube channel you will find in-depth videos that explain the various features of RV-Online in English and German.

### Fees for each INSTAND e.V. EQAS

Our prices are net prices which do not include VAT or shipping costs. Taxes and custom duties shall be borne by the participant. These prices apply exclusively to orders placed via INSTAND e.V. Prices and services may differ for orders placed via distributors.

You can find our current price catalog on RV-Online.

### Scope of services

An EQA scheme includes the sample material, which is used to determine the measurement values by the participant, as well as an evaluation by INSTAND e.V. of the submitted EQAS results. After evaluating the

EQAS, participants who have submitted their results on time will receive an individual report, a general overview where applicable, a certificate of participation, and a certificate if they have passed. In the event the EQAS is not passed, residual samples may be available after completion of the respective EQAS for a fee, so the participant can check your test systems.

**Note:** Even if the participant orders more than one sample set per EQAS/PT, we will issue certificates for the specific parameter analyzed in each case, provided all results are deemed accurate. We cannot issue certificates for individual instruments.

## Using this Catalog

### EQAS/PT required/not required by Rili-BÄK (German Medical Association)

This catalog clearly indicates which EQAS/PT are subject to the Rili-BÄK requirement. The EQAS/PT highlighted in orange in the table of contents include parameters for which participation is mandatory, in accordance with the German Medical Association's guidelines on quality assurance for laboratory medical tests (https://www.bundesaerztekammer.de/en/german-medical-association).

The orange highlighting of Rili-BÄK-mandated analytes is also reflected in the EQAS/PT descriptions. The participant can view the new structure in a sample scenario on page 8.

### Validity of Certificates

Certificates are dated with the closing date of the EQA scheme. Certificates for parameters which must undergo an EQAS are valid for twice as long as the mandatory EQAS interval. Certificates for parameters which are not subject to an EQAS in accordance with Rili-BÄK are usually valid for 12 months.

### Registration / Cancellation Deadlines

Orders can be changed or cancelled up until the respective registration/cancellation deadline. After the registration/cancellation deadline, it is no longer possible to change the order.

### Shipment Date

On the day of shipment, the packages will be picked up by the shipping service provider of our choice. Before every delivery, our shipping service provider will send a tracking number by e-mail. This e-mail is always sent to the main user registered with RV-Online. If the samples do not arrive within a very short period of time, customers of INSTAND should contact the customer service (info@instand-international.com) without delay. The sooner we are informed, the better we can respond to delivery delays.

### Submission Deadlines

EQAS/PT results must be entered by midnight CET on the closing date. After the closing date, it is no longer possible to correct or change the values.

### Prices

For 2027, we are offering a separate price list for our participants. The price list is available on the RV-Online.

## Using this Catalog

### A detailed explanation using a hypothetical EQAS/PT

1 **Molecular Oncology – PML::RARA qualitative** 2 NEW! 3 **702**

**EQAS/PT Properties** 7 4 POCT

**Samples:** 2 samples of 30 µL
**Sample Properties:** cDNA solution
**Max. number of sample sets:** 1
**Additional Information:**
As required by the RiliBÄK, the method used must have a detection limit of at least 5%.

**EQAS/PT Experts:** 5 6
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Eva Lorsy

8 **Requirement for EQAS/PT according to Rili-BAK:** half-yearly
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PML::RARA gene fusion

9 **Not subject to Rili-BAK:**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PML::RARA gene fusion

10 **Shipping Information:**
Shipping not cooled

11 **Safety Information:**
Process as patient sample material

12 **CMS-approved**

13

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | | Nov. |
| **Registration Deadline:** | | 27-01-08 | | | | 27-08-06 |
| **Sample Shipment:** | | 27-03-09 | | | | 27-10-05 |
| **Closing Date:** | | 27-04-09 | | | | 27-11-05 |

**Depending on the EQAS/PT, there may be additional specific comments or notes, such as infectivity, suitable measuring devices, etc.**

1. Name of the EQAS/PT
2. New EQAS/PT
3. Group number of the EQAS/PT
4. EQAS/PT groups suitable for POCT
5. EQAS/PT Expert / Deputy EQAS/PT Expert
6. Labeling of groups containing infectious sample material in accordance with UN3373, Category B biological substance, or UN2814, Category A infectious substance (only for EQAS/PT 425)
7. Detailed information about the sample material sent
8. Parameters examined in the EQAS/PT: Parameters highlighted in orange indicate compliance with Rili-BÄK requirements, as well as information on the frequency and validity period of the certificate as prescribed by Rili-BÄK.
9. Proficiency tests not subject to Rili-BÄK requirements: Parameters, black
10. Notes on Shipping Information
11. Important Safety Information regarding this EQAS/PT
12. Marking for EQAS/PT programs that are CMS-approved in the U.S. in accordance with CLIA
13. List of relevant dates by quarter. For Q1 and Q3, participants can take part in the EQAS/PT on two different dates each. The month listed for each EQAS/PT date refers to the submission deadline. The number of available dates may vary by EQAS/PT.

## EQA Schemes suitable for POCT

The following EQAS/PT include analytes relevant to point-of-care testing (POCT) and are generally suitable for participation using corresponding POCT systems.

Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

The corresponding EQA schemes are tagged in the catalog with:

**Also suitable for POCT:** POCT +  **Only POCT:** POCT

### EQAS/PT also suitable for POCT POCT +

| No. | EQAS/PT | Sample Material |
|---|---|---|
| 100 | Clinical Chemistry - Conventional Analysis | Lyophilised serum |
| 131 | Fecal Diagnostics - Hb, Hb-Hapto-complex | Lyophilised stool |
| 145 | HbA1c | Whole blood (EDTA), not stabilized |
| 151 | Lipids/Lipoproteins | Lyophilised serum |
| 161 | Blood Gas Analysis | Control solution |
| 162 | Blood Gas Analysis - Haemoglobin | Control solution |
| 163 | Blood Gas Analysis OPTI Systems | Control solution |
| 171 | Urine Chemistry Qualitative | Liquid urine |
| 173 | Urine Chemistry Quantitative | Lyophilised urine |
| 174 | Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative) | Lyophilised urine |
| 176 | Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative) | Lyophilised urine |
| 177 | Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative) | Lyophilised urine |
| 179 | Urine Chemistry Hormones | Lyophilised urine |
| 203 | Tricyclic Antidepressants 04 - Qualitative in Serum | Lyophilised serum |
| 204 | Tricyclic Antidepressants 05 - Qualitative in Urine | Lyophilised urine |
| 209 | Haematology - Blood Cell Count - QBC System | Whole blood (EDTA), not stabilized |
| 211 | Haematology - Blood Cell Count | Stabilized control blood |
| 226 | Haemostasis - D-Dimer | Lyophilised plasma |
| 240 | hsCRP | Serum |

| | | |
|---|---|---|
| 292 | Tumor Markers | Liquid Serum |
| 293 | Tumor Markers - PSA and Testosterone | Liquid Serum |
| 320 | Infection Serology - Procalcitonin | Serum |
| 322 | Infection Serology - C-Reactive Protein | Serum |
| 335 | Virus Immunology - HIV-1/HIV-2 (Ab) | Liquid serum/plasma |
| 337 | Virus Immunology - HIV-1 p24 Antigen | Liquid Serum |
| 344 | Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, Anti-HBe) | Liquid Serum |
| 346 | Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) | Liquid serum/plasma |
| 350 | Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) | Liquid serum (inactivated in case of Dengue Virus RNA positive samples) |
| 352 | Virus Immunology - Epstein Barr Virus (Ab) | Liquid Serum |
| 355 | Virus Immunology - Hantaviruses (Ab) | Liquid serum (inactivated in case of Hantavirus RNA positive samples) |
| 359 | Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus | Lyophilised cell culture material |
| 370 | Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses | Lyophilised cell culture material or allantoic fluid |
| 410 | Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag) | Liquid cell culture material (inactivated) |
| 481 | Mycoserology - Cryptococcus neoformans/ - gattii Antigen | Liquid Serum |
| 539 | Bacterial Genome Detection - MRSA or cMRSA | Lyophilised cell suspension |
| 545 | Bacterial Genome Detection - Clostridium difficile (Toxin Gene) | Lyophilised cell suspension |
| 546 | Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci) | Lyophilised ell suspension |
| 612 | Haematology - Differential Blood Count (Machine-Based Analysis) | Whole blood (EDTA), not stabilized |
| 760 | Myocardial Markers | Lyophilised Serum |
| 761 | Myocardial Markers BNP | Serum / Plasma |

## EQAS/PT only for POCT

| No. | EQAS/PT | Sample Material |
|---|---|---|
| 286 | Haemostasis - POCT | Whole blood (Citrat), not stabilized |
| 800 | Dry Chemistry - POCT: Glucose | Whole blood |
| 810 | Dry Chemistry - POCT: Abaxis Piccolo System | Lyophilised Serum |

## NEW as of 2027

**New as of 2027:**

1. We have optimized and modernized our layout for easier navigation.
   - Our experts are listed by full name for each EQAS/PT.
   - A new feature is the breakdown into “Rili-BÄK-mandatory” and “non-Rili-BÄK-mandatory” categories; see also page 8.
   - New symbols (NEW, Safety Notice, POCT Label) for quick reference.
2. CMS-approved EQAS/PT are clearly marked.
3. All shipping information is in a separate field.
4. Our separate 2027 price catalog is now available to you on RV-Online.
5. We expanded our index to make it easier to search for a specific EQAS/PT.

**EQAS/PT newly added to the Program**

### Molecular Genetics

- EQAS/PT 590 Molecular Pathology – PIK3CA and ESR1
- EQAS/PT 670 Molecular Genetics – Factor V-Gene (F5)
- EQAS/PT 671 Molecular Genetics – Factor VII-Gene (F7)
- EQAS/PT 672 Molecular Genetics – Factor VIII-Gene (F8)
- EQAS/PT 673 Molecular Genetics – Factor IX-Gene (F9)
- EQAS/PT 674 Molecular Genetics – Factor X-Gene (F10)
- EQAS/PT 675 Molecular Genetics – Factor XI-Gene (F11)
- EQAS/PT 676 Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)
- EQAS/PT 677 Molecular Genetics – Factor XIII-Gene (F13A1, F13B)
- EQAS/PT 678 Molecular Genetics – von Willebrand Factor-Gene (VWF)
- EQAS/PT 701 Molecular Genetics – FLT3 (internal tandem duplication)
- EQAS/PT 702Molecular Oncology – PML::RARA qualitative
- EQAS/PT 706 Molecular Genetics – Hereditary Fever Syndroms
- EQAS/PT 726 Molecular Genetics – UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood
- EQAS/PT 728 Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction

### Immunology

- EQAS/PT 256 Autoimmune Diseases – Myositis
- EQAS/PT 268 Autoimmune Diseases – Receptor Encephalitis
- EQAS/PT 657 NK-/ and T cell cytotoxicity

### Virus Diagnostics

- EQAS/PT 435 Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens

**New Parameter for the following EQAS/PT**

## Immunology

- EQAS/PT 251: Autoimmune Diseases - Connective Tissue Diseases (ANA)
- EQAS/PT 253: Autoimmune Diseases - Hepatic Syndromes
- EQAS/PT 255: Autoimmune Diseases - Connective Tissue Diseases (ENA)
- EQAS/PT 257: Autoimmune Diseases - Vasculitis / Glomerulopathies
- EQAS/PT 259: Autoimmune Diseases - Autoimmune Dermatitis
- EQAS/PT 265: Autoimmune Diseases - Paraneoplastic Neuropathies

## Clinical Chemistry

- EQAS/PT 850: Added new parameters: Bictegravir, Cabotegravir, Doravirine, and Ganciclovir
- EQAS/PT 871: Added new parameters: Brivaracetam and Perampanel
- EQAS/PT 875: Added “Cariprazine” parameter

## Virus Diagnostics

- EQAS/PT 410: Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)

**CMS approved EQAS/PT**

We submitted the documentation for conformity approval in accordance with the CLIA amendments for the following EQA/PT schemes: 344, 391, 409, 410, 421, 422, 423, 424, 435, 720. The decision of CMS is expected in autumn and the catalogue will be updated accordingly.

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **MOLECULAR GENETICS** | | |
| **Engraftment- and Chimerism Diagnostics** | | |
| Engraftment- and Chimerism Diagnostics | 618 | 26 |
| **Immunohematology** | | |
| Immunohaematology 06 - Molecular Diagnostic | 235 | 26 |
| **Conventional Genetics** | | |
| Molecular Genetics - Aldolase B (ALDOB) Variants (A149P, A174D, N334K) | 793 | 27 |
| Molecular Genetics - Alpha-Globin and beta-Globin | 794 | 27 |
| Molecular Genetics - Alpha1-Antitrypsin (SERPINA1) Variants (PiM, PiS, PiZ) | 743 | 28 |
| Molecular Genetics - Angiotensin Converting Enzyme | 763 | 28 |
| Molecular Genetics - Antithrombin (AT3; SERPINC1 Gene) | 792 | 29 |
| Molecular Genetics - Apolipoprotein (APOE) Variants (E2, E3, E4) - Whole Blood | 734 | 29 |
| Molecular Genetics - Apolipoprotein B APOB, R3500Q (HGVS: c.10580G>A; p.Arg3527Gln), R3500W (HGVS: c.10579C>T; p.Arg3527Trp)) | 771 | 30 |
| Molecular Genetics - Apolipoprotein E (APOE) Variants (E2, E3, E4) | 744 | 30 |
| Molecular Genetics - AZF (Y-Chromosome Microdeletions) | 788 | 31 |
| Molecular Genetics - BRCA1 BRCA2 | 779 | 31 |
| Molecular Genetics - C-C Motif Chemokine Receptor 5 | 764 | 32 |
| Molecular Genetics - CFTR Common Mutations | 778 | 32 |
| Molecular Genetics - Collagen Receptor (ITGA2) Variant C807T | 739 | 33 |
| Molecular Genetics - Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency (CY-P21A2 Gene) | 773 | 33 |
| Molecular Genetics - Connexin 26 (GJB2 Gene, GJB6 Gene) | 782 | 34 |
| Molecular Genetics - Copper-Binding Protein ATP7B Variant (H1069Q) | 745 | 34 |
| Molecular Genetics - ctDNA Tumour Panel | 752 | 35 |
| Molecular Genetics - CYP2C9 CYP2C19 VKORC1 TPMT | 775 | 35 |
| Molecular Genetics - CYP2D6 IL28B | 777 | 36 |
| Molecular Genetics - Dihydropyrimidin Dehydrogenase | 762 | 36 |
| Molecular Genetics - Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) (DMD Gene) | 780 | 37 |
| Molecular Genetics - Factor V-Leiden (F5) Variant | 740 | 37 |
| Molecular Genetics - Factor V-Leiden (F5) Variant - Whole Blood | 730 | 38 |
| Molecular Genetics - Fibrinogen Receptor (ITGB3) Variant HPA 1a/1b | 749 | 38 |
| Molecular Genetics - Fragile X Syndrome (FMR1 Gene, CGG Repeats) | 781 | 39 |
| Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) | 741 | 39 |
| Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) - Whole Blood | 733 | 40 |
| Molecular Genetics - Huntington Disease (HTT Gene, CAG Repeats) | 784 | 40 |
| Molecular Genetics - Lactase-Variant -13910T>C (MCM6 Gene, IVS13 C-T, rs4988235, HGVS: C.1917+326 C>T) | 770 | 41 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| Molecular Genetics - MLH1 MSH2 MSH6 PMS2 (Lynch) | 783 | 41 |
| Molecular Genetics - MTHFR Variants C677T (optional A1298C) | 747 | 42 |
| Molecular Genetics - MTHFR Variants C677T (optional A1298C) - Whole Blood | 732 | 42 |
| Molecular Genetics - NIPT - Determination of Fetal RhD Status | 727 | 43 |
| Molecular Genetics - NOD2 | 774 | 43 |
| Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) | 748 | 44 |
| Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) - Whole Blood | 735 | 44 |
| Molecular Genetics - Prader-Willi (PWS) und Angelman (AS) Syndromes (Chromosome region 15q11-13, SNRPN) | 786 | 45 |
| Molecular Genetics - Protein C (PROC Gene) | 790 | 45 |
| Molecular Genetics - Protein S (PROS1 Gene) | 791 | 46 |
| Molecular Genetics - Prothrombin (F2) Variant G20210A | 746 | 46 |
| Molecular Genetics - Prothrombin (F2) Variant G20210A - Whole Blood | 731 | 47 |
| Molecular Genetics - Spinal Muscular Atrophy (SMN1 and SMN2 Genes) | 787 | 47 |
| Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) Variants | 742 | 48 |
| Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood | 726 | 48 |
| Molecular Genetics – Factor IX-Gene (F9) | 673 | 49 |
| Molecular Genetics – Factor V-Gene (F5) | 670 | 49 |
| Molecular Genetics – Factor VII-Gene (F7) | 671 | 50 |
| Molecular Genetics – Factor VIII-Gene (F8) | 672 | 50 |
| Molecular Genetics – Factor X-Gene (F10) | 674 | 51 |
| Molecular Genetics – Factor XI-Gene (F11) | 675 | 51 |
| Molecular Genetics – Factor XIII-Gene (F13A1, F13B) | 677 | 52 |
| Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG) | 676 | 52 |
| Molecular Genetics – FLT3 (internal tandem duplication) | 701 | 53 |
| Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction | 728 | 53 |
| Molecular Genetics – von Willebrand Factor-Gene (VWF) | 678 | 54 |
| Molecular Oncology – PML::RARA qualitative | 702 | 54 |
| Molecular Pathology – PIK3CA and ESR1 | 590 | 55 |
| **Oncology** | | |
| Molecular Genetics - Hereditary Fever Syndroms | 706 | 56 |
| Molecular Genetics - Ret Proto-Oncogene (Multiple Endocrine Neoplasia Type 2, MEN2, RET Gene) | 738 | 56 |
| Molecular Oncology - AML-Panel (NGS) | 798 | 57 |
| Molecular Oncology - BRAF | 795 | 57 |
| Molecular Oncology - BTK | 796 | 58 |
| Molecular Oncology - KIT | 767 | 58 |
| Molecular Oncology - MYD88 | 766 | 59 |
| Molecular Oncology - Myeloproliferative Neoplasia | 768 | 59 |
| Molecular Oncology - SF3B1 | 797 | 60 |
| Molecular Oncology - STAT3 | 769 | 60 |
| Molecular Oncology - TP53 | 765 | 61 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **IMMUNOLOGY** | | |
| **Allergy Diagnostics** | | |
| Allergy Diagnostic | 720 | 62 |
| **Autoimmune Diseases** | | |
| Autoimmune Diseases - Antiphospholipid Syndrome | 275 | 62 |
| Autoimmune Diseases - Autoimmune Dermatitis | 259 | 63 |
| Autoimmune Diseases - Autoimmune Endocrinopathies | 263 | 63 |
| Autoimmune Diseases - Connective Tissue Diseases (ANA) | 251 | 64 |
| Autoimmune Diseases - Connective Tissue Diseases (ENA) | 255 | 64 |
| Autoimmune Diseases - Diabetes mellitus | 261 | 65 |
| Autoimmune Diseases - Gluten-Sensitive Enteropathies | 271 | 65 |
| Autoimmune Diseases - Hepatic Syndromes | 253 | 66 |
| Autoimmune Diseases - Myasthenia gravis | 269 | 66 |
| Autoimmune Diseases - Myositis | 256 | 67 |
| Autoimmune Diseases - Paraneoplastic Neuropathies | 265 | 67 |
| Autoimmune Diseases - Peripheral Neuropathies | 267 | 68 |
| Autoimmune Diseases - Receptor Encephalitis | 268 | 68 |
| Autoimmune Diseases - Rheumatoid Arthritis | 273 | 69 |
| Autoimmune Diseases - Vasculitis / Glomerulopathies | 257 | 69 |
| Basophil Activation Test | 653 | 70 |
| **HLA Typing** | | |
| HLA Diagnostics - High resolution, molecular HLA typing class I and II | 444 | 70 |
| HLA Diagnostics - HLA Antibody Screening and Identification | 445 | 71 |
| HLA Diagnostics - HLA Crossmatching | 443 | 71 |
| HLA Diagnostics - HLA Typing Class I and II of Serological Eqivalents | 441 | 72 |
| HLA Diagnostics - HLA-B27 Determination | 440 | 72 |
| HLA Diagnostics - HLA-DQ | 772 | 73 |
| HLA Diagnostics - Low resolution, molecular HLA typing class I and II | 442 | 73 |
| **Immunophenotyping** | | |
| Immunophenotyping - Cellular Immunodeficiency Diagnostic | 651 | 74 |
| **Functional Immunologic Assays** | | |
| Interferon Gamma Release Assay (IGRA) | 650 | 75 |
| Lymphozyte Transformation Test (LTT) | 656 | 76 |
| NK-/ and T cell cytotoxicity | 657 | 76 |
| Oxidative Burst / Phagocytosis Test | 654 | 77 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **Complement Analysis** | | |
| Complement Analysis - Anti-C1 Inhibitor Autoantibody | 250 | 77 |
| Complement Analysis - Anti-C1q Autoantibody | 245 | 78 |
| Complement Analysis - Anti-factor H (FH) Autoantibody | 249 | 78 |
| Complement Analysis - C3 - Nephritic Factor | 248 | 79 |
| Complement Analysis - Complement activation products | 247 | 79 |
| Complement Analysis - Functions (F) and Proteins (P) | 246 | 80 |
| **TRANSFUSION MEDICINE** | | |
| **Immunohematology** | | |
| Immunohaematology 01 | 231 | 81 |
| Immunohaematology 02 (incl. Antibody Identification) | 232 | 81 |
| Immunohaematology 03 - Platelet Immunology | 233 | 82 |
| Immunohaematology 04 - Granulocyte Immunology | 234 | 82 |
| Immunohaematology 05 - Machine-Based Analysis | 237 | 83 |
| Immunohaematology 07 - Machine-Based Analysis (incl. AB Quantitation) | 238 | 83 |
| Immunohaematology 08 - Compatibility Testing (Blood Transfusion) | 239 | 84 |
| **CLINICAL CHEMISTRY** | | |
| **Haematology** | | |
| CD19 CAR-T-Cells (quantitative) | 822 | 85 |
| CLL-MRD Immunophenotyping | 820 | 86 |
| Haematology - Blood Cell Count | 211 | 86 |
| Haematology - Blood Cell Count - QBC System | 209 | 87 |
| Haematology - Blood Smear Analysis | 212 | 87 |
| Haematology - Bone Marrow Cytology | 218 | 88 |
| Haematology - Differential Blood Count (Machine-Based Analysis) | 612 | 88 |
| Haematology - Free Haemoglobin | 236 | 89 |
| Haematology - Haemoglobinopathies | 210 | 89 |
| Haematology - Immunophenotyping | 214 | 90 |
| Haematology - Lymphocyte differentiation | 213 | 90 |
| Haematology - PNH Diagnostics | 616 | 91 |
| Haematology - Reticulocyte Analysis Machine-Based Analysis | 216 | 91 |
| Haematology - Reticulocyte Analysis Microscopy | 215 | 92 |
| Haematology - Stem/Progenitor Cells (CD34) | 217 | 92 |
| Haematology - Stem/Progenitor Cells (CD34) (stabilized) | 660 | 93 |
| Haematology - T, B and NK cells in cellular products (flow cytometry) | 617 | 93 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **Hemostaseology** | | |
| Haemostasis - Apixaban | 504 | 94 |
| Haemostasis - Argatroban | 230 | 94 |
| Haemostasis - AT, Protein C, Protein S, C1-Inhibitor | 225 | 95 |
| Haemostasis - Compact | 285 | 95 |
| Haemostasis - D-Dimer | 226 | 96 |
| Haemostasis - Dabigatran | 502 | 96 |
| Haemostasis - Edoxaban | 505 | 97 |
| Haemostasis - Emicizumab | 506 | 97 |
| Haemostasis - Factor II, V, VII,X | 223 | 98 |
| Haemostasis - Factor IX, XI, XII, XIII | 224 | 98 |
| Haemostasis - Factor VIII, WF | 227 | 99 |
| Haemostasis - FIB, TZ, FSP | 222 | 99 |
| Haemostasis - Fondaparinux | 501 | 100 |
| Haemostasis - Functional APC Resistance | 288 | 100 |
| Haemostasis - LMW Heparin | 281 | 101 |
| Haemostasis - Orgaran | 282 | 101 |
| Haemostasis - POCT | 286 | 102 |
| Haemostasis - PT, INR, aPTT | 221 | 102 |
| Haemostasis - Rivaroxaban | 503 | 103 |
| Haemostasis - ROTEM Sigma | 509 | 103 |
| Haemostasis - TEG/ROTEM | 283 | 104 |
| Haemostasis - UF Heparin | 280 | 104 |
| **Hormones** | | |
| Adrenal Gland / Pituitary | 298 | 105 |
| Aldosterone | 304 | 105 |
| Calcium Metabolism / Special Thyroid | 301 | 106 |
| Fertility | 297 | 106 |
| Gravidity - 1st Trimester Screening | 305 | 107 |
| Gravidity - 2nd Trimester Screening | 306 | 107 |
| Hematopoetic Growth Factors | 626 | 108 |
| Pancreas/Gastrointestinal Tract | 300 | 108 |
| Preeclampsia Marker | 625 | 109 |
| Steroid Hormones, Thyroid Gland | 302 | 109 |
| Thyroid Gland Antibodies | 295 | 110 |
| Thyroid Hormones | 294 | 110 |
| Virilization | 309 | 111 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **IgG Subclasses** | | |
| IgG Subclasses | 244 | 111 |
| **Cardiac Marker** | | |
| Myocardial Markers | 760 | 112 |
| Myocardial Markers BNP | 761 | 112 |
| **Conventional Clinical Chemistry** | | |
| ACE (Angiotensin-Converting-Enzyme) | 630 | 113 |
| Amino Acid Analysis | 710 | 113 |
| Ammonia | 118 | 114 |
| Biogenic Amines in Plasma | 185 | 114 |
| Capillary Zone Electrophoresis | 102 | 115 |
| Clinical Chemistry - Conventional Analysis | 100 | 115 |
| Ethanol | 700 | 116 |
| Fructosamine | 146 | 116 |
| G6PDH (Glucose-6 Phosphate Dehydrogenase) | 279 | 117 |
| Gammopathies | 243 | 117 |
| Glucose - Conventional Analysis | 111 | 118 |
| HbA1c | 145 | 118 |
| Lipids/Lipoproteins | 151 | 119 |
| Markers of Ethanol Abuse - Carbohydrate-Deficient Transferrin (CDT) | 750 | 119 |
| Plasma Cell Neoplasia-MRD Immunophenotyping | 821 | 120 |
| Serum Proteins/Electrophoresis | 141 | 120 |
| **Cerebrospinal Fluid** | | |
| Cerebrospinal Fluid Analysis - CSF Ferritin | 467 | 121 |
| Cerebrospinal Fluid Analysis - Dementia Markers | 466 | 121 |
| Cerebrospinal Fluid Analysis - Free light chains Kappa | 468 | 122 |
| Cerebrospinal Fluid Analysis - Lactate/ Glucose | 464 | 122 |
| Cerebrospinal Fluid Analysis - MRZ Reaction | 463 | 123 |
| Cerebrospinal Fluid Analysis - Neuroborreliosis | 465 | 123 |
| Cerebrospinal Fluid Analysis - Oligoclonal IgG | 462 | 124 |
| Cerebrospinal Fluid Analysis - Protein Analysis | 460 | 124 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **Newborn Analytic** | | |
| Neonatal Bilirubin | 110 | 125 |
| Newborn screening | 785 | 125 |
| **Pharmaceuticals** | | |
| Antiarrhytmics - Amiodaron | 190 | 126 |
| Antibacterials 01 - Teicoplanin | 193 | 126 |
| Antibacterials 02 | 890 | 127 |
| Anticonvulsants 01 | 191 | 127 |
| Anticonvulsants 02 | 192 | 128 |
| Anticonvulsants 03 | 871 | 128 |
| Anticonvulsants 04 | 872 | 129 |
| Antifungals / Immunosuppressants | 602 | 129 |
| Antifungals and Chloramphenicol | 198 | 130 |
| Antipsychotics/Antidepressives 01 | 200 | 130 |
| Antipsychotics/Antidepressives 02 | 873 | 131 |
| Antipsychotics/Antidepressives 03 | 874 | 131 |
| Antipsychotics/Antidepressives 04 | 875 | 132 |
| Antivirals | 850 | 132 |
| Benzodiazepines 01 | 876 | 133 |
| Benzodiazepines 02 | 877 | 133 |
| Benzodiazepines 03 | 878 | 134 |
| Immunosuppressants | 601 | 134 |
| Paracetamol and NSAIDs | 194 | 135 |
| Psychostimulants - ADHS-Treatment | 879 | 135 |
| Psychotherapeutic Drugs 01 | 860 | 136 |
| Psychotherapeutic Drugs 02 | 861 | 136 |
| Psychotherapeutic Drugs 03 | 862 | 137 |
| Psychotherapeutic Drugs 04 | 863 | 137 |
| Respiratory Stimulants - Caffeine | 870 | 138 |
| Therapeutic drugs - Antibiotics, Digitoxin, MTX | 197 | 138 |
| Therapeutic drugs - Antiepileptics, Digoxin, Lithium and others | 195 | 139 |
| Tri-/Tetracyclic Antidepressants 03 - Quantitative in Serum | 202 | 139 |
| Tricyclic Antidepressants 01 - Quantitative in Serum | 199 | 140 |
| Tricyclic Antidepressants 02 - Quantitative in Serum | 201 | 140 |
| Tricyclic Antidepressants 04 - Qualitative in Serum | 203 | 141 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **Photometry** | | |
| Photometer Controls | 181 | 141 |
| **Plasma Proteins** | | |
| Cystatin C | 242 | 142 |
| hsCRP | 240 | 142 |
| Infection Serology - C-Reactive Protein | 322 | 143 |
| Plasmaproteins | 241 | 143 |
| **POCT** | | |
| Blood Gas Analysis | 161 | 144 |
| Blood Gas Analysis - Haemoglobin | 162 | 144 |
| Blood Gas Analysis OPTI Systems | 163 | 145 |
| Dry Chemistry - POCT: Abaxis Piccolo System | 810 | 145 |
| Dry Chemistry - POCT: Glucose | 800 | 146 |
| **Trace Elements** | | |
| Trace Elements - whole blood | 208 | 146 |
| Trace Elements Plasma | 206 | 147 |
| Trace Elements Serum | 207 | 147 |
| **Stool Diagnostics** | | |
| Fecal Diagnostics - Calprotectin / Fecal Elastase | 130 | 148 |
| Fecal Diagnostics - Hb, Hb-Hapto-complex | 131 | 148 |
| **Tumor Marker** | | |
| Tumor Markers | 292 | 149 |
| Tumor Markers - Calcitonin, Pro-GRP, PIVKAII, AFP, AFP-L3 | 299 | 149 |
| Tumor Markers - PSA and Testosterone | 293 | 150 |
| **Urine Analysis** | | |
| Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative) | 174 | 150 |
| Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative) | 176 | 151 |
| Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative) | 177 | 151 |
| Markers of Ethanol Abuse - Ethylglucuronide | 751 | 152 |
| Systematic Toxicological Analysis (STA) | 188 | 152 |
| Trace Elements Urine | 205 | 153 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| Tricyclic Antidepressants 05 - Qualitative in Urine | 204 | 153 |
| Urinary Stone Analyses | 500 | 154 |
| Urine Chemistry Aminolaevulinic Acid / Porphobilinogen | 180 | 154 |
| Urine Chemistry Biogene Amines | 175 | 155 |
| Urine Chemistry Hormones | 179 | 155 |
| Urine Chemistry Porphyrins | 178 | 156 |
| Urine Chemistry Qualitative | 171 | 156 |
| Urine Chemistry Quantitative | 173 | 157 |
| Urine Chemistry Sediment Pictures | 172 | 157 |
| Urine Protein Differentiation | 182 | 158 |
| **Vitamins** | | |
| Vitamins - Methylmalonic Acid | 187 | 158 |
| Vitamins - Serum | 290 | 159 |
| Vitamins - Vitamin C | 296 | 159 |
| Vitamins - whole blood | 291 | 160 |
| **MICROBIOLOGY** | | |
| **Bacterial Genome Detection** | | |
| Bacterial Genome Detection - Bordetella pertussis | 532 | 161 |
| Bacterial Genome Detection - Borrelia burgdorferi | 535 | 161 |
| Bacterial Genome Detection - Carbapenemase-Genes | 544 | 162 |
| Bacterial Genome Detection - Chlamydia pneumoniae | 540 | 162 |
| Bacterial Genome Detection - Chlamydia trachomatis | 531 | 163 |
| Bacterial Genome Detection - Chlamydia trachomatis & Neisseria gonorrhoeae | 530 | 163 |
| Bacterial Genome Detection - Clostridium difficile (Toxin Gene) | 545 | 164 |
| Bacterial Genome Detection - Coxiella burnetii & Bacillus anthracis | 542 | 164 |
| Bacterial Genome Detection - EHEC / STEC | 534 | 165 |
| Bacterial Genome Detection - Francisella tularensis & Brucella spp. | 543 | 165 |
| Bacterial Genome Detection - Helicobacter pylori | 533 | 166 |
| Bacterial Genome Detection - Legionella pneumophila | 536 | 166 |
| Bacterial Genome Detection - Listeria spp. | 538 | 167 |
| Bacterial Genome Detection - MRSA or cMRSA | 539 | 167 |
| Bacterial Genome Detection - Mycoplasma pneumoniae | 541 | 168 |
| Bacterial Genome Detection - PCR/NAT Multiplex Detection Method for Gastrointestinal Pathogens | 548 | 168 |
| Bacterial Genome Detection - Salmonella enterica | 537 | 169 |
| Bacterial Genome Detection - Urogenital Panel | 547 | 169 |
| Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci) | 546 | 170 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| **Bacteriological Infection Serology** | | |
| Infection Serology - Bartonella Antibodies | 326 | 170 |
| Infection Serology - Bordetella pertussis Antibodies | 317 | 171 |
| Infection Serology - Borrelia burgdorferi Antibodies | 332 | 171 |
| Infection Serology - Brucella Antibodies | 327 | 172 |
| Infection Serology - Campylobacter Antibodies | 319 | 172 |
| Infection Serology - Chlamydia pneumoniae (Chlamydophila) Antibodies | 314 | 173 |
| Infection Serology - Chlamydia trachomatis Antibodies | 312 | 173 |
| Infection Serology - Chlamydia trachomatis Direct Detection (ELISA / PCR) | 313 | 174 |
| Infection Serology - Chlamydia trachomatis Direct Detection (Slide) | 316 | 174 |
| Infection Serology - Coxiella burnetii Antibodies | 325 | 175 |
| Infection Serology - Diphtheria Toxoid Antibodies | 318 | 175 |
| Infection Serology - Francisella tularensis Antibodies | 328 | 176 |
| Infection Serology - Helicobacter pylori Antibodies | 334 | 176 |
| Infection Serology - Leptospira Antibodies | 329 | 177 |
| Infection Serology - Mycoplasma pneumoniae Antibodies | 324 | 177 |
| Infection Serology - Procalcitonin | 320 | 178 |
| Infection Serology - Rheumatoid Factor | 323 | 178 |
| Infection Serology - Rickettsia Antibodies | 330 | 179 |
| Infection Serology - Salmonella Antibodies | 331 | 180 |
| Infection Serology - Streptococcal AB | 321 | 181 |
| Infection Serology - Tetanus Toxoid Antibodies | 310 | 181 |
| Infection Serology - Treponema pallidum Antibodies | 311 | 182 |
| Infection Serology - Yersinia Antibodies | 315 | 183 |
| **Human Microbiome** | | |
| Bacterial Genome Detection - Molecular Genetic Analysis of the Human Microbiome | 580 | 183 |
| **Conventional Bacteriology** | | |
| Bacteriology (3 Samples) | 411 | 184 |
| Bacteriology (5 Samples) | 412 | 185 |
| Bacteriology - Gram Stain | 413 | 185 |
| **Mycobacteriology** | | |
| Mycobacterial Diagnostics - Cultivation | 422 | 186 |
| Mycobacterial Diagnostics - Drug Susceptibility Testing of Mycobacterium tuberculosis | 425 | 186 |
| Mycobacterial Diagnostics - Drug Susceptibility Testing of Nontuberculous Mycobacteria | 427 | 187 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| Mycobacterial Diagnostics - Identification | 423 | 187 |
| Mycobacterial Diagnostics - Microscopy | 421 | 188 |
| Mycobacterial Diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria | 426 | 188 |
| Mycobacterial Diagnostics - NAT Mycobacterium tuberculosis | 424 | 189 |
| **Mycology** | | |
| Fungal Genome Detection - Pneumocystis jirovecii | 560 | 189 |
| Genome Detection of Dermatophytes | 492 | 190 |
| Mycology Dermatophytes, Yeasts, Mould Fungus | 491 | 190 |
| Mycology Mucorales, Yeasts, Coelomycetes, Hyphomycetes, Basidiomycetes | 490 | 191 |
| Mycoserology - Candida (Antigen and Antibodies) | 480 | 191 |
| Mycoserology - Cryptococcus neoformans/ - gattii Antigen | 481 | 192 |
| **Parasite Diagnostics** | | |
| Detection of Toxoplasma DNA (PCR) | 457 | 192 |
| Molecular Genetic Detection of Protozoa in Stool | 458 | 193 |
| Parasite Microscopy (Blood) | 456 | 193 |
| Parasite Serology - Amoebiasis and Echinococcosis | 455 | 194 |
| Parasite Serology - Malaria and Schistosomiasis | 454 | 194 |
| Parasite Serology - Toxoplasmosis | 452 | 195 |
| Virtual Parasite Microscopy (Blood) | 906 | 195 |
| Virtual Parasite Detection (Stool) | 907 | 196 |
| **VIRUS DIAGNOSTICS** | | |
| **Virus Genome Detection** | | |
| Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag) | 410 | 197 |
| Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses | 370 | 198 |
| Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus | 359 | 199 |
| Virus Genome Detection - Adenoviruses | 371 | 199 |
| Virus Genome Detection - BK Polyomavirus (BKPyV / BKV) | 364 | 200 |
| Virus Genome Detection - Borna Viruses | 404 | 200 |
| Virus Genome Detection - Chikungunya Virus | 392 | 201 |
| Virus Genome Detection - Coronaviruses incl. SARS-CoV-2 | 340 | 202 |
| Virus Genome Detection - Cytomegalovirus Program 1 | 365 | 203 |
| Virus Genome Detection - Cytomegalovirus Program 2 - additional Training Program (can only be ordered with program 365) | 368 | 203 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| Virus Genome Detection - Cytomegalovirus Resistance Determination | 349 | 204 |
| Virus Genome Detection - Dengue Viruses | 369 | 204 |
| Virus Genome Detection - Enteroviruses | 372 | 205 |
| Virus Genome Detection - Epstein Barr Virus | 376 | 205 |
| Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests | 430 | 206 |
| Virus Genome Detection - Hepatitis A Virus | 377 | 206 |
| Virus Genome Detection - Hepatitis B Virus Genotyping | 396 | 207 |
| Virus Genome Detection - Hepatitis B Virus Program 1 | 361 | 207 |
| Virus Genome Detection - Hepatitis B Virus Program 2 - additional Training Program (can only be ordered with program 361) | 378 | 208 |
| Virus Genome Detection - Hepatitis B Virus Resistance Determination | 397 | 208 |
| Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping | 375 | 209 |
| Virus Genome Detection - Hepatitis C Virus Program 1 | 362 | 209 |
| Virus Genome Detection - Hepatitis C Virus Program 2 - additional Training Program (can only be ordered with program 362) | 379 | 210 |
| Virus Genome Detection - Hepatitis C Virus Resistance Determination | 399 | 210 |
| Virus Genome Detection - Hepatitis D Virus | 400 | 211 |
| Virus Genome Detection - Hepatitis E Virus | 380 | 211 |
| Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2 | 363 | 212 |
| Virus Genome Detection - HIV-1 (RNA) Program 2 - additional Training Program (can only be ordered with program 360) | 382 | 212 |
| Virus Genome Detection - HIV-1 (RNA) Program 1 | 360 | 213 |
| Virus Genome Detection - HIV-1 Drug Resistance Determination - Standard Program for Protease and Reverse Transcriptase Inhibitors | 383 | 213 |
| Virus Genome Detection - HIV-1 Drug Resistance Determination - additional Program for Integrase Inhibitors and Tropism Determination | 384 | 214 |
| Virus Genome Detection - HIV-2 (RNA) | 395 | 214 |
| Virus Genome Detection - Human Herpesvirus 6 (HHV-6) | 405 | 215 |
| Virus Genome Detection - Human Herpesvirus 8 (HHV-8) | 406 | 215 |
| Virus Genome Detection - Human Metapneumovirus | 385 | 216 |
| Virus Genome Detection - Human Papillomaviruses (HPV) | 373 | 216 |
| Virus Genome Detection - Human Rhinoviruses | 393 | 217 |
| Virus Genome Detection - JC Polyomavirus (JCPyV / JCV) | 394 | 217 |
| Virus Genome Detection - Measles Virus | 386 | 218 |
| Virus Genome Detection - MPXV / Orthopoxviruses | 418 | 219 |
| Virus Genome Detection - Mumps Virus | 387 | 220 |
| Virus Genome Detection - Norovirus | 381 | 220 |
| Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens | 435 | 221 |
| Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests | 433 | 221 |
| Virus Genome Detection - Parainfluenza Viruses | 388 | 222 |
| Virus Genome Detection - Parechovirus | 407 | 222 |
| Virus Genome Detection - Parvovirus B19 | 367 | 223 |

# TABLE OF CONTENT


| EQAS/PT | No. | Page |
|---|---|---|
| Virus Genome Detection - Rabies Virus (Tollwutvirus) | 390 | 223 |
| Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests | 431 | 224 |
| Virus Genome Detection - Respiratory Virus Panel 2 | 432 | 225 |
| Virus Genome Detection - Rotaviruses | 401 | 226 |
| Virus Genome Detection - Rubella Virus | 389 | 226 |
| Virus Genome Detection - SARS-CoV-2 | 409 | 227 |
| Virus Genome Detection - SARS-CoV-2 sequence analysis | 417 | 227 |
| Virus Genome Detection - Torque Teno Virus (TTV) | 408 | 228 |
| Virus Genome Detection - Varicella Zoster Virus | 366 | 228 |
| Virus Genome Detection - West Nile Virus | 391 | 229 |
| Virus Genome Detection - Zika Virus | 403 | 229 |
| **Virus Immunology** | | |
| Virus Immunology - Borna Viruses (Ab) | 415 | 230 |
| Virus Immunology - Chikungunya Virus (Ab) | 402 | 230 |
| Virus Immunology - Cytomegalovirus (Ab) | 351 | 231 |
| Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) | 350 | 231 |
| Virus Immunology - Epstein Barr Virus (Ab) | 352 | 232 |
| Virus Immunology - Hantaviruses (Ab) | 355 | 232 |
| Virus Immunology - Hepatitis A Virus (Ab) | 343 | 233 |
| Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, An- | 344 | 233 |
| Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM) | 345 | 234 |
| Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) | 346 | 234 |
| Virus Immunology - Hepatitis D Virus (Ab) | 347 | 235 |
| Virus Immunology - Hepatitis E Virus (Ab) | 348 | 235 |
| Virus Immunology - Herpes Simplex Viruses (Ab) | 354 | 236 |
| Virus Immunology - HIV-1 p24 Antigen | 337 | 236 |
| Virus Immunology - HIV-1/HIV-2 (Ab) | 335 | 237 |
| Virus Immunology - HTLV-1/HTLV-2 (Ab) | 339 | 237 |
| Virus Immunology - Measles Virus (Ab) | 357 | 238 |
| Virus Immunology - Mumps Virus (Ab) | 356 | 238 |
| Virus Immunology - Parvovirus B19 (Ab) | 342 | 239 |
| Virus Immunology - Rabies Virus (Tollwutvirus) (Ab) | 336 | 239 |
| Virus Immunology - Rubella Virus (Ab) | 341 | 240 |
| Virus Immunology - SARS-CoV-2 (Ab) | 416 | 240 |
| Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab) | 358 | 241 |
| Virus Immunology - Varicella Zoster Virus (Ab) | 353 | 241 |
| Virus Immunology - Zika Virus (Ab) | 338 | 242 |

# MOLECULAR GENETICS

## Engraftment- and Chimerism Diagnostics

### Engraftment- and Chimerism Diagnostics 618

**EQAS/PT Properties**
**Samples:** 5 samples of 1.5 mL
**Sample Properties:** Whole blood (CPD),not stabilized
**Max. Number of Sample Sets:** 1
**Additional Information:**
- Sample from donors, patients before and after transplantation are sent per appointment. Only annual subscription possible!
- EQAS/PT results can only be submitted online!
- Successful participation in both EQAS rounds is necessary for the award of a certificate (10 samples per year).
- **Due to longer shipment times, labs using FISH-Analyses, cannot participate in this EQA.**

**EQAS/PT Experts:**
Dr. med. Roland Reibke

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick
Prof. Dr. med. Michael Spannagl

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Evaluation and diagnosis Receiver

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-03-12 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-11 | | | 27-10-12 |
| Closing Date: | | | 27-05-28 | | | 27-10-29 |

## Immunohematology

### Immunohaematology 06 - Molecular Diagnostic 235

**EQAS/PT Properties**
**Samples:** 4 samples
**Sample Properties:** DNA
**Max. number of sample sets:** 1
**Additional Information:**
A list of the alleles necessary for successful participation can be found at:
www.instand-ev.de/mandatory-alleles

**EQAS/PT Experts:**
Prof. Dr. med. Ulrich Sachs

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Willy A. Flegel
Dr. med. Christof Weinstock

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Red cells: ABO, MNS, RHD, RHD-Deletion, RHCE, LU, KEL, FY, JK, DI, YT, DO, CO, LW, KN, VEL. Platelets: HPA-1, 2, 3, 4, 5, 6, 9, 15. Granulocytes: HNA-1a, -1b, -1c; HNA-3, HNA-4, HNA-5.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Conventional Genetics

### Molecular Genetics - Aldolase B (ALDOB) Variants (A149P, A174D, N334K) 793

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Aldolase B: A 149 P<br>Aldolase B: A 174 D<br>Aldolase B: N 334 K |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

### Molecular Genetics - Alpha-Globin and beta-Globin 794

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µL<br>**Sample Properties:** DNA solution (approx. 50 ng/µL) | **EQAS/PT Experts:**<br>Dr. med. Claudia Frömmel<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Adriana Méndez |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Mutations in the alpha-globin gene (max. 4)<br>• Genotype of the alpha-globin gene (hemoglobinopathy nomenclature)<br>• Evaluation of the alpha-globin gene<br>• Mutations in the beta-globin gene (max. 4)<br>• Beta-globin gene genotype (hemoglobinopathy nomenclature)<br>• Beta-globin gene evaluation<br>• Report with findings from both the alpha- and beta-globin genes<br>• Report |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Alpha1-Antitrypsin (SERPINA1) Variants (PiM, PiS, PiZ) 743

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Alpha-1 antitrypsin S-Locus<br>Alpha-1 antitrypsin Z-Locus | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Angiotensin Converting Enzyme 763

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>N.N |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>ACE Insertions/ Deletions (I/D)- Polymorphismus | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Antithrombin (AT3; SERPINC1 Gene) 792

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 Samples of 50 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL)<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Analysis of the SERPINC1 gene for small base variations (SNVs) and/or copy number variations (CNVs) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Apolipoprotein (APOE) Variants (E2, E3, E4) - Whole Blood 734

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Whole blood<br>**Max. number of sample sets:** 3 | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Apo E (genotypes 2, 3, 4) | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-08<br>27-03-09<br>27-04-09 | | | 27-07-02<br>27-08-31<br>27-10-01 | |

## Molecular Genetics - Apolipoprotein B APOB, R3500Q (HGVS: c.10580G>A; p.Arg-3527Gln), R3500W (HGVS: c.10579C>T; p.Arg3527Trp)) 771

**EQAS/PT Properties**
**Samples:** 2 samples of 40 µl
**Sample Properties:** DNA solution (approx. 15 ng/µL)
**Additional Information:**
Annotation for the evaluation: The successful participation requires the correct identification if the variants R3S00Q (HGVS: c.10580G>A; p.Arg3527Gln) und R3500W (HGVS: c.10579C>T; p.Arg3527Trp) are present (homozygous/heterozygous) or not (negative) in the DNA samples.

**EQAS/PT Experts:**
Dr. rer. nat. Morten O. Christensen

**Deputy EQAS/PT Experts:**
Dr. med. Günther Kappert

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Apo B-100 (R3500Q; R3500W)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Interpretation of results

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Apolipoprotein E (APOE) Variants (E2, E3, E4) 744

**EQAS/PT Properties**
**Samples:** 3 samples of 20 µl
**Sample Properties:** DNA solution (approx. 20 ng/µL)

**EQAS/PT Experts:**
Dr. rer. nat. Ralf Flörke

**Deputy EQAS/PT Experts:**
Dr. med. Günther Kappert

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Apo E (genotypes 2, 3, 4)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - AZF (Y-Chromosome Microdeletions) 788

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>PD Dr. rer. nat. Julia Hentschel<br><br>**Deputy EQAS/PT Experts:**<br>MSc. Simone Ahting |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Y-Chromosome AZFa deletion<br>Y-Chromosome AZFb deletion<br>Y-Chromosome AZFc deletion | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - BRCA1 BRCA2 779

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Analysis of the BRCA1/BRCA2 genes for small base variations (SNVs) and/or copy number variations (CNVs) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - C-C Motif Chemokine Receptor 5 764

**EQAS/PT Properties**
**Samples:** 2 samples of 40 µl
**Sample Properties:** DNA solution (approx. 15 ng/µL)

**EQAS/PT Experts:**
Prof. Dr. med. Folker Wenzel

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
CCR5 gene (Δ32)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Interpretation of results

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - CFTR Common Mutations 778

**EQAS/PT Properties**
**Samples:** 2 samples of 40 µl
**Sample Properties:** DNA solution (approx. 15 ng/µL)
**Additional Information:**
- CFTR gene (NM_000492.4). The 34 most common variants detected by standard screening methods will be tested. Participants must be able to identify at least the 34 most common variants. See here for a list of mandatory mutations: www.instand-ev.de/cftr-mandatory-mutations
- Exception: Participants who only test the 31 variants of the child guidelines for CF. These participants are requested to communicate this in the comment field. Participants who only test for F508del cannot participate in this EQA scheme.
- Participants who analyze the complete CFTR gene are also welcome to participate. These participants please communicate variants that are not among the 34 most common variants via the comment field. Participants are asked to comment on the possibility of CFTR modulator therapy.

**EQAS/PT Experts:**
PD Dr. rer. nat. Julia Hentschel

**Deputy EQAS/PT Experts:**
MSc. Simone Ahting

**Requirement for EQAS/PT according to Rili-BÄK:** yearly
**Validity Certificate:** 24 months
**Parameter / Analytes:**
CFTR gene

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
- ACMG classification
- Interpretation of results / recommendation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Collagen Receptor (ITGA2) Variant C807T 739

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Collagen receptor GP Ia/IIa (C 807 T) | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency (CYP21A2 Gene) 773

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Analysis of the CYP21A2 gene for small base variations (SNVs) and/or copy number variations (CNVs) | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Connexin 26 (GJB2 Gene, GJB6 Gene) 782

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Analysis of the GJB2 gene for small base variations (SNVs) and/or copy number variations (CNVs) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>• Analysis of the GJB6 gene for copy number variations (CNVs)<br>• Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Copper-Binding Protein ATP7B Variant (H1069Q) 745

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>ATP 7 B: H 1069 Q | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - ctDNA Tumour Panel NEW! 752

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml (30 ng/ml cfDNA)
**Sample Properties:** DNA solution
**Max. number of sample sets:** 1
**Additional Information:**
Due to the complex nature of sample preparation, INSTAND e.V. reserves the right to no longer supply EQA samples to laboratories that have repeatedly failed to submit results. Link to the list of mutations: www.instand-ev.de/ctDNA_mutations

**EQAS/PT Experts:**
Prof. Dr. med. Stefan Holdenrieder

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
BRAF V600-variant(s)
EGFR T790M-variant(s)
KRAS Codon 12-variant(s)
KRAS Codon 13-variant(s)
KRAS Codon 61-variant(s)
NRAS Codon 61-variant(s)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
ESR1-variant(s)
PIK3CA-variant(s)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-28 | | | 27-11-05 |

## Molecular Genetics - CYP2C9 CYP2C19 VKORC1 TPMT 775

**EQAS/PT Properties**
**Samples:** 2 samples of 40 µl
**Sample Properties:** DNA solution (approx. 15 ng/µL)

**EQAS/PT Experts:**
Prof. Dr. med. Folker Wenzel

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
CYP2C19*2 Allele: G 681 A
CYP2C19*3 Allele: G 636 A
CYP2C9*2 Allele: C 430 T
CYP2C9*3 Allele: A 1075 C
TPMT (nt. A 719 G) TPMT (nt. G 460 A)
TPMT*2 Allele (nt. G 238 C)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
VKORC1: C 1173 T
VKORC1: G -1639 A

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-28 | | | 27-11-05 |

## Molecular Genetics - CYP2D6 IL28B 777

**EQAS/PT Properties**
**Samples:** 2 samples of 40 µl
**Sample Properties:** DNA solution (approx. 15 ng/µL)

**EQAS/PT Experts:**
Prof. Dr. med. Folker Wenzel

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
CYP2D6 gene Duplication
CYP2D6*3: A2637 del
CYP2D6*4: G 1934 A
CYP2D6*5: complete Deletion
CYP2D6*6: T1795 del

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
IL-28B C/T: rs 12979860

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-28 | | | 27-11-05 |

## Molecular Genetics - Dihydropyrimidin Dehydrogenase 762

**EQAS/PT Properties**
**Samples:** 2 samples of 40 µl
**Sample Properties:** DNA solution (approx. 15 ng/µL)

**EQAS/PT Experts:**
Dr. rer. nat. Susanna Schubert

**Deputy EQAS/PT Experts:**
PD Dr. rer. nat. Julia Hentschel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
The following variants are tested in this EQA scheme:
Haplotype B3 (c.1236G>A; c.1129-5923C>G)
c.1679T>G
c.1905+1G>A
c.2846A>T

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Assessment of the influence on enzyme function as well as the dose recommendation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-28 | | | 27-11-05 |

## Molecular Genetics - Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) (DMD Gene) 780

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Analysis of the DMD gene for small base variations (SNVs) and/or copy number variations (CNVs) | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Factor V-Leiden (F5) Variant 740

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL)<br>**Additional Information:**<br>Please note that this EQA scheme is intended for laboratories that test only for the Factor V Leiden SNP. If you perform a complete genetic analysis of the F5 gene, please participate in EQA scheme 670 - Molecular Genetics – Factor V-Gene (F5). | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Factor V-Leiden | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Factor V-Leiden (F5) Variant - Whole Blood 730

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Whole blood<br>**Max. number of sample sets:** 3<br>**Additional Information:**<br>Please note that this EQA scheme is intended for laboratories that test only for the Factor V Leiden SNP. If you perform a complete genetic analysis of the F5 gene, please participate in EQA scheme 670 - Molecular Genetics – Factor V-Gene (F5). | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Factor V-Leiden | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-08<br>27-03-09<br>27-04-09 | | | 27-07-02<br>27-08-31<br>27-10-01 | |

## Molecular Genetics - Fibrinogen Receptor (ITGB3) Variant HPA 1a/1b 749

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Fibrinogen Receptor HPA: 1a, 1b |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Fragile X Syndrome (FMR1 Gene, CGG Repeats) 781

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>FMR1: determination of CGG-repeats in 5‘ UTR | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>• FMR1: determination of the variant category<br>• Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) 741

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>HFE: C 282 Y HFE: H 63 D HFE: S 65 C | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) - Whole Blood 733

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Whole blood<br>**Max. number of sample sets:** 3 | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>HFE: C 282 Y HFE: H 63 D HFE: S 65 C | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | **Apr.** | | | **Oct.** | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-08<br>27-03-09<br>27-04-09 | | | 27-07-02<br>27-08-31<br>27-10-01 | |

## Molecular Genetics - Huntington Disease (HTT Gene, CAG Repeats) 784

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Determination of CAG-repeats | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Lactase-Variant -13910T>C (MCM6 Gene, IVS13 C-T, rs4988235, HGVS: C.1917+326 C>T) 770

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Laktase-Gene (LCT) (-13910 C>T; HGVS: c.1917+326C>T) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - MLH1 MSH2 MSH6 PMS2 (Lynch) 783

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>PD Dr. rer. nat. Julia Hentschel<br><br>**Deputy EQAS/PT Experts:**<br>MSc. Simone Ahting |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>MLH1 gene MSH2 gene MSH6 gene PMS2 gene - gene analysis (SNVs und CNVs) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>• HNPCC interpretation<br>• Interpretation of results / recommendation |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - MTHFR Variants C677T (optional A1298C) 747

**EQAS/PT Properties**
**Samples:** 3 samples of 20 µl
**Sample Properties:** DNA solution (approx. 20 ng/µL)

**EQAS/PT Experts:**
Dr. rer. nat. Ralf Flörke

**Deputy EQAS/PT Experts:**
Dr. med. Günther Kappert

**Requirement for EQAS/PT according to Rili-BÄK:**: bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
MTHFR (A 1298 C) MTHFR (C 677 T)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-28 | | | 27-11-05 |

## Molecular Genetics - MTHFR Variants C677T (optional A1298C) - Whole Blood 732

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Whole blood
**Max. number of sample sets:** 3

**EQAS/PT Experts:**
Dr. rer. nat. Ralf Flörke

**Deputy EQAS/PT Experts:**
Dr. med. Günther Kappert

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
MTHFR (A 1298 C) MTHFR (C 677 T)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| Registration Deadline: | | 27-01-08 | | | 27-07-02 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-31 | |
| Closing Date: | | 27-04-09 | | | 27-10-01 | |

## Molecular Genetics - NIPT - Determination of Fetal RhD Status 727

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1.5 ml<br>**Sample Properties:** Liquid plasma (Plasma)<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Ingo Schellenberg |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Determination of the fetal RhD status |
| **Shipping Information:**<br>• Shipping not cooled<br>• Shipping is limited to EU, Switzerland and UK. | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Molecular Genetics - NOD2 774

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>N.N. |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>NOD2 mutation(s) NOD2 Nomenclature cDNA |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) 748

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK:**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Plasminogenactivator-Inhibitor (PAI-1): 4G, 5G | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) - Whole Blood 735

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Whole blood<br>**Max. number of sample sets:** 3 | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Plasminogenactivator-Inhibitor (PAI-1): 4G, 5G | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | **Apr.** | | | **Oct.** | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-08<br>27-03-09<br>27-04-09 | | | 27-07-02<br>27-08-31<br>27-10-01 | |

## Molecular Genetics - Prader-Willi (PWS) und Angelman (AS) Syndromes (Chromosome region 15q11-13, SNRPN) 786

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Methylation analysis deletion analysis | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Protein C (PROC Gene) 790

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 Samples of 50 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL)<br>**Max. number of sample sets:** 1 | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the PROC gene for single-nucleotide variants (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of Results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Protein S (PROS1 Gene) 791

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 Samples of 50 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL)<br>**Max. number of sample sets:** 1 | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the PROS1 gene for single-nucleotide variants (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of Results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Prothrombin (F2) Variant G20210A 746

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Prothrombin G20210A | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - Prothrombin (F2) Variant G20210A - Whole Blood 731

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Whole blood<br>**Max. number of sample sets:** 3 | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Prothrombin G20210A | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-08<br>27-03-09<br>27-04-09 | | | 27-07-02<br>27-08-31<br>27-10-01 | |

## Molecular Genetics - Spinal Muscular Atrophy (SMN1 and SMN2 Genes) 787

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL)<br>**Max. number of sample sets:** 9 | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** yearly<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Determination of the copy numbers of the SMN1 and SMN2 genes<br>SMN2 Gen | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Interpretation of results |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) Variants 742

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 3 samples of 20 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>UDP-G1 UGT1A1*28 UDP-G1 UGT1A1*6 | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood NEW! 726

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 mL<br>**Sample Properties:** Whole blood | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Ralf Flörke<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>UDP-G1 UGT1A1*28 UDP-G1 UGT1A1*6 | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | **Apr.** | | | **Oct.** | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-08<br>27-03-09<br>27-04-09 | | | 27-07-02<br>27-08-31<br>27-10-01 | |

## Molecular Genetics – Factor IX-Gene (F9) NEW! 673

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 50 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F9 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Factor V-Gene (F5) NEW! 670

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 80 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL)<br>**Additional Information:**<br>• Please note that this EQA scheme is intended for laboratories that perform a complete genetic analysis of the F5 gene.<br>• If you are only testing for the Factor V Leiden SNP, please participate in scheme 730 or 740. | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F5 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Factor VII-Gene (F7) NEW! 671

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 50 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F7 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Factor VIII-Gene (F8) NEW! 672

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 100 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F8 gene for intron 1 and intron 22 inversions and/or small nucleotide variations (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Factor X-Gene (F10) NEW! 674

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 50 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F7 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Factor XI-Gene (F11) NEW! 675

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 50 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F11 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Factor XIII-Gene (F13A1, F13B) NEW! 677

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 80 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the F13A1 and F13B genes for small nucleotide variations (SNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG) NEW! 676

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 80 µL<br>**Sample Properties:** DNA solution (approx. 25 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the FGA, FGB, and FGG genes for small nucleotide variations (SNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Genetics – FLT3 (internal tandem duplication) NEW! 701

**EQAS/PT Properties**
**Samples:** 2 samples of 10 µL
**Sample Properties:** DNA solution (approx. 100 ng/µL)
**Max. number of sample sets:** 1
**Additional Information:**
- As required by the RiliBÄK, the method used must have a detection limit of at least 5%.
- Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.

**EQAS/PT Experts:**
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Eva Lorsy

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
FLT3 internal tandem duplication

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline: | 26-11-13 | | | 27-04-23 | | |
| Sample Shipment: | 27-01-12 | | | 27-06-22 | | |
| Closing Date: | 27-02-12 | | | 27-07-23 | | |

## Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction NEW! 728

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Plasma

**EQAS/PT Experts:**
Prof. Dr. med. Folker Wenzel

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Aneuploidy
Determination of fetal fraction
Determination of fetal sex

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
- Shipping not cooled
- Shipping is limited to EU, Switzerland and UK
- Please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-07-02 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-31 | |
| Closing Date: | | 27-03-19 | | | 27-09-10 | |

## Molecular Genetics – von Willebrand Factor-Gene (VWF) NEW! 678

**EQAS/PT Properties**
**Samples:** 2 samples of 100 µL
**Sample Properties:** DNA solution (approx. 25 ng/µL)

**EQAS/PT Experts:**
Dr. rer. nat. Morten O. Christensen

**Deputy EQAS/PT Experts:**
Dr. med. Günther Kappert

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** not applicable
**Parameter / Analytes:**

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Analysis of the VWF gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs)
- Interpretation of results

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Oncology – PML::RARA qualitative NEW! 702

**EQAS/PT Properties**
**Samples:** 2 samples of 30 µL
**Sample Properties:** cDNA solution
**Max. number of sample sets:** 1
**Additional Information:**
As required by the RiliBÄK, the method used must have a detection limit of at least 5%.

**EQAS/PT Experts:**
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Eva Lorsy

**Requirement for EQAS/PT according to Rili-BÄK:** half-yearly
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PML::RARA gene fusion

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-08<br>27-03-09<br>27-04-09 | | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Pathology – PIK3CA and ESR1 NEW! 590

**EQAS/PT Properties**
**Samples:** 2 samples of 35 µL
**Sample Properties:** DNA (approx. 5 ng/µL)
**Max. number of sample sets:** 1
**Additional Information:**
This EQA scheme addresses the requirements of EBM codes 19463 (PIK3CA) and 19466 (ESR1), which call for the targeted detection of activating mutations in circulating tumor DNA to guide treatment in advanced breast cancer.

**EQAS/PT Experts:**
Dr. Harald Bartsch

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
ESR1-variant(s) PIK3CA-variant(s)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | | 27-08-13<br>27-10-12<br>27-11-19 |

## Oncology

### Molecular Genetics - Hereditary Fever Syndroms NEW! 706

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 40 µL<br>**Sample Properties:** DNA solution (approx. 15 ng/µL) | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the MEFV, NLRP3, MVK, and TNFRSF1A genes,<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

### Molecular Genetics - Ret Proto-Oncogene (Multiple Endocrine Neoplasia Type 2, MEN2, RET Gene) 738

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 Samples of 50 µl<br>**Sample Properties:** DNA solution (approx. 15 ng/µL)<br>**Max. number of sample sets:** 1 | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Morten O. Christensen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Günther Kappert |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Analysis of the RET gene for small base variations (SNVs) (complete gene or the exons 5, 8, 10, 11, 13-16) and/or copy number variations (CNVs)<br>• Interpretation of results | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-28 | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Molecular Oncology - AML-Panel (NGS) 798

**EQAS/PT Properties**
**Samples:** 1 samples of 10 µl
**Sample Properties:** DNA solution (approx. 50 ng/µL)

**EQAS/PT Experts:**
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Eva Lorsy

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** not applicable
**Parameter / Analytes:**
ASXL1 (NM_015338.6) Exon 13 Mutation(s)
ASXL1 Nomenclature
CEBPA (NM_004364.5) Mutation(s)
CEBPA Nomenclature
FLT3 (NM_004119.3) Mutation(s) Exon 20
FLT3 Nomenclature
IDH1 (NM_005896.4) Exon 4 Mutation(s)
IDH1 Nomenclature
IDH2 (NM_002168.4) Exon 4 Mutation(s)
IDH2 Nomenclature
NPM1 (NM_002520.7) Exon 11 Mutation(s)
NPM1 Nomenclature
RUNX1 (NM_001754.5) Mutation(s)
RUNX1 Nomenclature
TP53 (NM_000546.6) Mutation(s)
TP53 Nomenclature

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline: | 26-11-13 | | | 27-04-23 | | |
| Sample Shipment: | 27-01-12 | | | 27-06-22 | | |
| Closing Date: | 27-02-12 | | | 27-07-23 | | |

## Molecular Oncology - BRAF 795

**EQAS/PT Properties**
**Samples:** 2 samples of 10 µl
**Sample Properties:** DNA solution (approx. 20 ng/µL)
**Additional Information:**
As required by the RiliBÄK, the method used must have a detection limit of at least 5%.

**EQAS/PT Experts:**
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Eva Lorsy

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
BRAF p.V600 BRAF Nomenclature

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline: | 26-11-13 | | | 27-04-23 | | |
| Sample Shipment: | 27-01-12 | | | 27-06-22 | | |
| Closing Date: | 27-02-12 | | | 27-07-23 | | |

## Molecular Oncology - BTK 796

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | **EQAS/PT Experts:**<br>Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>BTK p.C481 BTK Nomenclature |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

## Molecular Oncology - KIT 767

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL)<br>**Additional Information:**<br>As required by the RiliBÄK, the method used must have a detection limit of at least 0,1%. | **EQAS/PT Experts:**<br>Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>KIT p.D816V | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

## Molecular Oncology - MYD88 766

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>MYD88 p.L265P |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

## Molecular Oncology - Myeloproliferative Neoplasia 768

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 50 ng/µL)<br>**Additional Information:**<br>As required by the RiliBÄK, the method used must have a detection limit of at least 5%. | Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>JAK2 p.V617F<br>JAK2 Exon 12 mutation<br>JAK2 Exon 12 nomenclature | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>CALR Exon 9 Mutation(s)<br>CALR Nomenclature<br>MPL p.W515<br>MPL Nomenclature |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

## Molecular Oncology - SF3B1 797

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 30 ng/µL) | Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>SF3B1 Exon 14-15 Mutation(s) SF3B1 Nomenclature |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

## Molecular Oncology - STAT3 769

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 20 ng/µL) | Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>STAT3 Exon 21 Mutation(s) STAT3 Nomenclature |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

## Molecular Oncology - TP53 765

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 10 µl<br>**Sample Properties:** DNA solution (approx. 30 ng/µL)<br>**Additional Information:**<br>As required by the RiliBÄK, the method used must have a detection limit of at least 5%. | Prof. Dr. Karl-Anton Kreuzer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Eva Lorsy |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>TP53 Mutation(s) TP53 Nomenclature | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | July | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-02-12 | | | 27-04-23<br>27-06-22<br>27-07-23 | | |

# IMMUNOLOGY

## Allergy Diagnostics

### Allergy Diagnostic 720

**EQAS/PT Properties**
**Samples:** 5 samples of 1.0 or 0.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Deputy EQAS/PT Experts:**
Dr. Nathalie Weiss

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Qualitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Quantitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples), determination of total IgE (5 samples)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

**Information will be updated at the end of autumn.**

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Autoimmune Diseases

### Autoimmune Diseases - Antiphospholipid Syndrome 275

**EQAS/PT Properties**
**Samples:** 2 samples of 0.3 ml
**Sample Properties:** Serum / Plasma

**EQAS/PT Experts:**
Dr. rer. nat. Martin Blüthner

**Deputy EQAS/PT Experts:**
Dr. Marie Mayrhofer

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months / 24 months
**Parameter / Analytes:**

| | |
|---|---|
| anti-Cardiolipin (IgG) | anti-ß2-Glycoprotein (IgG) |
| anti-Cardiolipin (IgM) | anti-ß2-Glycoprotein (IgM) |
| anti-Cardiolipin (IgA) | anti-ß2-Glycoprotein (IgA) |
| anti-Cardiolipin (polyvalent) | anti-ß2-Glykoprotein (polyvalent) |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| Registration Deadline: | | | | | 27-06-11 | |
| Sample Shipment: | | | | | 27-08-10 | |
| Closing Date: | | | | | 27-08-27 | |

## Autoimmune Diseases - Autoimmune Dermatitis 259

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | **EQAS/PT Experts:**<br>Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti- Desmosomes<br>anti-Hemidesmosomes<br>anti-Desmoglein 1<br>anti-Desmoglein 3<br>anti-BPAg 230<br>anti-BPAg 180<br>anti-Desmoplakin I / II<br>anti-Kollagen Typ VII |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 26-12-18<br>27-02-23<br>27-03-12 | | | | |

## Autoimmune Diseases - Autoimmune Endocrinopathies 263

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | **EQAS/PT Experts:**<br>Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-adrenal cortex<br>anti-P450 C21 - Hydroxylase<br>anti-P450 C17 - Hydroxylase<br>anti-P450 ssc - Hydroxylase |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | 27-06-11<br>27-08-10<br>27-08-27 | |

## Autoimmune Diseases - Connective Tissue Diseases (ANA) 251

**EQAS/PT Properties**
**Samples:** 2 samples of 0.3 ml
**Sample Properties:** Serum / Plasma

**EQAS/PT Experts:**
Dr. rer. nat. Martin Blüthner

**Deputy EQAS/PT Experts:**
Dr. Marie Mayrhofer

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Autoantibodies against ANA
Autoantibodies against dsDNA

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Collagenosis Screening
anti-DFS70 / LEDGF
Autoantibodies against nucleosomes
Autoantibodies against histones

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

## Autoimmune Diseases - Connective Tissue Diseases (ENA) 255

**EQAS/PT Properties**
**Samples:** 2 samples of 0.3 ml
**Sample Properties:** Serum / Plasma

**EQAS/PT Experts:**
Dr. rer. nat. Martin Blüthner

**Deputy EQAS/PT Experts:**
Dr. Marie Mayrhofer

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
anti-U1-snRNP
anti-SmD anti-Sm
anti-SS-A / Ro
anti-SS-A / Ro (52 kD - proteins)
anti-SS-A / Ro (60 kD - proteins)
anti-SS-B / La
anti-Topoisomerase-1 (Scl 70)
anti-CENP A
anti-CENP B
anti-ribosomales P-protein

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| Registration Deadline: | | | | | 27-06-11 | |
| Sample Shipment: | | | | | 27-08-10 | |
| Closing Date: | | | | | 27-08-27 | |

## Autoimmune Diseases - Diabetes mellitus 261

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-Islet cells - JDFU<br>Diabetes Screen<br>anti-Islet cells (ICA)<br>anti-Insulin (IAA)<br>anti-Glutamic Acid Decarboxylase (GAD)<br>anti-Tyrosine Phosphatase (IA2)<br>anti-Zinc Transporter 8 (ZnT8A) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | 27-06-11<br>27-08-10<br>27-08-27 | |

## Autoimmune Diseases - Gluten-Sensitive Enteropathies 271

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>anti-Transglutaminase IgA | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>anti-Gliadin IgG<br>anti-Gliadin IgA<br>anti-deamidated Gliadin IgG<br>anti-deamidated Gliadin IgA<br>anti-Endomysium IgA |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 26-12-18<br>27-02-23<br>27-03-12 | | | 27-06-11<br>27-08-10<br>27-08-27 | |

## Autoimmune Diseases - Hepatic Syndromes 253

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Plasma / Serum | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>anti-Mitochondria<br>anti-Microsomes (LKM 1)<br>anti-smooth muscle<br>anti-Actin<br>anti-Parietal cells<br>anti-H+/K+-ATPase<br>anti-gp210<br>anti-SLA/LP<br>anti-Sp100<br>anti-Intrinsic factor |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| **Registration Deadline:** | | 26-12-18 | | | 27-06-11 | |
| **Sample Shipment:** | | 27-02-23 | | | 27-08-10 | |
| **Closing Date:** | | 27-03-12 | | | 27-08-27 | |

## Autoimmune Diseases - Myasthenia gravis 269

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-Acetylcholin receptors<br>anti-musclespecific Receptor Tyrosinkinase (MuSK)<br>anti-skeletal muscle<br>anti-Titin<br>anti-calcium channel P/Q |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| **Registration Deadline:** | | 26-12-18 | | | | |
| **Sample Shipment:** | | 27-02-23 | | | | |
| **Closing Date:** | | 27-03-12 | | | | |

## Autoimmune Diseases - Myositis NEW! 256

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-cN-1A<br>anti-PM / Scl<br>anti-Jo1 (Histidyl-tRNA synthetase)<br>anti-PL7 (Threonyl-tRNA synthetase)<br>anti-PL12 (Alanyl-tRNA synthetase)<br>anti-EJ (Glycyl-tRNA synthetase)<br>anti-OJ (Isoleucyl-tRNA synthetase)<br>anti-KS (Asparaginyl-tRNA synthetase)<br>anti-Mi-2<br>anti-SRP (IgG)<br>anti-TIF1<br>anti-SAE1<br>anti-NXP2<br>anti-MDA5 |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| **Registration Deadline:** | | | | | 27-06-11 | |
| **Sample Shipment:** | | | | | 27-08-10 | |
| **Closing Date:** | | | | | 27-08-27 | |

## Autoimmune Diseases - Paraneoplastic Neuropathies 265

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Serum / Plasma | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-Purkinje cells<br>anti-Neuronal nuclei<br>anti-Yo (CDR62)<br>anti-HuD anti-Ri / Nova 1<br>anti-Amphiphysin 1<br>anti-Ta (Ma 2)<br>anti - Glia Cell nuclear Antibody<br>(AGNA)<br>anti-SOX1<br>anti-ZIC4 anti-Recoverin<br>anti-CRMP5/CV2 |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| **Registration Deadline:** | | 26-12-18 | | | | |
| **Sample Shipment:** | | 27-02-23 | | | | |
| **Closing Date:** | | 27-03-12 | | | | |

## Autoimmune Diseases - Peripheral Neuropathies 267

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Plasma / Serum | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-Myelin-associated Glycoprotein (MAG)<br>anti-Asialoganglioside (AGA1)<br>anti-Monosialoganglioside (GM1)<br>anti-Monosialoganglioside (GM2)<br>anti-Monosialoganglioside (GM3)<br>anti-Disialoganglioside (GD1a)<br>anti-Disialoganglioside (GD1b)<br>anti-Quadrosialoganglioside (GQ1b)<br>anti-Trisialoganglioside (GT1b) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-12 | | | | |

## Autoimmune Diseases - Receptor Encephalitis NEW! 268

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Plasma / Serum | Dr. rer. nat. Martin Blüthner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Marie Mayrhofer |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>anti-MOG anti-Aquaporin 4<br>anti-CASPR2<br>anti-LGI1<br>anti-NMDA receptor<br>anti-GABA-B-Rez.<br>anti-AMPA 1/2 |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-12 | | | | |

## Autoimmune Diseases - Rheumatoid Arthritis 273

**EQAS/PT Properties**
**Samples:** 2 samples of 0.3 ml
**Sample Properties:** Serum / Plasma

**Additional Information:**
Additional terms for the rheuma factor see EQA scheme 323 - Infection Serology - Rheumatoid Factor!

**EQAS/PT Experts:**
Dr. rer. nat. Martin Blüthner

**Deputy EQAS/PT Experts:**
Dr. Marie Mayrhofer

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Rheumatoid Factor
Rheumatoid Factor (isotypes)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
anti-CCP (cyclic citrulline peptide)
anti-MCV (mutated citrullinated Vimentin)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

## Autoimmune Diseases - Vasculitis / Glomerulopathies 257

**EQAS/PT Properties**
**Samples:** 2 samples of 0.3 ml
**Sample Properties:** Plasma / Serum

**EQAS/PT Experts:**
Dr. rer. nat. Martin Blüthner

**Deputy EQAS/PT Experts:**
Dr. Marie Mayrhofer

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
c-ANCA anti-PR3
p-ANCA anti-MPO

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
anti-glomerular basement membrane (GBM)
anti-PLA2R
anti-THSD7A

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

## Basophil Activation Test 653

**EQAS/PT Properties**
**Samples:** 2 samples of 2.6 ml
**Sample Properties:** Whole blood (EDTA), not stabilized
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. med. Ulrich Sack

**Deputy EQAS/PT Experts:**
Dr. Uwe Kölsch

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Basophil activation by allergens bee and wasp.

**Shipping Information:**
- Overnight delivery.
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!
- The stimulants are not sent with the samples!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Sep. | Oct. |
| Registration Deadline: | | 27-01-08 | 27-03-12 | | 27-07-02 | 27-08-13 |
| Sample Shipment: | | 27-03-02 | 27-05-11 | | 27-08-31 | 27-10-12 |
| Closing Date: | | 27-03-12 | 27-05-21 | | 27-09-10 | 27-10-22 |

# HLA Typing

## HLA Diagnostics - High resolution, molecular HLA typing class I and II 444

**EQAS/PT Properties**
**Samples:** 5 samples of 1.5 mL
**Sample Properties:** Isolated lymphocytes (buffy coat)
**Max. number of sample sets:** 1
**Additional Information:**
- Molecular HLA typing class I and II in high resolution according to standards of the European Federation for Immunogenetics (EFI).
- In addition, HLA-B*57:01 associated with Abacavir hypersensitivity and HLA-DR epitopes associated with rheumatoid arthritis may be reported.
- It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).

**EQAS/PT Experts:**
Dr.-Ing. Nils Lachmann

**Deputy EQAS/PT Experts:**
Sükran Zaralioglu

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HLA-B 57:01 typing of DNA

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HLA-A typing of DNA (high resolution)
HLA-B typing of DNA (high resolution)
HLA-C typing of DNA (high resolution)
HLA-DPA1 typing of DNA (high resolution)
HLA-DPB1 typing of DNA (high resolution)
HLA-DQA1 typing of DNA (high resolution)
HLA-DQB1 typing of DNA (high resolution)
HLA-DRB 3/4/5 DNA-Typisierung (high resolution)
HLA-DRB1 typing of DNA (Shared Epitope)
HLA-DRB1 typing of DNA (high resolution)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | Apr. | Aug. | | Dec. |
| Registration Deadline: | 26-11-13 | | 27-01-15 | 27-05-14 | | 27-09-10 |
| Sample Shipment: | 27-01-11 | | 27-03-15 | 27-07-12 | | 27-11-08 |
| Closing Date: | 27-02-05 | | 27-04-09 | 27-08-06 | | 27-12-03 |

## HLA Diagnostics - HLA Antibody Screening and Identification 445

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 5 samples of 1 mL<br>**Sample Properties:** Liquid serum<br>**Max. number of sample sets:** 2 | **EQAS/PT Experts:**<br>Dr.-Ing. Nils Lachmann<br><br>**Deputy EQAS/PT Experts:**<br>Sükran Zaralioglu |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>HLA antibody determination:<br>• HLA antibody screening by complement-dependent cytotoxicity test (CDC) and/or with solid phase immunoassays<br>• antibody identification by CDC and/or antibody identification by solid phase immunoassays (ELISA, Luminex)<br>• solid phase complement binding assays (C1q, C3d, C4d etc.). |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | Aug. | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-11<br>27-02-19 | | | 27-05-14<br>27-07-12<br>27-08-20 | | |

## HLA Diagnostics - HLA Crossmatching 443

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 1 serum set (20 Sera à 100 µL and 2x ACD blood à 8 ml)<br>**Sample Properties:** Liquid serum and platelet-depleted blood (ACD)<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Dr.-Ing. Nils Lachmann<br><br>**Deputy EQAS/PT Experts:**<br>Sükran Zaralioglu |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>HLA crossmatching |
| **Shipping Information:**<br>• Shipping not cooled<br>• Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours! | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | Apr. | | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-01-15<br>27-03-15<br>27-04-16 | | | |

## HLA Diagnostics - HLA Typing Class I and II of Serological Eqivalents 441

**EQAS/PT Properties**
**Samples:** 5 samples of 8 mL
**Sample Properties:** Platelet-depleted blood (ACD)
**Max. number of sample sets:** 1
**Additional Information:**
It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).

**EQAS/PT Experts:**
Dr.-Ing. Nils Lachmann

**Deputy EQAS/PT Experts:**
Sükran Zaralioglu

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HLA Typing of serological equivalents of class I (HLA A, B) and/or HLA class II (HLA-DR, DQ) by serological and/or molecular means on the level of serological equivalents.

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | Apr. | Aug. | | Dec. |
| Registration Deadline: | 26-11-13 | | 27-01-15 | 27-05-14 | | 27-09-10 |
| Sample Shipment: | 27-01-11 | | 27-03-15 | 27-07-12 | | 27-11-08 |
| Closing Date: | 27-02-05 | | 27-04-09 | 27-08-06 | | 27-12-03 |

## HLA Diagnostics - HLA-B27 Determination 440

**EQAS/PT Properties**
**Samples:** 5 blood samples of 3 mL
**Sample Properties:** Whole blood (EDTA), not stabilized
**Max. number of sample sets:** 1
**Additional Information:**
Determination of HLA-B27 by molecular and/or serological means

**EQAS/PT Experts:**
Dr.-Ing. Nils Lachmann

**Deputy EQAS/PT Experts:**
Sükran Zaralioglu

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Determination of HLA-B27

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | Apr. | Aug. | | Dec. |
| Registration Deadline: | 26-11-13 | | 27-01-15 | 27-05-14 | | 27-09-10 |
| Sample Shipment: | 27-01-11 | | 27-03-15 | 27-07-12 | | 27-11-08 |
| Closing Date: | 27-02-05 | | 27-04-09 | 27-08-06 | | 27-12-03 |

## HLA Diagnostics - HLA-DQ 772

**EQAS/PT Properties**
**Samples:** 2 samples of 1-1.5 ml
**Sample Properties:** Whole blood (EDTA), not stabilized

**EQAS/PT Experts:**
Dr.-Ing. Nils Lachmann

**Deputy EQAS/PT Experts:**
Sükran Zaralioglu

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** not applicable
**Parameter / Analytes:**

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HLA DQA1*05 HLA DQB1*02 HLA DQB1*03:02

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | Apr. | | | Dec. |
| Registration Deadline: | | | 27-01-15 | | | 27-09-10 |
| Sample Shipment: | | | 27-03-15 | | | 27-11-08 |
| Closing Date: | | | 27-04-09 | | | 27-12-03 |

## HLA Diagnostics - Low resolution, molecular HLA typing class I and II 442

**EQAS/PT Properties**
**Samples:** 5 samples of 7 mL
**Sample Properties:** Whole blood (ACD), not stabilized
**Max. number of sample sets:** 1
**Additional Information:**
- Molecular HLA typing class I and II in low resolution (1-field).
- It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).

**EQAS/PT Experts:**
Dr.-Ing. Nils Lachmann

**Deputy EQAS/PT Experts:**
Sükran Zaralioglu

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HLA-A DNA Typing (low resolution)
HLA-B DNA Typing (low resolution)
HLA-C DNA Typing (low resolution)
HLA-DPA1 DNA Typing (low resolution)
HLA-DPB1 DNA Typing (low resolution)
HLA-DQA1 DNA Typing (low resolution)
HLA-DQB1 DNA typing (low resolution)
HLA-DRB1 DNA typing (low resolution)
HLA-DRB3,4,5 DNA typing (low resolution)
HLA-DRB3,4,5 DNA typing (phenotypic)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | Apr. | Aug. | | Dec. |
| Registration Deadline: | 26-11-13 | | 27-01-15 | 27-05-14 | | 27-09-10 |
| Sample Shipment: | 27-01-11 | | 27-03-15 | 27-07-12 | | 27-11-08 |
| Closing Date: | 27-02-05 | | 27-04-09 | 27-08-06 | | 27-12-03 |

## Immunophenotyping

### Immunophenotyping - Cellular Immunodeficiency Diagnostic 651

**EQAS/PT Properties**
**Samples:** 2 samples of 4 mL
**Sample Properties:** Whole blood (EDTA), not stabilized
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. med. Ulrich Sack

**Deputy EQAS/PT Experts:**
Dr. Uwe Kölsch

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Analysis based on the case description for T-, NK-, and B-cell subpopulations, as well as monocytes and granulocytes, including naive, memory, effector, and activated T cells, TH1/2, TH17, and regulatory cells, with the markers CD11a, CD18, HLA-DR, TCR alpha/beta, TCR gamma/delta, CD45RA/CD45RO, CCR7, and CD31.
- Possible B-cell subpopulations: transitional, naive, non-switched, switched, IgM-only, IgA+, IgG+, CD21low/CD38low, and plasmablasts.
- NK subpopulations based on expression of: CD94, Nkp30, Nkp44, Nkp46, CD56 bright, cytolytic NK, NK-like
- Monocytes: classical/non-classical monocytes
- Granulocytes: expression of CD11a, CD18 on granulocytes
- TCR Vß typing
- Only individual markers or subsets of these markers may also be used.

**Shipping Information:**
- Shipping not cooled
- Overnight delivery
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-05-28 | | | 27-08-13<br>27-10-12<br>27-10-22 |

## Functional Immunologic Assays

### Interferon Gamma Release Assay (IGRA) 650

**EQAS/PT Properties**
**Samples:** 2 samples of approx. 4 ml
**Sample Properties:** Whole blood (Heparin), not stabilized
**Max. number of sample sets:** 1
**Additional Information:**
- Due to high demand three different sets of samples will be sent (Gr. 650 = Gr. 950 or Gr. 951). INSTAND e. V. reassigns the group number you receive before each EQAS/PT shipment. All groups are equivalent!
- Please note: This EQA scheme is based on stimulation with Mycobacterium Tuberculosis antigens and is designed for participants who use a TB Elispot (e.g., T-SPOT®.TB) or a test with pre-stimulation in a tube (e.g. QuantiFeron®-TB Gold Plus) or RIDA-SCREEN® TB Assay.

**EQAS/PT Experts:**
Prof. Dr. med. Ulrich Sack

**Deputy EQAS/PT Experts:**
Dr. Uwe Kölsch

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Interferon Gamma Release Assay (IGRA)

**Shipping Information:**
- Shipping not cooled
- Overnight delivery
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 24 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-19<br>27-05-18<br>27-06-04 | | | 27-08-13<br>27-10-12<br>27-10-29 |

## Lymphozyte Transformation Test (LTT) 656

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Whole blood (Heparin), not stabilized
**Max. number of sample sets:** 1
**Additional Information:**
This EQA scheme is intended for laboratories that perform lymphocyte proliferation assays to clarify lymphocyte dysfunction. Proliferation can be measured with cell tracer dyes, by 3H-thymidine incorporation or by MTT. Stimulation indices (3H-thymidine method and MTT) or proliferation indices (flow cytometric methods) and an evaluation can be reported.

**EQAS/PT Experts:**
Dr. Uwe Kölsch

**Deputy EQAS/PT Experts:**
Prof. Dr. Dr. med. Fabian Hauck

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Proliferation index after stimulation with PHA, PMA/ionomycin, anti-CD3 and anti-CD3/anti-CD28
- Evaluation.

**Shipping Information:**
- Shipping not cooled
- Shipping within the DACH region only
- Overnight delivery. The samples should ideally be stimulated and measured within 24-36 h after blood collection. The stimulants are not sent with the samples!
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-12<br>27-05-10<br>27-06-04 | | | 27-07-30<br>27-09-27<br>27-10-22 |

## NK-/ and T cell cytotoxicity NEW! 657

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Whole blood (Heparin) not stabilized
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Dr. Uwe Kölsch

**Deputy EQAS/PT Experts:**
Dr. rer. physiol. Eva-Maria Jacobsen

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
CD107a expression or lysis indices and evaluation

**Shipping Information:**
- Shipping not cooled
- Shipping is only available in the DACH- region
  Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-12<br>27-05-10<br>27-06-04 | | | 27-07-30<br>27-09-27<br>27-10-22 |

## Oxidative Burst / Phagocytosis Test 654

**EQAS/PT Properties**
**Samples:** 4 samples of 2 ml
**Sample Properties:** Whole blood (Heparin), not stabilized
**Max. number of sample sets:** 1
**Additional Information:**
- The samples should ideally be stimulated and measured within 24-36 h after blood collection. The stimulants are not sent with the samples!
- This EQA scheme is intended for laboratories that determine oxygen radical production in granulocytes to clarify a granulocyte dysfunction.

**EQAS/PT Experts:**
Dr. Uwe Kölsch

**Deputy EQAS/PT Experts:**
Prof. Dr. Dr. med. Fabian Hauck

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Oxygen radical production in granulocytes after stimulation with PMA and with E. coli (also individually) Stimulation index (DHR) and evaluation (DHR/ NBT) as well as phagocytosis of opsonised E. coli in granulocytes Stimulation index and evaluation.

**Shipping Information:**
- Shipping not cooled
- Overnight delivery
- Shipping within the DACH region only
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-12<br>27-05-10<br>27-06-04 | | | 27-07-30<br>27-09-27<br>27-10-22 |

# Complement Analysis

## Complement Analysis - Anti-C1 Inhibitor Autoantibody 250

**EQAS/PT Properties**
**Samples:** 2 samples of 300 µl
**Sample Properties:** Serum
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. Zoltan Prohaszka

**Deputy EQAS/PT Experts:**
Prof. Dr. Michael Kirschfink

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Auto-anti-C1 inhibitor IgA (qualitative)
Auto-anti-C1 inhibitor IgG (qualitative)
Auto-anti-C1 inhibitor IgM (qualitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Complement Analysis - Anti-C1q Autoantibody 245

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 300 µl<br>**Sample Properties:** Serum<br>**Max. number of sample sets:** 1 | Prof. Dr. Zoltan Prohaszka<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Michael Kirschfink |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Auto-anti C1q (IgG)<br>Auto-anti C1q (IgG) (qualitative) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-26 | | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Complement Analysis - Anti-factor H (FH) Autoantibody 249

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 300 µl<br>**Sample Properties:** Serum<br>**Max. number of sample sets:** 1 | Prof. Dr. Zoltan Prohaszka<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Michael Kirschfink |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Auto-anti FH-(qualitative) Auto-anti-FH (quantitative) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Complement Analysis - C3 - Nephritic Factor 248

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 300 µl<br>**Sample Properties:** Lyophilised serum<br>**Max. number of sample sets:** 1 | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. Zoltan Prohaszka<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Michael Kirschfink |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>C3-nephritic factor (qualitative) | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Complement Analysis - Complement activation products 247

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 300 µl<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 3<br>**Additional Information:**<br>Participation with one parameter (e.g. sC5b-9) possible | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. Zoltan Prohaszka<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Michael Kirschfink |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>C3a, C3d, Bb, sC5b-9 | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | | 27-08-06<br>27-10-05<br>27-11-05 |

## Complement Analysis - Functions (F) and Proteins (P) 246

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised serum<br>**Max. number of sample sets:** 3<br>**Additional Information:**<br>Analysis of the total function of the 3 complement activation pathways (classical, alternative and lectin pathways) either by functional ELISA (WIELISA), by haemolytic (CH50, AH50) or by liposome-based assay (classical pathway). Participation with one parameter (e.g. CH50) is possible. | Prof. Dr. Zoltan Prohaszka<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Michael Kirschfink |

| Requirement for EQAS/PT according to Rili-BÄK: not applicable | Not subject to Rili-BÄK<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Classical pathway (F), Alternative pathway (F), Lectin pathway (FH), C1q, (P) C4 (P), C3 (P), C1 Inhibitor (F) (P), Factor H (P), Factor I (P) |
|---|---|
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-26 | | | | 27-08-06<br>27-10-05<br>27-11-05 |

# TRANSFUSION MEDICINE

## Immunohematology

### Immunohaematology 01 — 231

**EQAS/PT Properties**
**Samples:** 2 x 5 ml serum / 2 x 5 ml erythrocytes suspension
**Sample Properties:** Serum + Erythrocytes suspension

**EQAS/PT Experts:**
PD Dr. med. Franz F. Wagner

**Deputy EQAS/PT Experts:**
Dr. Nathalie Weiss

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Kell antigen

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | July | | Oct. |
| Registration Deadline: | | 26-11-27 | 27-01-29 | 27-03-26 | | 27-07-09 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | 27-07-09 | | 27-10-22 |

### Immunohaematology 02 (incl. Antibody Identification) — 232

**EQAS/PT Properties**
**Samples:** 2 x 5 ml serum / 2 x 3 ml serum / 2 x 5 ml erythrocytes suspension
**Sample Properties:** Serum + Erythrocytes suspension

**EQAS/PT Experts:**
PD Dr. med. Franz F. Wagner

**Deputy EQAS/PT Experts:**
Dr. Nathalie Weiss

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Kell antigen
Antibody identification
AB quantitation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | July | | Oct. |
| Registration Deadline: | | 26-11-27 | 27-01-29 | 27-03-26 | | 27-07-09 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | 27-07-09 | | 27-10-22 |

## Immunohaematology 03 - Platelet Immunology 233

**EQAS/PT Properties**
**Samples:** 3 serum samples, 2 samples of DNA, 2 samples of platelet suspension
**Sample Properties:** Serum + Cell suspension + DNA
**Max. number of sample sets:** 1
**Additional Information:**
This EQA scheme is intended for laboratories which are able to detect platelet alloantibodies and antigens. The EQA scheme 235 - Immunohaematology 06 - Molecular Diagnostic was designed for laboratories which only want to carry out platelet antigen genotyping.

**EQAS/PT Experts:**
Prof. Dr. med. Ulrich Sachs

**Deputy EQAS/PT Experts:**
Dr. med. Hartmut Kroll

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Platelet antibodies
Platelet antigens

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Immunohaematology 04 - Granulocyte Immunology 234

**EQAS/PT Properties**
**Samples:** 3 samples of plasma, 2 samples of DNA
**Sample Properties:** Plasma + DNA
**Max. number of sample sets:** 1
**Additional Information:**
- This EQA scheme includes all HNA specifications. It is dedicated to laboratories which are able to detect granulocyte alloantibodies and antigens. The EQA scheme - 235 Immunohaematology 06 - Molecular Diagnostic was designed for laboratories which only want to perform HNA genotyping.
- Because of the complicated preparation of the samples, INSTAND e.V. reserves the right to no longer supply laboratories with EQAS/PT samples, which have repeatedly not sent back any results.

**EQAS/PT Experts:**
Dr. Torsten J. Schulze

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HNA/granulocyte antibodies
HNA/granulocyte (neutrophil) antigens

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Immunohaematology 05 - Machine-Based Analysis 237

**EQAS/PT Properties**
**Samples:** 2 samples of 5 mL
**Sample Properties:** Whole blood

**EQAS/PT Experts:**
PD Dr. med. Franz F. Wagner

**Deputy EQAS/PT Experts:**
Dr. Nathalie Weiss

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Kell antigen
Antibody identification

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | July | | Oct. |
| Registration Deadline: | | 26-11-27 | 27-01-29 | 27-03-26 | | 27-07-09 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | 27-07-09 | | 27-10-22 |

## Immunohaematology 07 - Machine-Based Analysis (incl. AB Quantitation) 238

**EQAS/PT Properties**
**Samples:** 2 x 5 ml whole blood + 2 x 5 ml serum
**Sample Properties:** Whole blood + Serum

**EQAS/PT Experts:**
PD Dr. med. Franz F. Wagner

**Deputy EQAS/PT Experts:**
Dr. Nathalie Weiss

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
A B 0 - Typing
Rh (D) Factor
A - Subtyping
Rh - Subtyping (without Cw)
Antibody Screening
Direct Antiglobulin Test

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Kell antigen
Antibody identification
AB quantitation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | July | | Oct. |
| Registration Deadline: | | 26-11-27 | 27-01-29 | 27-03-26 | | 27-07-09 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | 27-07-09 | | 27-10-22 |

## Immunohaematology 08 - Compatibility Testing (Blood Transfusion) 239

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** serum + erythrocytes suspension<br>**Sample Properties:** serum + erythrocytes suspension<br>**Max. number of sample sets:** 1 | PD Dr. med. Franz F. Wagner<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Nathalie Weiss |

| Requirement for EQAS/PT according to Rili-BÄK: quarterly | Not subject to Rili-BÄK |
|---|---|
| **Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>Antibody Screening | **Validity Certificate:** 12 months / 12 months<br>**Parameter / Analytes:**<br>Blood type check (AB0 without isoagglutinins, RhD)<br>Cross-match |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | July | | Oct. |
| **Registration Deadline:** | | 26-11-27 | 27-01-29 | 27-03-26 | | 27-07-09 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | 27-06-22 | | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | 27-07-09 | | 27-10-22 |

# CLINICAL CHEMISTRY

## Haematology

## CD19 CAR-T-Cells (quantitative) 822

**EQAS/PT Properties**
**Samples:** 2 samples á 2 ml
**Sample Properties:** Whole blood(EDTA), stabilized
**Max. number of sample sets:** 1
**Additional Information:**
- The number of participants is currently limited to a maximum of 40 per term. Note: The planned date may be postponed if donor availability cannot be realised at short notice.
- Due to the time-consuming nature of sample preparation, INSTAND reserves the right to discontinue supplying interlaboratory comparison samples to laboratories that have repeatedly failed to submit results.

**EQAS/PT Experts:**
Prof. Dr. Marion Subklewe

**Deputy EQAS/PT Experts:**
Dr. Gerulf Hänel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
CD19 CAR-T-cells

**Shipping Information:**
- Shipping not cooled
- Shipping to the DACH region only.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-07 | | | 27-08-27<br>27-10-26<br>27-11-05 |

## CLL-MRD Immunophenotyping 820

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Whole blood (EDTA), not stabilized
**Max. number of sample sets:** 1
**Additional Information:**
- To successfully participate in the EQAS/PT, your method must have a minimum limit of detection (LoD) of 0.01%.
- Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.
- Because of the complicated preparation of the samples, INSTAND e.V. reserves the right to no longer supply laboratories with EQAS/PT samples, which have repeatedly not sent back any results.

**EQAS/PT Experts:**
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. Michaela Patz

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
% CLL-cells
Rating of MRD

**Shipping Information:**
- Cooled shipping
- Cooled shipping to Germany and Austria only.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Feb. | | | Sep. | |
| Registration Deadline: | | 26-12-04 | | | 27-07-23 | |
| Sample Shipment: | | 27-02-02 | | | 27-09-21 | |
| Closing Date: | | 27-02-05 | | | 27-09-24 | |

## Haematology - Blood Cell Count 211

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Stabilized control blood
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Analysis of Haemoglobin with HemoCue systems is possible!

POCT +

**EQAS/PT Experts:**
Dr. med. Benedikt Lohr

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Nebe

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Erythrocytes
Haemoglobin
Haematocrit centrif.
Leucocytes
Haematocrit el.count
Thrombocytes

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
MCV

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Haematology - Blood Cell Count - QBC System 209

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Whole blood (EDTA), not stabilized
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- This EQA scheme is only for participants with hematology systems based on QBC (Quantitative Buffy Coat) technology.

**EQAS/PT Experts:**
Dr. med. Benedikt Lohr

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Nebe

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Haematocrit centrif.
Haemoglobin
Leucocytes
Thrombocytes

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Cooled shipping
Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Sep. | Oct. |
| **Registration Deadline:** | 26-11-13 | | 27-03-12 | | 27-07-09 | 27-08-13 |
| **Sample Shipment:** | 27-01-12 | | 27-05-11 | | 27-09-07 | 27-10-12 |
| **Closing Date:** | 27-01-22 | | 27-05-21 | | 27-09-17 | 27-10-22 |

## Haematology - Blood Smear Analysis 212

**EQAS/PT Properties**
**Samples:** 2 peripheral blood smears
**Sample Properties:** Slides
**Max. number of sample sets:** 1
**Additional Information:**
plus one special case for internal training purposes

**EQAS/PT Experts:**
Prof. Dr. med. Dr. phil. Torsten Haferlach

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Wolfgang Kern

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Blood Cell Differentiation in %

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Diagnostic comment
- Morphology of erythrocytes, leucocytes and platelets

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| **Registration Deadline:** | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| **Closing Date:** | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Haematology - Bone Marrow Cytology 218

**EQAS/PT Properties**
**Samples:** Digital slides in a virtual microscope of bone marrow aspirate
**Sample Properties:** Digital slides
**Max. number of sample sets:** 1
**Additional Information:**
Available online in digital microscopy! - No shipment!

**EQAS/PT Experts:**
Prof. Dr. med. Dr. phil. Torsten Haferlach

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Winfried Gassmann

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Evaluation and diagnosis

**Shipping Information:**
No shipment!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 27-02-19 | | | 27-08-06 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

## Haematology - Differential Blood Count (Machine-Based Analysis) 612

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Whole blood (EDTA), not stabilized
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Due to high demand, two different sets of samples will be sent (Gr. 612 = Gr. 912). The group number you receive will be set by INSTAND e.V. before each EQAS shipment. Both groups are equivalent.

**EQAS/PT Experts:**
Dr. med. Benedikt Lohr

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Nebe

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Erythrocytes
Haematocrit centrif.
Haematocrit el.count
Haemoglobin
Leucocytes
Thrombocytes

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Basophilic Granulocytes
Eosinophilic Granulocytes
Lymphocytes
MCV
Monocytes
Neutrophilic Granulocytes

**Shipping Information:**
Cooled shipping
Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Sep. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-03-12 | | 27-07-09 | 27-08-13 |
| Sample Shipment: | 27-01-12 | | 27-05-11 | | 27-09-07 | 27-10-12 |
| Closing Date: | 27-01-22 | | 27-05-21 | | 27-09-17 | 27-10-22 |

## Haematology - Free Haemoglobin 236

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Lyophilised erythrocytes preparation
**Additional Information:**
The samples are not suitable for methods based on photometric measurements of the oxyhaemoglobin peaks around 540 nm and/or 577 nm. The Harboe method (415 nm peak) is suitable. The quantitative hemolysis index from automated chemistry analysers can also provide a suitable result.

**EQAS/PT Experts:**
Prof. Dr. med. Nicolas von Ahsen

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Haemoglobin (free)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haematology - Haemoglobinopathies 210

**EQAS/PT Properties**
**Samples:** 2 samples of 0.8 mL
**Sample Properties:** Whole blood, stabilized
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Dr. med. Claudia Frömmel

**Deputy EQAS/PT Experts:**
Dr. Adriana Méndez

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Hemoglobin analysis with evaluation and presumptive diagnosis

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-04-09 | | | 27-08-13 |
| Sample Shipment: | | | 27-06-08 | | | 27-10-12 |
| Closing Date: | | | 27-06-25 | | | 27-10-29 |

## Haematology - Immunophenotyping 214

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Whole blood (EDTA), not stabilized

**EQAS/PT Experts:**
Dr. med. Richard Schabath

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Wolfgang Kern

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Immunophenotyping of leukamias/lymphomas
Immunophenotyping of hematologic neoplasms

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-03-12 | 27-04-30 | | 27-08-13 |
| Sample Shipment: | 27-01-12 | | 27-05-11 | 27-06-29 | | 27-10-12 |
| Closing Date: | 27-01-22 | | 27-05-21 | 27-07-09 | | 27-10-22 |

## Haematology - Lymphocyte differentiation 213

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Whole blood (EDTA), not stabilized

**EQAS/PT Experts:**
Prof. Dr. med. Wolfgang Kern

**Deputy EQAS/PT Experts:**
Dr. med. Richard Schabath

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Lymphocyte-immunophenotyping - peripheral blood:
CD4 pos. lymphocytes with CD3-expression (%)
CD8 pos. lymphocytes with CD3-expression (%)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Lymphocyte-immunophenotyping - peripheral blood:
B-Lymphocytes
CD4 pos. lymphocytes with CD3-expression (/nl)
CD8 pos. lymphocytes with CD3-expression (/nl)
Leucocytes
Lymphocytes
NK-cells without CD3-expression
T-lymphocytes

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | | July | | Oct. |
| Registration Deadline: | 26-11-13 | 27-01-15 | | 27-04-30 | | 27-08-13 |
| Sample Shipment: | 27-01-12 | 27-03-16 | | 27-06-29 | | 27-10-12 |
| Closing Date: | 27-01-22 | 27-03-26 | | 27-07-09 | | 27-10-22 |

## Haematology - PNH Diagnostics 616

**EQAS/PT Properties**
**Samples:** 2 samples of 1.5 mL
**Sample Properties:** Whole blood (EDTA), not stabilized
**Additional Information:**
Due to high demand 3 different sets of samples will be sent (No. 616 = No. 916 or No. 917). The group number you receive will be set by INSTAND e.V. before each EQAS shipment. All groups are equivalent!

**EQAS/PT Experts:**
Dr. med. Britta Höchsmann

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Nebe

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
GPI-deficient cells

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 56 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-03-12 | | | 27-07-23 |
| Sample Shipment: | | | 27-05-11 | | | 27-09-21 |
| Closing Date: | | | 27-05-28 | | | 27-10-08 |

## Haematology - Reticulocyte Analysis Machine-Based Analysis 216

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Whole blood (EDTA), not stabilized

**EQAS/PT Experts:**
Prof. Dr. med. Kai Gutensohn

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Nebe

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Concentration of Hb in reticulocytes
Immature reticulocytes
Reticulated Platelets
Reticulocyte production Index (RPI)
Reticulocytes
Reticulocytes concentration

**Shipping Information:**
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Sep. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-03-12 | | 27-07-09 | 27-08-13 |
| Sample Shipment: | 27-01-12 | | 27-05-11 | | 27-09-07 | 27-10-12 |
| Closing Date: | 27-01-22 | | 27-05-21 | | 27-09-17 | 27-10-22 |

## Haematology - Reticulocyte Analysis Microscopy 215

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 blood smears for microscopic analysis<br>**Sample Properties:** Slides | Prof. Dr. med. Kai Gutensohn<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Thomas Nebe |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Reticulocytes |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | | July | | |
| Registration Deadline: | 26-11-13 | | | 27-04-30 | | |
| Sample Shipment: | 27-01-12 | | | 27-06-29 | | |
| Closing Date: | 27-01-22 | | | 27-07-09 | | |

## Haematology - Stem/Progenitor Cells (CD34) 217

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 mL<br>**Sample Properties:** Whole blood (EDTA), not stabilized | Prof. Dr. med. Kai Gutensohn<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Andreas Humpe |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Flow cytometric determination of CD34+ stem and progenitor cells and viability measurements |
| **Shipping Information:**<br>• Cooled shipping<br>• Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours! | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | | July | Sep. | |
| Registration Deadline: | 26-11-13 | 27-01-15 | | 27-04-30 | 27-07-09 | |
| Sample Shipment: | 27-01-12 | 27-03-16 | | 27-06-29 | 27-09-07 | |
| Closing Date: | 27-01-22 | 27-03-26 | | 27-07-09 | 27-09-17 | |

## Haematology - Stem/Progenitor Cells (CD34) (stabilized) 660

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Whole blood(EDTA), stabilized
**Additional Information:**
For determination of CD34+ events plus vital CD34+ events, see Group 217 (native sample material).

**EQAS/PT Experts:**
Prof. Dr. med. Kai Gutensohn

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Andreas Humpe

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Flow cytometric analysis of stem and progenitor cells (CD34) without vitality measurement.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | | July | Sep. | |
| Registration Deadline: | 26-11-13 | 27-01-15 | | 27-04-30 | 27-07-09 | |
| Sample Shipment: | 27-01-12 | 27-03-16 | | 27-06-29 | 27-09-07 | |
| Closing Date: | 27-01-22 | 27-03-26 | | 27-07-09 | 27-09-17 | |

## Haematology - T, B and NK cells in cellular products (flow cytometry) 617

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Cellular products (CPD )

**EQAS/PT Experts:**
Prof. Dr. med. Andreas Humpe

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Kai Gutensohn

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
For flow cytometric determination of T, B and NK cells in cellular products only

**Shipping Information:**
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-03-12 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-11 | | | 27-10-12 |
| Closing Date: | | | 27-05-21 | | | 27-10-22 |

## Hemostaseology

### Haemostasis - Apixaban 504

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Apixaban | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

### Haemostasis - Argatroban 230

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Argatroban Thrombin Time aPTT | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | **Jan.** | | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - AT, Protein C, Protein S, C1-Inhibitor 225

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Inhibitors (AT, PC, PS)
Antithrombin
C1-Inhibitor
Free Protein S immun. (conc.)
Free Protein S funct. (act.)
Protein S total
Total Protein C

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - Compact 285

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Prothrombintime (PT, INR)
Prothrombintime (PT, Quick)
aPTT

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Antithrombin
D-Dimer (quantitative)
Fibrinogen
Thrombin Time

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - D-Dimer 226

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
D-Dimer (qualitative) D-Dimer (quantitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - Dabigatran 502

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Dabigatran

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Haemostasis - Edoxaban 505

| EQAS/PT Properties<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | | | | | | EQAS/PT Experts:<br>Prof. Dr. med. Michael Spannagl<br><br>Deputy EQAS/PT Experts:<br>Dr. rer. biol. hum. Andrea Dick |
|---|---|---|---|---|---|---|
| Requirement for EQAS/PT according to Rili-BÄK: not applicable | | | Not subject to Rili-BÄK<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Edoxaban | | | |
| Shipping Information:<br>Shipping not cooled | | | Safety Information:<br>Process as patient sample material | | | |
| Dates | Q1 | | Q2 | Q3 | | Q4 |
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - Emicizumab 506

| EQAS/PT Properties<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | | | | | | EQAS/PT Experts:<br>Prof. Dr. med. Michael Spannagl<br><br>Deputy EQAS/PT Experts:<br>Dr. rer. biol. hum. Andrea Dick |
|---|---|---|---|---|---|---|
| Requirement for EQAS/PT according to Rili-BÄK: not applicable | | | Not subject to Rili-BÄK<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Emicizumab | | | |
| Shipping Information:<br>Shipping not cooled | | | Safety Information:<br>Process as patient sample material | | | |
| Dates | Q1 | | Q2 | Q3 | | Q4 |
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - Factor II, V, VII,X 223

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | **EQAS/PT Experts:**<br>Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Single factors A (via PT): factor II, factor V, factor VII, factor X |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | **Jan.** | | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - Factor IX, XI, XII, XIII 224

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | **EQAS/PT Experts:**<br>Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Single factors B (via APTT, etc.): factor IX, factor XI, factor XII, factor XIII |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | **Jan.** | | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - Factor VIII, WF 227

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Factor VIII akt.
Willebrand fact. Ag
Willebrand fact. CBA
Willebrand fact. RiCof
Willebrand fact. activity

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - FIB, TZ, FSP 222

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Global test II: TZ, FIB, FSP screening FSP screening, using batroxobin time or heparin-independent thrombin time

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - Fondaparinux 501

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Fondaparinux |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - Functional APC Resistance 288

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma | Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>APC resistance Diagnostic comments |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - LMW Heparin 281

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | **EQAS/PT Experts:**<br>Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>LMW Heparin |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | **Jan.** | | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:** | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - Orgaran 282

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | **EQAS/PT Experts:**<br>Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Orgaran |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | **Jan.** | | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:** | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - POCT 286

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml; Starting reagent of 1 ml
**Sample Properties:** Whole blood (Citrat), not stabilized
**Max. number of sample sets:** 2
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Please note the short completion time!
- Due to different detection techniques that are applied, not every sample material can be guarenteed to be suitable for every POCT machine. The machines microINR by Axon Lab as well as Xprecia Stride by Siemens are not suitable for this EQAS!

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. med. Georg Wittmann

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Prothrombintime (PT, INR) Prothrombintime (PT, Quick)
aPTT

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
ACT

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | June | | Sep. | Nov. |
| Registration Deadline: | 26-11-13 | | 27-04-16 | | 27-07-30 | 27-09-10 |
| Sample Shipment: | 27-01-12 | | 27-06-15 | | 27-09-28 | 27-11-09 |
| Closing Date: | 27-01-14 | | 27-06-17 | | 27-09-30 | 27-11-11 |

## Haemostasis - PT, INR, aPTT 221

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2
**Additonal Information:**
No. 221 is only for measuring in plasma samples. For measurements of whole blood in POCT systems, please register for No. 286!

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Prothrombintime (PT, INR) Prothrombintime (PT, Quick)
aPTT

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Haemostasis - Rivaroxaban 503

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Rivaroxaban |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - ROTEM Sigma 509

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 x 3 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma<br>**Max. number of sample sets:** 2 | Prof. Dr. med. Michael Spannagl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. biol. hum. Andrea Dick |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Extrinsic: A20 [mm] — Intrinsic: A20 [mm]<br>Extrinsic: CT[s] r[min] — Intrinsic: CT[s] r[min]<br>Extrinsic: MCF [mm] — Intrinsic: MCF [mm] |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Haemostasis - TEG/ROTEM 283

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Extrinsic: A20 [mm]
Extrinsic: CT[s] r[min]
Extrinsic: MCF [mm]
Intrinsic: A20 [mm]
Intrinsic: CT[s] r[min]
Intrinsic: MCF [mm]

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Haemostasis - UF Heparin 280

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma
**Max. number of sample sets:** 2

**EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Deputy EQAS/PT Experts:**
Dr. rer. biol. hum. Andrea Dick

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Thrombin Time UF Heparin aPTT

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Hormones

### Adrenal Gland / Pituitary 298

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Peter B. Luppa<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>1-39 ACTH, DHEA-S, Prolactin<br>DHEA, HGH |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Aug. | Oct. |
| **Registration Deadline:** | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

### Aldosterone 304

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Peter B. Luppa<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Aldosterone |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Calcium Metabolism / Special Thyroid 301

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Dr. med. Jürgen Durner<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Peter B. Luppa |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>1-84 PTH Calcitonin Thyreoglobulin |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| **Registration Deadline:** | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| **Closing Date:** | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Fertility 297

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Thomas Lutz |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>FSH | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>LH anti-Mullerian hormone |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Aug. | Oct. |
| **Registration Deadline:** | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Gravidity - 1st Trimester Screening 305

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 mL<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Thomas Lutz |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>Free beta-chain hCG | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PAPP-A |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | **Mar.** | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:** | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Gravidity - 2nd Trimester Screening 306

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 mL<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Thomas Lutz |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>AFP hCG intact hCG intact +beta-hCG free | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | **Mar.** | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:** | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Hematopoetic Growth Factors 626

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised serum<br>**Max. number of sample sets:** 1 | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. med. Folker Wenzel<br><br>**Deputy EQAS/PT Experts:**<br>M.Sc. Luisa Toll |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Erythropoietin Thrombopoietin | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Pancreas/Gastrointestinal Tract 300

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised serum | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Dr. med. Jürgen Durner<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Peter B. Luppa |
| **Requirement for EQAS/PT according to Rili-BÄK:**<br>**Validity Certificate:** not applicable<br>**Parameter / Analytes:** | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>C-Peptide Glucagon Pro-insuline<br>Gastrin Insulin | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | **Jan.** | | **May** | **July** | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | 27-04-23<br>27-06-22<br>27-07-09 | | 27-08-06<br>27-10-05<br>27-10-22 |

## Preeclampsia Marker 625

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised serum<br>**Max. number of sample sets:** 1 | Prof. Dr. med. Peter B. Luppa<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PlGF (placental growth factor)<br>sFLT-1 (soluble fms-like tyrosine kinase-1) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| **Registration Deadline:** | | | 27-02-26 | | | 27-08-06 |
| **Sample Shipment:** | | | 27-04-27 | | | 27-10-05 |
| **Closing Date:** | | | 27-05-14 | | | 27-10-22 |

## Steroid Hormones, Thyroid Gland 302

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2 ml<br>**Sample Properties:** Liquid serum | Prof. Dr. med. Peter B. Luppa<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>17-beta-Estradiol, Testosterone<br>Cortisol, free T3 (f-triiodothyronine)<br>Progesterone, free T4 (f-thyroxine)<br>TSH | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>T3 total (triiodothyronine), T4 total (thyroxine) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Thyroid Gland Antibodies 295

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Peter B. Luppa

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
TRAK/THYBIA, anti-TPO, anti-Microsome, anti-Thyroglobuline

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Thyroid Hormones 294

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Peter B. Luppa

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
TSH, free T3 (f-triiodothyronine), free T4 (f-thyroxine)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
T3 total (triiodothyronine), T4 total (thyroxine)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Virilization 309

| EQAS/PT Properties<br>**Samples:** 2 samples of 1 mL<br>**Sample Properties:** Lyophilised serum | | | | | | EQAS/PT Experts:<br>Prof. Dr. med. Folker Wenzel<br><br>Deputy EQAS/PT Experts:<br>Dr. med. Thomas Lutz |
|---|---|---|---|---|---|---|
| Requirement for EQAS/PT according to Rili-BÄK: not applicable | | | Not subject to Rili-BÄK<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>17-Hydroxyprogesterone Androstendion | | | |
| Shipping Information:<br>Shipping not cooled | | | Safety Information:<br>Process as patient sample material | | | |
| Dates | Q1 | | Q2 | Q3 | | Q4 |
| | | Mar. | May | | Aug. | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-12 | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

# IgG Subclasses

## IgG Subclasses 244

| EQAS/PT Properties<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised serum | | | | | | EQAS/PT Experts:<br>Prof. Dr. rer. nat. Ingo Schellenberg<br><br>Deputy EQAS/PT Experts:<br>Dr. rer. nat. Manfred Falck |
|---|---|---|---|---|---|---|
| Requirement for EQAS/PT according to Rili-BÄK: not applicable | | | Not subject to Rili-BÄK<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>IgG1 IgG2 IgG3 IgG4 | | | |
| Shipping Information:<br>Shipping not cooled | | | Safety Information:<br>Process as patient sample material | | | |
| Dates | Q1 | | Q2 | Q3 | | Q4 |
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Cardiac Marker

### Myocardial Markers 760

**EQAS/PT Properties**
**Samples:** 2 samples of 2 ml
**Sample Properties:** Lyophilised serum
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Please note that this EQA scheme is not suitable for methods that require whole blood.

**EQAS/PT Experts:**
Prof. Dr. med. Hannsjörg Baum

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Troponin I
Troponin T

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
CK-MB (activity)
CK-MB (mass)
CK-MB (qualitative)
Myoglobin
Myoglobin (qualitative)
NT-pro BNP
Troponin I (qualitative)
Troponin T (qualitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

### Myocardial Markers BNP 761

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Serum / Plasma
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 5 Days!

**EQAS/PT Experts:**
Prof. Dr. med. Hannsjörg Baum

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
BNP

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Conventional Clinical Chemistry

### ACE (Angiotensin-Converting-Enzyme) 630

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

**Deputy EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
ACE

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | July | | Oct. |
| Registration Deadline: | | 26-12-18 | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | 27-07-09 | | 27-10-22 |

### Amino Acid Analysis 710

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
M. Sc. Irina Keßel

**Deputy EQAS/PT Experts:**
Dr. Gernot Brauers

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

4-Hydroxyproline (free)
Alanine
Arginine
Argininosuccinic acid
Asparagine
Aspartic acid
Citrulline
Cystathionine
Cysteine-Homocysteine-disulfide
Cystine
Glutamic acid
Glutamine
Glycine
Histidine
Isoleucine
Leucine
Lysine
Methionine
Ornithine
Phenylalanine
Phosphoethanolamine
Proline
Sarcosine
Serine
Taurine
Threonine
Tryptophan
Tyrosine
Valine
allo-Isoleucine
alpha-Aminoadipic acid
b-Alanine proposed diagnosis

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Ammonia 118

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 ml<br>**Sample Properties:** Liquid controls | Dr. rer. nat. Manfred Falck<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Matthias Nauck |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Ammonia |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Biogenic Amines in Plasma 185

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 5 ml<br>**Sample Properties:** Lyophilised Plasma | Dr. rer. nat Heike Schneider<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Peter B. Luppa |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>3-Methoxytyramine, Dopamine, Epinephrine, Metanephrine, Norepinephrine, Normetanephrine, Serotonin |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

## Capillary Zone Electrophoresis 102

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Albumin (electrophoresis)
a1-Globulins
a2-Globulins
beta-Globulins
gamma-Globulins

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Clinical Chemistry - Conventional Analysis 100

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Deputy EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
AP
Albumin
Bilirubin
CK
Calcium
Chloride
Cholesterol
Creatinine
GGT
GOT (ASAT)
GPT (ALAT)
Glucose
IgA
IgG
IgM
LDH
Lactate
Lithium
Magnesium
Phosphate
Potassium
Protein
Sodium
Transferrine
Triglycerides
Urea
Uric Acid

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Acid phosphatase
Albumin (electrophoresis)
Aldolase
Bilirubin conj.
CHE
Copper
GLDH
HBDH
Iron
Iron binding capacity
Lipase
Osmolality
Pancreas amylase
Prostatic acid
Posphatase
alpha-Amylase
gamma-Globulins

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Ethanol 700

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2 ml<br>**Sample Properties:** Liquid serum | Prof. Dr. rer. nat. Ingo Schellenberg<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Manfred Falck |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>Ethanol | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Fructosamine 146

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 mL<br>**Sample Properties:** Lyophilised serum | Dr. med. Christoph Niederau<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Patricia Kaiser (PhD) |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Fructosamine |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## G6PDH (Glucose-6 Phosphate Dehydrogenase) 279

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Lyophilised whole blood | **EQAS/PT Experts:**<br>Dr. Patricia Kaiser (PhD)<br><br>**Deputy EQAS/PT Experts:**<br>Udo Kramer, Dipl.-Ing. (FH) |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>G6PDH |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | **Mar.** | | | **Aug.** | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 26-12-18<br>27-02-23<br>27-03-12 | | | 27-06-11<br>27-08-10<br>27-08-27 | |

## Gammopathies 243

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised plasma | **EQAS/PT Experts:**<br>Dr. med. Christoph Niederau<br><br>**Deputy EQAS/PT Experts:**<br>N.N |
| **Requirement for EQAS/PT according to Rili-BÄK:**<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>IgA IgG IgM | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Free light chains type kappa (quantitative)<br>Free light chains type lambda (quantitative)<br>Gammopathies<br>kappa/lambda (ratio) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | **Jan.** | | **May** | **July** | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | 27-04-23<br>27-06-22<br>27-07-09 | | 27-08-06<br>27-10-05<br>27-10-22 |

## Glucose - Conventional Analysis 111

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Glucose

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## HbA1c 145

**EQAS/PT Properties**
**Samples:** 2 samples of 0.3 ml
**Sample Properties:** Whole blood (EDTA), not stabilized
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- The samples must be measured within 2 days of receipt!

POCT +

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
HbA1c

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
- Cooled shipping
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Sep. | Oct. |
| Registration Deadline: | 26-11-20 | 27-01-15 | 27-03-12 | 27-05-07 | 27-07-09 | 27-08-20 |
| Sample Shipment: | 27-01-19 | 27-03-16 | 27-05-11 | 27-07-06 | 27-09-07 | 27-10-19 |
| Closing Date: | 27-01-22 | 27-03-19 | 27-05-14 | 27-07-09 | 27-09-10 | 27-10-22 |

## Lipids/Lipoproteins 151

**EQAS/PT Properties**
**Samples:** 2 samples of 3 mL
**Sample Properties:** Lyophilised serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Apolipoprotein A1, Cholesterol
Apolipoprotein B, Triglycerides

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Apolipoprotein E, Homocystein, Lp (a)
HDL-cholesterol, LDL-cholesterol, Phospholipids

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Markers of Ethanol Abuse - Carbohydrate-Deficient Transferrin (CDT) 750

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Peter B. Luppa

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Asialotransferrin
Asialotransferrin+Disialotransferrin
Disialotransferrin

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Aug. | Oct. |
| Registration Deadline: | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Plasma Cell Neoplasia-MRD Immunophenotyping 821

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Whole blood (EDTA), not stabilized
**Additional Information:**
- To successfully participate in the interlaboratory test, your method must have a minimum limit of detection (LoD) of 0.01%.
- Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.

**EQAS/PT Experts:**
Prof. Dr. Karl-Anton Kreuzer

**Deputy EQAS/PT Experts:**
Dr. Michaela Patz

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
% Plasma cell neoplasia-cells Rating of MRD

**Shipping Information:**
- Cooled shipping
- Cooled shipping to Germany and Austria only.
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | Apr. | | | Nov. |
| Registration Deadline: | | | 27-02-19 | | | 27-09-17 |
| Sample Shipment: | | | 27-04-20 | | | 27-11-16 |
| Closing Date: | | | 27-04-23 | | | 27-11-19 |

## Serum Proteins/Electrophoresis 141

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum
**Additional Information:**
Participants using the method capillary zone electrophoresis please order EQA scheme 102 - Capillary Zone Electrophoresis

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Albumin Protein

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Albumin (electrophoresis)
a1-Globulins
a2-Globulins
beta-Globulins
gamma-Globulins

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Cerebrospinal Fluid

### Cerebrospinal Fluid Analysis - CSF Ferritin 467

**EQAS/PT Properties**
**Samples:** 1 CSF sample of 1 ml
**Sample Properties:** CSF
**Max. number of sample sets:** 1
**Additional Information:**
Neurochemical diagnostics of hemorrhages

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Inga Zerr

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Ferritin - CSF

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | |

### Cerebrospinal Fluid Analysis - Dementia Markers 466

**EQAS/PT Properties**
**Samples:** 1 sample of 1 ml
**Sample Properties:** CSF
**Max. number of sample sets:** 1
**Additional Information:**
Neurochemical dementia diagnostics: Support for differential diagnosis of dementia by interpretation of the combined analysis of different marker proteins in CSF.

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Inga Zerr

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Amyloid ß Peptid 40 (Aß40)
Amyloid ß Peptid 42 (Aß42)
Amyloid ß Peptid Ratio (Aß 42/40)
PhosphoTau Protein (pTau)
Total Tau Protein (Tau)
p-Tau/ß-Amyloid (1-42) Ratio

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Cerebrospinal Fluid Analysis - Free light chains Kappa 468

**EQAS/PT Properties**
**Samples:** 2 sets = CSF + serum of 1 ml
**Sample Properties:** CSF + serum
**Max. number of sample sets:** 1
**Additional Information:**
Neurochemical diagnostics of inflammatory CNS processes

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Inga Zerr

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
kappa-free light chains - CSF
kappa-free light chains - serum

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | |
| Registration Deadline: | | | 27-02-26 | | | |
| Sample Shipment: | | | 27-04-27 | | | |
| Closing Date: | | | 27-05-14 | | | |

## Cerebrospinal Fluid Analysis - Lactate/ Glucose 464

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** CSF + Serum (Lyophilised)
**Max. number of sample sets:** 1
**Additional Information:**
Calculation of the CSF/serum ratio of glucose. Interpretation with respect to the reference range.

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Thomas Zimmermann

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Glucose - CSF Lactate

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Glucose quotient (CSF/Serum)
Glucose quotient - diagnostic comment
Interpretation of the report
Lactate - diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Cerebrospinal Fluid Analysis - MRZ Reaction 463

**EQAS/PT Properties**
**Samples:** 4 samples of 1ml
**Sample Properties:** Serum / Plasma
**Max. number of sample sets:** 1
**Additional Information:**
Detection of titers is not suitable. Evaluation as antibody index and interpretation of combined data.

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Thomas Zimmermann

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Antibodies against Measles viruses, Rubella viruses, Varicella zoster viruses, Herpes simplex viruses (1+2). Analysis of virus-specific antibodies in CSF and serum for detection of specific antibody response in central nervous system (MRZ reaction).

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Cerebrospinal Fluid Analysis - Neuroborreliosis 465

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5ml
**Sample Properties:** CSF + Serum
**Max. number of sample sets:** 1
**Additional Information:**
Detection of titers is not suitable. Calculation of antibody index (Certificate) and interpretation (Certificate of Participation).

**EQAS/PT Experts:**
Dr. rer. nat. Thomas Zimmermann

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Borrelia IgG Antibody Index (AI) calculation
Interpretation of the report

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Cerebrospinal Fluid Analysis - Oligoclonal IgG 462

**EQAS/PT Properties**
**Samples:** 2 samples of 100 µl
**Sample Properties:** CSF + Serum
**Max. number of sample sets:** 1
**Additional Information:**
The acquisition of samples is demanding, as it is not possible to use pooled CSF, i.e. the samples are from individual patients (catheter, drainage, etc.).

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Thomas Zimmermann

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Oligoclonal IgG

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Interpretation of the report

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Cerebrospinal Fluid Analysis - Protein Analysis 460

**EQAS/PT Properties**
**Samples:** 4 samples of 1ml
**Sample Properties:** Serum / Plasma
**Max. number of sample sets:** 1
**Additional Information:**
Sample volumes in the CSF EQAS/PTs are limited as it is difficult to acquire large volumes of CSF.

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Manfred Uhr

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Thomas Zimmermann

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Albumin
Albumin - CSF
IgA
IgA - CSF
IgG
IgG - CSF
IgM
IgM - CSF
Protein - CSF

**Not subject to Rili-BÄK**
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Evaluation of CSF/serum quotients in diagrams and age-related interpretation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Newborn Analytic

### Neonatal Bilirubin 110

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 2 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Dr. med. Christoph Niederau<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Manfred Falck |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>Neonatal Bilirubin | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

### Newborn screening 785

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples<br>**Sample Properties:** Filter papers, each with 2 dried blood spots<br>**Max. number of sample sets:** 1<br>**Additional Information:**<br>This EQAS/PT scheme is currently in the planning stages, and we will share details on the website and in the INSTAND e.V. newsletter. | **EQAS/PT Experts:**<br>N.N.<br><br>**Deputy EQAS/PT Experts:**<br>N.N |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>TSH<br>17-hydroxy Progesteron<br>IRT<br>PAP | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | |
| **Registration Deadline:** | | | | | | |
| **Sample Shipment:** | | | | | | |
| **Closing Date:** | | | | | | |

## Pharmaceuticals

### Antiarrhytmics - Amiodaron 190

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Amiodarone Desethylamiodarone |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| **Registration Deadline:** | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| **Closing Date:** | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

### Antibacterials 01 - Teicoplanin 193

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 2 ml<br>**Sample Properties:** Lyophilised serum | **EQAS/PT Experts:**<br>Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Teicoplanin |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample materia |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| **Registration Deadline:** | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| **Closing Date:** | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Antibacterials 02 890

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Dr. rer. nat. Heike Schneider

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Ampicillin | Meropenem |
| Cefepime | Piperacillin |
| Ceftazidime | Sulbactam |
| Linezolid | Tazobactam |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Anticonvulsants 01 191

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Lamotrigine Levetiracetam Sulthiame

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Anticonvulsants 02 192

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>10-OH-Carbamazepine<br>Carbamazepine-epoxide<br>N-Desmethylmethsuximide |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Anticonvulsants 03 871

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2.5 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Brivaracetam, Lacosamide<br>Eslicarbazepine, Perampanel<br>Felbamate, Rufinamide |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Anticonvulsants 04 — 872

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2.5 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Gabapentin, Pregabalin, Tiagabine, Topiramate, Vigabatrin, Zonisamide |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Antifungals / Immunosuppressants — 602

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 1 mL<br>**Sample Properties:** Lyophilised plasma | Prof. Dr. med. Nicolas von Ahsen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Patricia Kaiser (PhD) |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Hydroxy-Itraconazole<br>Itraconazole<br>Mycophenolic acid |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 26-12-18 | | | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | | | 27-10-05 |
| Closing Date: | | 27-03-12 | | | | 27-10-22 |

## Antifungals and Chloramphenicol 198

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 5 ml (+ 2 samples of 3 ml antibiotics)<br>**Sample Properties:** Lyophilised serum | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Chloramphenicol, Fluconazole, Flucytosine, Posaconazole, Voriconazole | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Antipsychotics/Antidepressives 01 200

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 2 ml<br>**Sample Properties:** Lyophilised serum | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Clozapine, N-Desmethylclozapine | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | **Jan.** | **Mar.** | **May** | **July** | **Aug.** | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | 26-12-18<br>27-02-23<br>27-03-12 | 27-02-26<br>27-04-27<br>27-05-14 | 27-04-23<br>27-06-22<br>27-07-09 | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Antipsychotics/Antidepressives 02 873

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Amisulpride | Pipamperone |
| Desmethylsertraline | Reboxetine |
| Fluvoxamine | Sertraline |
| Levomepromazine | Ziprasidone |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Antipsychotics/Antidepressives 03 874

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Desmethylfluoxetine | Mianserine |
| Fluoxetine | Perazine |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Antipsychotics/Antidepressives 04 875

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Cariprazine
Chlorprotixene
Desmethylolanzapine
Olanzapine
Paroxetine

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Antivirals 850

**EQAS/PT Properties**
**Samples:** 2 samples of 1 - 3 ml
**Sample Properties:** Lyophilised serum
**Additional Information:**
Please note that some analytes may interfere with the HPLC methods with UV detection. For this reason, the schedule-based composition will be adjusted as shown in the following pdf-download-link: https://www.instand-ev.de/EQA850-Analytes

**EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Aciclovir
Atazanavir
Bictegravir
Cabotegravir
Darunavir
Dolutegravir
Doravirine
Efavirenz
Elvitegravir
Etravirine
Ganciclovir
Lopinavir
Maraviroc
Nevirapine
Raltegravir
Ribavirin
Rilpivirin
Ritonavir T
enofovir

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Aug. | Oct. |
| Registration Deadline: | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Benzodiazepines 01 876

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Alprazolam
Chlordiazepoxide
Desalkylflurazepam
Diazepam
Nordiazepam
Oxazepam
Trazodone

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Benzodiazepines 02 877

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Clonazepam
Flunitrazepam
Flurazepam
Nitrazepam
Temazepam

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Benzodiazepines 03 878

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2.5 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Bromazepam<br>Clobazam (Clobazepam)<br>Lorazepam |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Immunosuppressants 601

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 4 samples of 1 ml<br>**Sample Properties:** Lyophilised whole blood | Prof. Dr. med. Nicolas von Ahsen<br><br>**Deputy EQAS/PT Experts:**<br>Dr. Patricia Kaiser (PhD) |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Cyclosporine A<br>Everolimus<br>Sirolimus<br>Tacrolimus |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-12 | | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Paracetamol and NSAIDs 194

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 4 samples of 1 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Paracetamol Salicylic acid |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Psychostimulants - ADHS-Treatment 879

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2.5 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Atomoxetine Methylphenidate Ritalinic acid |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Psychotherapeutic Drugs 01 860

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

**Deputy EQAS/PT Experts:**
Florian Ridders

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| 10-OH-Carbamazepine | O-Desmethylvenlafaxine |
| Aripiprazole | Perazine |
| Citalopram | Quetiapine |
| Lamotrigine | Venlafaxine |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Psychotherapeutic Drugs 02 861

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

**Deputy EQAS/PT Experts:**
Florian Ridders

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Amisulpride | O-Desmethylvenlafaxine |
| Escitalopram | Quetiapine |
| Mirtazapine | Venlafaxine |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Psychotherapeutic Drugs 03 — 862

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

**Deputy EQAS/PT Experts:**
Florian Ridders

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
9-OH-Risperidone / Paliperidone
Clozapine
Duloxetine
Haloperidol
N-Desmethylclozapine
Olanzapine
Quetiapine
Risperidone
Ziprasidone

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Psychotherapeutic Drugs 04 — 863

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen

**Deputy EQAS/PT Experts:**
Florian Ridders

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Amitriptyline
Clomipramine
Clozapine
Desipramine
Doxepin
Imipramine
Maproptiline
N-Desmethylclozapine
Norclomipramine
Nordoxepin

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Respiratory Stimulants - Caffeine 870

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 2.5 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Caffeine |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Therapeutic drugs - Antibiotics, Digitoxin, MTX 197

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 5 ml<br>**Sample Properties:** Lyophilised serum | Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider<br>Dr. Patricia Kaiser (PhD) |
| **Requirement for EQAS/PT according to Rili-BÄK:** quarterly<br>**Validity Certificate:** 6 months<br>**Parameter / Analytes:**<br>Digitoxin Vancomycin | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Amicacin Methotrexate<br>Gentamicin Tobramycin |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | 26-11-13<br>27-01-12<br>27-01-29 | 26-12-18<br>27-02-23<br>27-03-12 | 27-02-26<br>27-04-27<br>27-05-14 | 27-04-23<br>27-06-22<br>27-07-09 | 27-06-11<br>27-08-10<br>27-08-27 | 27-08-06<br>27-10-05<br>27-10-22 |

## Therapeutic drugs - Antiepileptics, Digoxin, Lithium and others 195

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider
Dr. Patricia Kaiser (PhD)

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Carbamacepine, Phenytoin, Lithium, Theophylline, Phenobarbital, Valproic Acid

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Digoxin, Ethosuximid, Primidon

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Tri-/Tetracyclic Antidepressants 03 - Quantitative in Serum 202

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Desipramine, Maproptiline, Imipramine, Normaproptiline, Tricyclic Antidepressants - Screen

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Tricyclic Antidepressants 01 - Quantitative in Serum 199

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Amitriptyline
Clomipramine
Norclomipramine
Nortriptyline
Tricyclic Antidepressants - Screen

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Tricyclic Antidepressants 02 - Quantitative in Serum 201

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Doxepin
Nordoxepin
Nortrimipramine
Tricyclic Antidepressants - Screen
Trimipramine

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Tricyclic Antidepressants 04 - Qualitative in Serum 203

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Lyophilised serum
**Additional Information:**
- May contain the following substances:Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Norclomipramine, Nordoxepin, Nortrimipramine, Nortriptyline, Trimipramine
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Tricyclic Antidepressants (qualitative)- Screening

**Not subject to Rili-BÄK:**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Norclomipramine, Nordoxepin, Nortrimipramine, Nortriptyline, Trimipramine

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

# Photometry

## Photometer Controls 181

**EQAS/PT Properties**
**Samples:** 2 samples of 6 mL
**Sample Properties:** Potassium picrate solution

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Wavelengths 334, 340, 365, 405 and 436 nm

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Plasma Proteins

### Cystatin C 242

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Liquid serum
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Cystatin C

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

### hsCRP 240

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 mL
**Sample Properties:** Liquid serum
**Max. number of sample sets:** 1
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
hsCRP

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Infection Serology - C-Reactive Protein 322

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
C-Reactive Protein (quantitative)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
C-Reactive Protein (qualitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | | 27-08-27 | 27-10-22 |

## Plasmaproteins 241

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Liquid plasma

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
C-Reactive Protein (quantitative)
Ferritin
IgA
IgG
IgM
Transferrine

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
C3
C4
Coeruloplasmin
Haptoglobin
Hemopexin
sTfR
a1-Antitrypsine
a1-Glycoprotein
a2-Makroglobulin
Quantitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples)
determination of total IgE (5 samples)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## POCT

### Blood Gas Analysis 161

**EQAS/PT Properties**
**Samples:** 2 samples of 2.5 ml
**Sample Properties:** Control solution
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Peter B. Luppa

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**

| | | |
|---|---|---|
| Chloride | Potassium | pH |
| Creatinine | Sodium | pO2 |
| Glucose | Urea | |
| Lactate | ionized Calcium | |
| Magnesium | pCO2 | |

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

### Blood Gas Analysis - Haemoglobin 162

**EQAS/PT Properties**
**Samples:** 2 samples of 2 ml
**Sample Properties:** Control solution
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Dr. med. Benedikt Lohr

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Nebe

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Haemoglobin

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Fraction CO-Hb Fraction Met-Hb Fraction O2-Hb

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Blood Gas Analysis OPTI Systems 163

**EQAS/PT Properties**
**Samples:** 2 samples of 1.7 ml
**Sample Properties:** Control solution
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. med. Peter B. Luppa

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**

| | | |
|---|---|---|
| Chloride | Sodium | pH |
| Haemoglobin | Urea | pO2 |
| Lactate | ionized Calcium | |
| Potassium | pCO2 | |

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
sO2

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| **Registration Deadline:** | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| **Closing Date:** | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Dry Chemistry - POCT: Abaxis Piccolo System 810

**EQAS/PT Properties**
**Samples:** 2 samples of 5 mL
**Sample Properties:** Lyophilised serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT

**EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Matthias Nauck

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**

| | | |
|---|---|---|
| AP | GGT | Potassium |
| Albumin | GOT (ASAT) | Protein |
| Bilirubin | GPT (ALAT) | Sodium |
| CK | Glucose | Triglycerides |
| Calcium | LDH | Urea |
| Chloride | Lactate | Uric Acid |
| Cholesterol | Magnesium | |
| Creatinine | Phosphate | |

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Bilirubin conj. | VLDL-cholesterol |
| HDL-cholesterol | alpha-Amylase |
| LDL-cholesterol | tCO2 |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Kammel | Mar. | May | | Aug. | Oct. |
| **Registration Deadline:** | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Dry Chemistry - POCT: Glucose 800

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 mL
**Sample Properties:** Whole blood
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- For point-of-care testing (POCT) devices which work with unit-use reagents and preferably use whole blood as patient sample material.

POCT

**EQAS/PT Experts:**
Prof. Dr. med. Dipl.-Biol. Astrid Petersmann

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Matthias Nauck

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Glucose

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Sep. | Oct. |
| Registration Deadline: | 26-11-27 | 27-01-08 | 27-03-12 | 27-05-14 | 27-07-16 | 27-08-27 |
| Sample Shipment: | 27-01-26 | 27-03-02 | 27-05-11 | 27-07-13 | 27-09-14 | 27-10-26 |
| Closing Date: | 27-01-29 | 27-03-05 | 27-05-14 | 27-07-16 | 27-09-17 | 27-10-29 |

# Trace Elements

## Trace Elements - whole blood 208

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised whole blood

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Magnesium

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Antimony, Arsenic, Cadmium, Chromium, Cobalt, Lead, Manganese, Mercury, Nickel, Selenium, Zinc

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 26-12-18 | | | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | | | 27-10-05 |
| Closing Date: | | 27-03-19 | | | | 27-10-29 |

## Trace Elements Plasma 206

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Aluminium | Iodine |
| Arsenic | Iron |
| Cadmium | Manganese |
| Chromium | Nickel |
| Cobalt | Platinum |
| Copper | Selenium |
| Fluoride | Zinc |
| Gold | |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 26-12-18 | | | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | | | 27-10-05 |
| Closing Date: | | 27-03-19 | | | | 27-10-29 |

## Trace Elements Serum 207

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Antimony | Molybdenum |
| Beryllium | Tin |
| Bismuth | Vanadium |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 26-12-18 | | | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | | | 27-10-05 |
| Closing Date: | | 27-03-19 | | | | 27-10-29 |

## Stool Diagnostics

### Fecal Diagnostics - Calprotectin / Fecal Elastase 130

**EQAS/PT Properties**
**Samples:** 2 samples of 0.75 ml
**Sample Properties:** Lyophilised stool
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Calprotectin
Calprotectin (qualitative)
Fecal elastase
Fecal elastase (qualitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | July | | Oct. |
| Registration Deadline: | | 26-12-18 | | 27-04-23 | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | 27-06-22 | | 27-10-05 |
| Closing Date: | | 27-03-12 | | 27-07-09 | | 27-10-22 |

### Fecal Diagnostics - Hb, Hb-Hapto-complex 131

**EQAS/PT Properties**
**Samples:** 2 samples of 0.75 ml
**Sample Properties:** Lyophilised stool
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Dr. med. Jürgen Durner

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Michael Spannagl

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Haemoglobin
Haemoglobin (qualitative)
Hemoglobin-Haptoglobin-complex
Hemoglobin-Haptoglobin-complex (qualitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 26-12-18 | | | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | | | 27-10-05 |
| Closing Date: | | 27-03-12 | | | | 27-10-22 |

## Tumor Marker

### Tumor Markers 292

**EQAS/PT Properties**
**Samples:** 2 samples of 2 ml
**Sample Properties:** Liquid Serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. med. Stefan Holdenrieder

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**

| | |
|---|---|
| AFP | PSA, total |
| CA 15-3 | hCG intact |
| CEA | hCG intact +beta-hCG free |

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | | |
|---|---|---|
| CA 125 | HER2/new | SCC |
| CA 19-9 | NSE | TPA |
| CA 72-4 | PSA, free | TPS |
| CYFRA 21-1 | ROMA-Score | Thyreoglobulin |
| HE4 | S100 | beta-2-Microglobulin |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

### Tumor Markers - Calcitonin, Pro-GRP, PIVKAII, AFP, AFP-L3 299

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Liquid Serum

**EQAS/PT Experts:**
Prof. Dr. med. Stefan Holdenrieder

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| AFP | PIVKAII |
| AFP-L3 | Progastrin-releasing |
| Calcitonin GAAD-Score | Peptide |
| GALAD-Score | |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Tumor Markers - PSA and Testosterone 293

**EQAS/PT Properties**
**Samples:** 2 samples of 2 mL
**Sample Properties:** Liquid Serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Stefan Holdenrieder

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
PSA, totalTestosterone

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PSA, free

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

# Urine Analysis

## Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative) 174

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml
**Sample Properties:** Lyophilised urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Benzoylecgonine (qualitative)
Opiate / Morphin (qualitative)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Amphetamine (qualitative)
Amphetamine (quantitative)
Barbiturate-Phenobarbital (qualitative)
Barbiturate-Phenobarbital (quantitative)
Benzoylecgonine (quantitative)
Opiate / Morphin (quantitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative) 176

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml
**Sample Properties:** Lyophilised urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Methadone (qualitative)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
(d-)Methamphetamine (quantitative)
(d-)Methamphetamine (qualitative)
Buprenorphine (qualitative)
Buprenorphine (quantitative)
LSD (qualitative)
LSD (quantitative)
Methadone (quantitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative) 177

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml
**Sample Properties:** Lyophilised urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
EDDP (qualitative)
delta-9-THC-COOH (qualitative)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Benzodiazepine Lorazepam (qualitative)
Benzodiazepine Lorazepam (quantitative)
EDDP (quantitative)
MDMA (qualitative)
MDMA (quantitative)
delta-9-THC-COOH (quantitative)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Markers of Ethanol Abuse - Ethylglucuronide 751

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 1 ml<br>**Sample Properties:** Lyophilised urine | **EQAS/PT Experts:**<br>Prof. Dr. med. Peter B. Luppa<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Ethylglucuronide |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | **Mar.** | **May** | | **Aug.** | **Oct.** |
| **Registration Deadline:** | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| **Sample Shipment:** | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| **Closing Date:** | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Systematic Toxicological Analysis (STA) 188

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 10 ml<br>**Sample Properties:** Lyophilised urine<br>**Max. number of sample sets:** 1<br>**Additional Information:**<br>• This EQAS/PT scheme is still in the planning stages, and we will announce details on the website and in the INSTAND e.V. newsletter.<br>• From a list of 30 substances, the proof of 6 - 8 substances with chromatographic methods is required in both samples. | **EQAS/PT Experts:**<br>Prof. Dr. med. Werner Steimer<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat Heike Schneider |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Chromatographic analysis with identification of the active substance (STA) | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | | | | |
| **Registration Deadline:** | | | | | | |
| **Sample Shipment:** | | | | | | |
| **Closing Date:** | | | | | | |

## Trace Elements Urine 205

**EQAS/PT Properties**
**Samples:** 2 samples of 10 ml
**Sample Properties:** Lyophilised urine

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | | |
|---|---|---|
| Aluminium | Copper | Manganese |
| Arsenic | Fluoride | Mercury |
| Cadmium | Iodine | Nickel |
| Chromium | Iron | Selenium |
| Cobalt | Lead | Zinc |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 26-12-18 | | | | 27-08-06 |
| Sample Shipment: | | 27-02-23 | | | | 27-10-05 |
| Closing Date: | | 27-03-19 | | | | 27-10-29 |

## Tricyclic Antidepressants 05 - Qualitative in Urine 204

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Werner Steimer

**Deputy EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Tricyclic Antidepressants (qualitative)- Screening

**Not subject to Rili-BÄK:**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | | |
|---|---|---|
| Amitriptylin | Imipramin | Nortriptylin |
| Clomipramin | Norclomipramin | Trimipramin |
| Desipramin | Nordoxepin | |
| Doxepin | Nortrimipramin | |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Urinary Stone Analyses 500

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples<br>**Sample Properties:** Urinary stone (powdered) | | | | | | **EQAS/PT Experts:**<br>Dr. rer. nat. Stefan Neubeck<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Karl H. Reuner |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>urinary stone analysis (chemical)<br>urinary stone analysis (physical) | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Urine Chemistry Aminolaevulinic Acid / Porphobilinogen 180

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 3 ml<br>**Sample Properties:** Lyophilised urine | | | | | | **EQAS/PT Experts:**<br>Dr. Patricia Kaiser (PhD)<br><br>**Deputy EQAS/PT Experts:**<br>Udo Kramer, Dipl.-Ing. (FH) |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Aminolaevulinic acid Porphobilinogen | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **May** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Urine Chemistry Biogene Amines 175

**EQAS/PT Properties**
**Samples:** 2 samples of 8 ml
**Sample Properties:** Lyophilised urine

**EQAS/PT Experts:**
Dr. rer. nat Heike Schneider

**Deputy EQAS/PT Experts:**
Dr. med. Thomas Lutz

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| 3-Methoxytyramine | Metanephrine |
| 5-Hydroxyindolea acid | Norepinephrine |
| Dopamine | Normetanephrine |
| Epinephrine | Serotonin |
| Homovanillic acid | Vanillylmandelic acid |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Aug. | Oct. |
| Registration Deadline: | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Urine Chemistry Hormones 179

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Aldosterone Cortisol free hCG intact

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Urine Chemistry Porphyrins 178

**EQAS/PT Properties**
**Samples:** 2 samples of 3 ml
**Sample Properties:** Lyophilised urine

**EQAS/PT Experts:**
Dr. Patricia Kaiser (PhD)

**Deputy EQAS/PT Experts:**
Udo Kramer, Dipl.-Ing. (FH)

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Coproporphyrin 1 | Hexaporphyrin |
| Coproporphyrin 3 | Pentaporphyrin |
| Coproporphyrin total | Porphyrins total |
| Heptaporphyrin | Uroporphorin |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Urine Chemistry Qualitative 171

**EQAS/PT Properties**
**Samples:** 2 samples of 10 ml
**Sample Properties:** Liquid urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Dr. Roman Fried

**Deputy EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**

| | |
|---|---|
| Albumin - Urine | Nitrite |
| Ascorbic acid | Protein |
| Bilirubin | Urobilinogen |
| Erythrocytes | hCG |
| Glucose | pH |
| Ketone bodies | specific gravity |
| Leucocytes | |

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Urine Chemistry Quantitative 173

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised urine
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Dr. Roman Fried

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Albumin - Urine
Calcium
Creatinine
Glucose
Phosphate
Potassium
Sodium
Urea
Uric Acid
total Protein - Urine

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Chloride
Magnesium
Osmolality
alpha-Amylase

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | Mar. | May | July | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | 26-12-18 | 27-02-26 | 27-04-23 | 27-06-11 | 27-08-06 |
| Sample Shipment: | 27-01-12 | 27-02-23 | 27-04-27 | 27-06-22 | 27-08-10 | 27-10-05 |
| Closing Date: | 27-01-29 | 27-03-12 | 27-05-14 | 27-07-09 | 27-08-27 | 27-10-22 |

## Urine Chemistry Sediment Pictures 172

**EQAS/PT Properties**
**Samples:** Pictures
**Sample Properties:** Digital slides
**Max. number of sample sets:** 1
**Additional Information:**
Available online in the virtual microscope! - No shipment!

**EQAS/PT Experts:**
Dr. Roman Fried

**Deputy EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Requirement for EQAS/PT according to Rili-BÄK:** yearly
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Urine sediment

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 27-01-08 | | 27-04-23 | 27-06-18 | | 27-10-01 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Urine Protein Differentiation 182

**EQAS/PT Properties**
**Samples:** 2 samples of 1 mL
**Sample Properties:** Liquid urine

**EQAS/PT Experts:**
Dr. Roman Fried

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Manfred Falck

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Albumin - Urine

**Not subject to Rili-BÄK**
**Validity Certificate:** 6 months / 12 months
**Parameter / Analytes:**
Creatinine
IgG
Retinol binding protein
Transferrine
alpha-1-Microglobulin
alpha-2-macroglobulin
beta-2-Microglobulin

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

# Vitamins

## Vitamins - Methylmalonic Acid 187

**EQAS/PT Properties**
**Samples:** 2 samples of 1 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Methylmalonic acid

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Vitamins - Serum 290

**EQAS/PT Properties**
**Samples:** 2 samples of 5 ml
**Sample Properties:** Lyophilised serum

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
1,25-OH Cholecalciferol
25-OH CCF (Vitamin D)
Biotin (Vitamin H)
Cobalamin (Vitamin B12)
Folic acid Holotranscobalamine
Pantothenic acid (Vitamin B5)
Pyridoxal-5-phosphate (Vitamin B6)
Retinol (Vitamin A)
Riboflavin (Vitamin B2)
Thiamine total (Vitamin B1)
Tocopherol (Vitamin E)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Vitamins - Vitamin C 296

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Dr. med. Christoph Niederau

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Ingo Schellenberg

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Ascorbic acid (Vitamin C)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | May | July | | Oct. |
| Registration Deadline: | 26-11-13 | | 27-02-26 | 27-04-23 | | 27-08-06 |
| Sample Shipment: | 27-01-12 | | 27-04-27 | 27-06-22 | | 27-10-05 |
| Closing Date: | 27-01-29 | | 27-05-14 | 27-07-09 | | 27-10-22 |

## Vitamins - whole blood 291

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 2 ml<br>**Sample Properties:** Lyophilised whole blood | **EQAS/PT Experts:**<br>Dr. med. Christoph Niederau<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Ingo Schellenberg |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Flavine Adenine Dinucleotide (FAD)<br>Flavine mononucleotid (FMN)<br>Pyridoxal-5-phosphate (Vitamin B6)<br>Riboflavin (Vitamin B2)<br>Thiamine total (Vitamin B1)<br>Thiaminpyrophosphat (TPP) |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | **Jan.** | | **May** | **July** | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | 26-11-13<br>27-01-12<br>27-01-29 | | 27-02-26<br>27-04-27<br>27-05-14 | 27-04-23<br>27-06-22<br>27-07-09 | | 27-08-06<br>27-10-05<br>27-10-22 |

# MICROBIOLOGY

## Bacterial Genome Detection

### Bacterial Genome Detection - Bordetella pertussis 532

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist | |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** not applicable<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Bordetella pertussis | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

### Bacterial Genome Detection - Borrelia burgdorferi 535

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. Volker Fingerle | |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Borrelia burgdorferi | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Carbapenemase-Genes 544

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Carbapenemases | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Chlamydia pneumoniae 540

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Chlamydia pneumoniae | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Chlamydia trachomatis 531

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** not applicable<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Chlamydia trachomatis | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Chlamydia trachomatis & Neisseria gonorrhoeae 530

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension<br>**Additional Information:**<br>Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early. | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Chlamydia trachomatis and Neisseria gonorrhoeae | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Clostridium difficile (Toxin Gene) 545

**EQAS/PT Properties**
**Samples:** 4 samples of 0.3 ml
**Sample Properties:** Lyophilised cell suspension
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Udo Reischl

**Deputy EQAS/PT Experts:**
PD Dr. Andreas Hiergeist

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PCR or other procedures for nucleic acid amplification/detection of Clostridium difficile toxin-genes

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Coxiella burnetii & Bacillus anthracis 542

**EQAS/PT Properties**
**Samples:** 4 samples of 0.3 ml
**Sample Properties:** Lyophilised cell suspension

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Udo Reischl

**Deputy EQAS/PT Experts:**
PD Dr. med. Dimitrios Frangoulidis
PD Dr. rer. nat. Gregor Grass

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PCR or other procedures for nucleic acid amplification/detection of Coxiella burnetii

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
and Bacillus anthracis

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - EHEC / STEC 534

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of EHEC / STEC | | | **Not subject to Rili-BÄK** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Francisella tularensis & Brucella spp. 543

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>Dr. med. vet. Heiner von Buttlar<br>Prof. Dr. rer. nat. Holger C. Scholz |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Francisella tularensis | | | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>and Brucella spp. | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Helicobacter pylori 533

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Helicobacter pylori | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Legionella pneumophila 536

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Legionella pneumophila | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Listeria spp. 538

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Listeria spp. | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - MRSA or cMRSA 539

| | | | | | | |
|---|---|---|---|---|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension<br>**Additional Information:**<br>For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. | | | | | | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of MRSA / cMRSA | | | **Not subject to Rili-BÄK:** not applicable | | | |
| **Shipping Information:**<br>Shipping not cooled | | | **Safety Information:**<br>Process as patient sample material | | | |
| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Mycoplasma pneumoniae 541

**EQAS/PT Properties**
**Samples:** 4 samples of 0.3 ml
**Sample Properties:** Lyophilised cell suspension

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Udo Reischl

**Deputy EQAS/PT Experts:**
PD Dr. Andreas Hiergeist

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PCR or other procedures for nucleic acid amplification/detection of Mycoplasma pneumoniae

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Nov. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-11 | | | 27-11-05 |

## Bacterial Genome Detection - PCR/NAT Multiplex Detection Method for Gastrointestinal Pathogens 548

**EQAS/PT Properties**
**Samples:** 4 samples of 0.3 ml
**Sample Properties:** Lyophilised cell suspension
**Max. number of sample sets:** 1
**Additional Information:**

- In order to take into account the usually very different pathogen coverage of commercially available multiplex PCR/NAT concepts, each of the parameters listed above is certified separately as part of the evaluation.
- Only results from multiplex PCR/NAT test systems with a precisely specified test/kit designation are accepted.
- The parallel use of singleplex PCR/NAT detection methods for individual pathogens in the panel is not certified. The relatively broad spectrum of pathogen-specific EQA programmes for bacterial genome detection PCR/NAT is still available for this purpose.
- Mixtures of 0 to 4 of the different pathogens specified in the panel are to be expected in the respective individual samples.

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Udo Reischl

**Deputy EQAS/PT Experts:**
PD Dr. Andreas Hiergeist

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Clostridium difficile (toxin-producing)
Enterohemorrhagic
E. coli (EHEC / STEC)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Aeromonas spp.
Campylobacter spp.
Enterohemorrhagic
E. coli (EHEC / STEC)
Enterotoxigenic E. coli (ETEC)
Enteropathogenic E. coli (EPEC)
Enteroaggregative E. coli (EAEC)
Escherichia coli O157
Plesiomonas spp.
Salmonella spp.
Shigella/EIEC
Vibrio spp.
Yersinia enterocolitica

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Nov. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-11 | | | 27-11-05 |

## Bacterial Genome Detection - Salmonella enterica 537

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Salmonella enterica | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - Urogenital Panel 547

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of specific DNA:<br>Selection of Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma parvum, Ureaplasma urealyticum, Trichomonas vaginalis, Gardnerella vaginalis, Treponema pallidum |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **June** | | | **Nov.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci) 546

**EQAS/PT Properties**
**Samples:** 4 samples of 0.3 ml
**Sample Properties:** Lyophilised cell suspension
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

POCT +

**EQAS/PT Experts:**
Prof. Dr. rer. nat. Udo Reischl

**Deputy EQAS/PT Experts:**
PD Dr. Andreas Hiergeist

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
PCR or other procedures for nucleic acid amplification/detection of Vancomycin restant enterococci (VRE)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Nov. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-11 | | | 27-11-05 |

# Bacteriological Infection Serology

## Infection Serology - Bartonella Antibodies 326

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| Registration Deadline: | | | | | 27-06-11 | |
| Sample Shipment: | | | | | 27-08-10 | |
| Closing Date: | | | | | 27-08-27 | |

## Infection Serology - Bordetella pertussis Antibodies 317

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgM (qualitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Oct. |
| Registration Deadline: | | | | | | 27-08-13 |
| Sample Shipment: | | | | | | 27-10-12 |
| Closing Date: | | | | | | 27-10-29 |

## Infection Serology - Borrelia burgdorferi Antibodies 332

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
- For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
- A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
polyvalent (qualitative)
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
IgG-Blot
IgM-Blot

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample materia

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Brucella Antibodies 327

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| Registration Deadline: | | | | | 27-06-11 | |
| Sample Shipment: | | | | | 27-08-10 | |
| Closing Date: | | | | | 27-08-27 | |

## Infection Serology - Campylobacter Antibodies 319

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | |
| Registration Deadline: | | | 27-03-19 | | | |
| Sample Shipment: | | | 27-05-18 | | | |
| Closing Date: | | | 27-06-04 | | | |

## Infection Serology - Chlamydia pneumoniae (Chlamydophila) Antibodies 314

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Chlamydia trachomatis Antibodies 312

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
IgG (qualitative)
IgG (semiquantitativ)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Chlamydia trachomatis Direct Detection (ELISA / PCR) 313

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.4 ml<br>**Sample Properties:** Urine<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Prof. Dr. med. K.-P. Hunfeld<br><br>**Deputy EQAS/PT Experts:**<br>Ulyana Gräf |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Direct detection of Chlamydia trachomatis antigen (ELISA, PCR) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>diagnostic comment |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **June** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-04 | | | 27-08-13<br>27-10-12<br>27-10-29 |

## Infection Serology - Chlamydia trachomatis Direct Detection (Slide) 316

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 slides<br>**Sample Properties:** Slides<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Prof. Dr. med. K.-P. Hunfeld<br><br>**Deputy EQAS/PT Experts:**<br>Ulyana Gräf |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Direct detection of Chlamydia trachomatis antigen (dir. IFA) | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>diagnostic comment |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **June** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-04 | | | 27-08-13<br>27-10-12<br>27-10-29 |

## Infection Serology - Coxiella burnetii Antibodies 325

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
IgG - Phase I (qualitative)
IgG - Phase I (semiquantitative)
IgG - Phase II (qualitative)
IgG - Phase II (semiquantitative)
IgA (qualitative)
IgM (qualitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Oct. |
| Registration Deadline: | | | | | | 27-08-13 |
| Sample Shipment: | | | | | | 27-10-12 |
| Closing Date: | | | | | | 27-10-29 |

## Infection Serology - Diphtheria Toxoid Antibodies 318

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
AB against Diphtherie toxoid (qualitative)
AB against Diphtherie toxoid ((semi-)quantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Francisella tularensis Antibodies 328

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| Registration Deadline: | | | | | 27-06-11 | |
| Sample Shipment: | | | | | 27-08-10 | |
| Closing Date: | | | | | 27-08-27 | |

## Infection Serology - Helicobacter pylori Antibodies 334

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgA (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Leptospira Antibodies 329

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
polyvalent (qualitative)
polyvalent (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgM (qualitative)
IgM (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| Registration Deadline: | | | | | 27-06-11 | |
| Sample Shipment: | | | | | 27-08-10 | |
| Closing Date: | | | | | 27-08-27 | |

## Infection Serology - Mycoplasma pneumoniae Antibodies 324

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgM (qualitative)
polyvalent (qualitative)
polyvalent (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Oct. |
| Registration Deadline: | | | | | | 27-08-13 |
| Sample Shipment: | | | | | | 27-10-12 |
| Closing Date: | | | | | | 27-10-29 |

## Infection Serology - Procalcitonin 320

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Procalcitonin (qualitative)
Procalcitonin (semi-quantitative)
Procalcitonin (quantitative)
Diagnostic comments

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Rheumatoid Factor 323

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** quarterly
**Validity Certificate:** 6 months
**Parameter / Analytes:**
Rheumatoid factor (RF) (qualitative)
Rheumatoid factor (RF) (quantitative)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | June | | Aug. | Oct. |
| Registration Deadline: | 26-11-13 | | 27-03-19 | | 27-06-11 | 27-08-13 |
| Sample Shipment: | 27-01-12 | | 27-05-18 | | 27-08-10 | 27-10-12 |
| Closing Date: | 27-01-29 | | 27-06-04 | | 27-08-27 | 27-10-29 |

## Infection Serology - Rickettsia Antibodies 330

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.4 ml<br>**Sample Properties:** Serum<br>**Max. number of sample sets:** 1<br>**Additional Information:**<br>For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.<br>A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics. | Prof. Dr. med. K.-P. Hunfeld<br><br>**Deputy EQAS/PT Experts:**<br>Ulyana Gräf |

| Requirement for EQAS/PT according to Rili-BÄK: not applicable | Not subject to Rili-BÄK<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>polyvalent (qualitative)<br>polyvalent (semiquantitative)<br>IgG (qualitative)<br>IgG (semiquantitative)<br>IgM (qualitative)<br>IgM (semiquantitative)<br>diagnostic comment |
|---|---|
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Aug. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | 27-06-11<br>27-08-10<br>27-08-27 | |

## Infection Serology - Salmonella Antibodies 331

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
typhi, O-Antigen (qualitative)
typhi, O-Antigen (semiquantitative)
typhi, OH-Antigen (qualitative)
typhi, OH-Antigen (semiquantitative)
enteritidis, OH-Antigen (qualitative)
enteritidis, OH-Antigen (semiquantitative)
typhimurium, OH-Antigen (qualitative)
typhimurium, OH-Antigen (semiquantitative)
paratyphi B, OH-Antigen (qualitative)
paratyphi B, OH-Antigen (semiquantitative)
Group A, O-Antigen (qualitative)
Group A, O-Antigen (semiquantitative)
Group B, O-Antigen (qualitative)
Group B, O-Antigen (semiquantitative)
Group C, O-Antigen (qualitative)
Group C, O-Antigen (semiquantitative)
polyvalent (qualitative)
IgA (qualitative)
IgG (qualitative)
IgM (qualitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| Registration Deadline: | | | 27-03-19 | | | 27-08-13 |
| Sample Shipment: | | | 27-05-18 | | | 27-10-12 |
| Closing Date: | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Streptococcal AB 321

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.4 ml<br>**Sample Properties:** Serum<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Prof. Dr. med. K.-P. Hunfeld<br><br>**Deputy EQAS/PT Experts:**<br>Ulyana Gräf |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>anti-streptolysin O (ASO) (qualitative)<br>anti-streptolysin O (ASO) (quantitative)<br>anti-streptodornase (aDNase) (qualitative)<br>anti-streptodornase (aDNase) (quantitative) | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-04 | | | 27-08-13<br>27-10-12<br>27-10-29 |

## Infection Serology - Tetanus Toxoid Antibodies 310

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.4 ml<br>**Sample Properties:** Serum<br>**Max. number of sample sets:** 1<br>**Additional Information:**<br>For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.<br>A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics. | **EQAS/PT Experts:**<br>Prof. Dr. med. K.-P. Hunfeld<br><br>**Deputy EQAS/PT Experts:**<br>Ulyana Gräf |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>AB against Tetanus toxoid (qualitative)<br>AB against Tetanus toxoid ((semi-)quantitative)<br>diagnostic comment |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-04 | | | 27-08-13<br>27-10-12<br>27-10-29 |

## Infection Serology - Treponema pallidum Antibodies 311

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
TPHA (qualitative)
TPHA (semiquantitative)
TPPA (qualitative)
TPPA (semiquantitative)
polyvalent (qualitative)
IgG (qualitative)
FTA-Abs IgG (semiquantitative)
FTA-Abs IgM (qualitative)
FTA-Abs IgM (semiquantitative)
IgG (semiquantitative)
IgM (qualitative)
IgG - Immunoblot
IgM - Immunoblot
FTA-Abs IgG (qualitative)

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
AB against Cardiolipin (qualitative)
AB against Cardiolipin (semiquantitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Oct. |
| **Registration Deadline:** | | | 27-03-19 | | | 27-08-13 |
| **Sample Shipment:** | | | 27-05-18 | | | 27-10-12 |
| **Closing Date:** | | | 27-06-04 | | | 27-10-29 |

## Infection Serology - Yersinia Antibodies 315

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 ml
**Sample Properties:** Serum
**Max. number of sample sets:** 1
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. K.-P. Hunfeld

**Deputy EQAS/PT Experts:**
Ulyana Gräf

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
enterocolitica O3 (qualitative)
enterocolitica O3 (semiquantitative)
enterocolitica O9 (qualitative)
enterocolitica O9 (semiquantitative)
pseudotuberculosis (qualitative)
pseudotuberculosis (semiquantitative)
IgG (qualitative)
IgG (semiquantitative)
IgA (qualitative)
IgM (qualitative)
diagnostic comment

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-03-19<br>27-05-18<br>27-06-04 | | | |

# Human Microbiome

## Bacterial Genome Detection - Molecular Genetic Analysis of the Human Microbiome 580

**EQAS/PT Properties**
**Samples:** 4 samples of 0.5 mL
**Sample Properties:** Stool suspension
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. Dr. rer. nat. André Gessner

**Deputy EQAS/PT Experts:**
Prof. Dr. rer. nat. Udo Reischl

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
NGS-Analysis (next generation sequencing)

**Shipping Information:**
- Cooled shipping
- Delivered with dry ice!
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 5 Days!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | Aug. | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-04-16<br>27-06-15<br>27-08-20 | | | |

## Conventional Bacteriology

### Bacteriology (3 Samples) 411

**EQAS/PT Properties**
**Samples:** 3 samples
**Sample Properties:** Lyophilised strains + Bouillon
**Additional Information:**

- Participants in the EQA schemes in bacteriology will get a certificate for Gram staining when successful in this part.
- **Additional participation in EQA scheme No. 413 ´Gram Stain´ is not required.**
- Participants will be notified in advance in case the panel of tested antibiotics will be changed:

| | |
|---|---|
| Ampicillin | Oxacillin |
| Ampicillin/Sulbactam | Trimethoprim/Sulfamethoxazol |
| Cefpodoximproxetil | Fosfomycintrometamol |
| Ceftazidim | Nitrofurantoin Pivmecillinam |
| Ciprofloxacin | Nitroxolin |
| Levofloxacin Penicillin | Gentamicin |
| Meropenem | |

**EQAS/PT Experts:**
Prof. Dr. med. Dirk Schlüter

**Deputy EQAS/PT Experts:**
Dr. med. Marc Lindenberg
Dr. med. Stefan Ziesing

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Cultivation, identification and susceptibility testing of fast-growing bacteria and accompanying bacterial flora of the urogenital tract, incl. yeasts
Gram staining

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Jan. | | Mar. | July | | Nov. |
| Registration Deadline: | 26-11-20 | | 27-01-08 | 27-04-30 | | 27-09-03 |
| Sample Shipment: | 27-01-19 | | 27-03-02 | 27-06-29 | | 27-11-02 |
| Closing Date: | 27-01-29 | | 27-03-12 | 27-07-09 | | 27-11-12 |

## Bacteriology (5 Samples) 412

**EQAS/PT Properties**
**Samples:** 5 samples of 1 mL
**Sample Properties:** Lyophilised strains
**Additional Information:**
- Participants in the EQA schemes in bacteriology will get a certificate for Gram staining when successful in this part.
- **Additional participation in EQA scheme No. 413 ´Gram Stain´ is not required.**
- Participants will be notified in advance in case the panel of tested antibiotics will be changed:

Ampicillin
Cefotaxim
Ceftazidim Cefuroxim
Ciprofloxacin
Erythromycin Gentamicin High Level
Meropenem
Levofloxacin Linezolid
Oxacillin
Penicillin Piperacillin/Tazobactam
Trimethoprim/Sulfamethoxazol
Tobramycin Vancomycin

**EQAS/PT Experts:**
Prof. Dr. med. Dirk Schlüter

**Deputy EQAS/PT Experts:**
Dr. med. Marc Lindenberg
Dr. med. Stefan Ziesing

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Cultivation, identification and susceptibility testing of bacteria Gram staining

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | | Sep. | |
| Registration Deadline: | 26-12-04 | | | | 27-07-02 | |
| Sample Shipment: | 27-02-02 | | | | 27-08-31 | |
| Closing Date: | 27-02-12 | | | | 27-09-10 | |

## Bacteriology - Gram Stain 413

**EQAS/PT Properties**
**Samples:** 3 samples
**Sample Properties:** Slides
**Additional Information:**
Participants of the EQA schemes in bacteriology No. 411 or 412 will get a certificate for gram staining if they are successful in this part.

**EQAS/PT Experts:**
Prof. Dr. med. Dirk Schlüter

**Deputy EQAS/PT Experts:**
Dr. med. Marc Lindenberg
Dr. med. Stefan Ziesing

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Gram staining

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Oct. |
| Registration Deadline: | | 27-01-08 | | | | 27-08-06 |
| Sample Shipment: | | 27-03-09 | | | | 27-10-05 |
| Closing Date: | | 27-03-19 | | | | 27-10-15 |

## Mycobacteriology

### Mycobacterial Diagnostics - Cultivation 422

**EQAS/PT Properties**
**Samples:** 5 samples of 1 mL
**Sample Properties:** Artificial sputum, mixed with accompanying flora and possibly Mycobacterium tuberculosis complex or Non tuberculous Mycobacteria
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Dr. Sönke Andres

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Cultivation of Mycobacteria
Differentiation of Tuberculosis Bacteria

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | May | | | Nov. | |
| Registration Deadline: | | 27-01-15 | | | 27-07-09 | |
| Sample Shipment: | | 27-03-16 | | | 27-09-07 | |
| Closing Date: | | 27-05-28 | | | 27-11-19 | |

### Mycobacterial Diagnostics - Drug Susceptibility Testing of Mycobacterium tuberculosis 425

**EQAS/PT Properties**
**Samples:** 5 samples of 1 mL
**Sample Properties:** Mycobacterium tuberculosis complex suspensions for phenotypic resistance testing (incl. second-line drugs)
**Max. number of sample sets:** 1
**Additional Information:**
- Note: EQA scheme containing infectious substances according to UN2814, infectious substances category A.
- Each registration for this group must confirm that the test is performed in a laboratory with security level S3 and with appropriately qualified personnel.

**EQAS/PT Experts:**
Dr. Sönke Andres

**Deputy EQAS/PT Experts:**
N.N.

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Susceptibility Testing of Tuberculosis Bacteria

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | May | | | Nov. | |
| Registration Deadline: | | 27-01-15 | | | 27-07-09 | |
| Sample Shipment: | | 27-03-16 | | | 27-09-07 | |
| Closing Date: | | 27-05-28 | | | 27-11-19 | |

## Mycobacterial Diagnostics - Drug Susceptibility Testing of Nontuberculous Mycobacteria 427

**EQAS/PT Properties**
**Samples:** 5 samples of 1 mL
**Sample Properties:** Suspensions of Nontuberculous Mycobacteria
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Dr. Sönke Andres

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Susceptibility Testing of Nontuberculous Mycobacteria

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | May | | | Oct. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-15<br>27-03-16<br>27-05-07 | | | 27-07-09<br>27-09-07<br>27-10-29 | |

## Mycobacterial Diagnostics - Identification 423

**EQAS/PT Properties**
**Samples:** 5 samples of 1 mL
**Sample Properties:** Mycobacterial suspensions (non-tuberculous mycobacteria or Mycobacterium bovis BCG)
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Dr. Sönke Andres

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Identification of Mycobacteria

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | May | | | Oct. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-15<br>27-03-16<br>27-05-07 | | | 27-07-09<br>27-09-07<br>27-10-29 | |

## Mycobacterial Diagnostics - Microscopy 421

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 6 samples<br>**Sample Properties:** Slides<br>**Max. number of sample sets:** 1 | Dr. Sönke Andres<br><br>**Deputy EQAS/PT Experts:**<br>N.N |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Microscopic Detection of Mycobacteria | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Sep. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-15<br>27-03-16<br>27-04-02 | | | 27-07-09<br>27-09-07<br>27-09-24 | |

## Mycobacterial Diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria 426

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 5 samples of 1 mL<br>**Sample Properties:** Suspensions of inactivated Mycobacterium tuberculosis complex strains for molecular resistance testing<br>**Max. number of sample sets:** 1 | Dr. Sönke Andres<br><br>**Deputy EQAS/PT Experts:**<br>N.N |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Susceptibility Testing of Tuberculosis Bacteria | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-15<br>27-03-16<br>27-04-23 | | | 27-07-09<br>27-09-07<br>27-10-15 | |

## Mycobacterial Diagnostics - NAT Mycobacterium tuberculosis 424

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 5 samples of 1 mL<br>**Sample Properties:** Artificial sputum, with accompanying flora and in individual cases mixed with Mycobacterium tuberculosis Complex<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Dr. Sönke Andres<br><br>**Deputy EQAS/PT Experts:**<br>N.N |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Nucleic Acid Amplification of Tuberculosis Bacteria | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Sep. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | 27-01-15<br>27-03-16<br>27-04-02 | | | 27-07-09<br>27-09-07<br>27-09-24 | |

# Mycology

## Fungal Genome Detection - Pneumocystis jirovecii 560

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Lyophilised cell suspension | **EQAS/PT Experts:**<br>Prof. Dr. rer. nat. Udo Reischl<br><br>**Deputy EQAS/PT Experts:**<br>PD Dr. Andreas Hiergeist |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>PCR or other procedures for nucleic acid amplification/detection of Pneumocystis jirovecii |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | June | | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-03-19<br>27-05-18<br>27-06-11 | | | 27-08-13<br>27-10-12<br>27-11-05 |

## Genome Detection of Dermatophytes 492

**EQAS/PT Properties**
**Samples:** 4 samples of 0.05 ml
**Sample Properties:** Lyophilised strains

**EQAS/PT Experts:**
PD Dr. rer. nat. et med. habil Cornelia Wiegand

**Deputy EQAS/PT Experts:**
Dr. rer. med. Silke Uhrlaß
Prof. Dr. med. Pietro Nenoff

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other procedures for Genome detection of dermatophytes

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| **Registration Deadline:** | | 27-01-08 | | | 27-07-09 | |
| **Sample Shipment:** | | 27-03-09 | | | 27-09-07 | |
| **Closing Date:** | | 27-04-02 | | | 27-10-01 | |

## Mycology Dermatophytes, Yeasts, Mould Fungus 491

**EQAS/PT Properties**
**Samples:** 4 samples
**Sample Properties:** Strains
**Additional Information:**
Living strains of causative agents or contaminantes will be sent, that had been isolated from patients with skin mycoses or mucosal fungal infections.

**EQAS/PT Experts:**
PD Dr. rer. nat. et med. habil Cornelia Wiegand

**Deputy EQAS/PT Experts:**
Dr. rer. med. Silke Uhrlaß
Prof. Dr. med. Pietro Nenoff
Prof. Dr. med. Dipl.-Biol. Gerhard Haase

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Identification of dermatophytes, yeasts and moulds

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Oct. | |
| **Registration Deadline:** | | 27-01-08 | | | 27-07-09 | |
| **Sample Shipment:** | | 27-03-09 | | | 27-09-07 | |
| **Closing Date:** | | 27-04-23 | | | 27-10-22 | |

## Mycology Mucorales, Yeasts, Coelomycetes, Hyphomycetes, Basidiomycetes 490

**EQAS/PT Properties**
**Samples:** 5 samples
**Sample Properties:** Strains

**EQAS/PT Experts:**
Prof. Dr. med. Dipl.-Biol. Gerhard Haase

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Walter Geißdörfer

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Cultivation and species identification of fungi (Mucorales, ascomycetes, yeast-like species, coelomycetes, hyphomycetes, basidiomycetes) known to cause mucosal, organ, systemic, or traumatic mycoses in humans, as well as contaminants that may be present in human specimens. Furthermore, a preliminary medical commentary should be provided to evaluate the respective fungus in the specified context.

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | | Oct. | |
| **Registration Deadline:** | 26-11-20 | | | | 27-07-16 | |
| **Sample Shipment:** | 27-01-19 | | | | 27-09-14 | |
| **Closing Date:** | 27-02-12 | | | | 27-10-08 | |

## Mycoserology - Candida (Antigen and Antibodies) 480

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 mL
**Sample Properties:** Liquid serum
**Additional Information:**
For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. med. Michael S. Weig

**Deputy EQAS/PT Experts:**
PD Dr. rer. nat. Oliver Bader

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Candida IgA (qual)
Candida IgG (qual)
Candida IgM (qual)
Candida antigen (qual)
Candida total AB (qual)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | | Oct. | |
| **Registration Deadline:** | 26-11-20 | | | | 27-07-16 | |
| **Sample Shipment:** | 27-01-19 | | | | 27-09-14 | |
| **Closing Date:** | 27-02-05 | | | | 27-10-01 | |

## Mycoserology - Cryptococcus neoformans/ - gattii Antigen 481

**EQAS/PT Properties**
**Samples:** 2 samples of 0.4 mL
**Sample Properties:** Liquid serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
PD Dr. med. Volker Rickerts

**Deputy EQAS/PT Experts:**
Ilka McCormick Smith

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Detection of Cryptococcus neoformans / Cryptococcus gattii Antigen

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | Feb. | | | | Oct. | |
| Registration Deadline: | 26-11-20 | | | | 27-07-16 | |
| Sample Shipment: | 27-01-19 | | | | 27-09-14 | |
| Closing Date: | 27-02-05 | | | | 27-10-01 | |

# Parasite Diagnostics

## Detection of Toxoplasma DNA (PCR) 457

**EQAS/PT Properties**
**Samples:** 4 samples
**Sample Properties:** Stabilized amniotic fluid (and/or EDTA blood or other fluids), buffer

**EQAS/PT Experts:**
Prof. Dr. Marc Hübner

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Achim Hörauf

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Toxoplasma gondii (DNA) - qualitative

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline: | | 26-12-18 | | | 27-06-11 | |
| Sample Shipment: | | 27-02-23 | | | 27-08-10 | |
| Closing Date: | | 27-03-12 | | | 27-08-27 | |

## Molecular Genetic Detection of Protozoa in Stool 458

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.5 mL<br>**Sample Properties:** Lyophilisate<br>**Max. number of sample sets:** 1 | Prof. Dr. med. Egbert Tannich<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Iris Bruchhaus |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Cryptosporidium spp. (DNA) - qualitative<br>Entamoeba histolytica (DNA) - qualitative<br>Giardia duodenalis (DNA) - qualitative |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Parasite Microscopy (Blood) 456

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of thin or thick blood smear<br>**Sample Properties:** Slides<br>**Max. number of sample sets:** 1 | Prof. Dr. Marc Hübner<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Achim Hörauf |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Blood parasites - specification | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Aug. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 26-12-18<br>27-02-23<br>27-03-12 | | | 27-06-11<br>27-08-10<br>27-08-27 | |

## Parasite Serology - Amoebiasis and Echinococcosis 455

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples variable volumes<br>**Sample Properties:** Serum / Plasma | Prof. Dr. Marc Hübner<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Achim Hörauf |

| Requirement for EQAS/PT according to Rili-BÄK: yearly | Not subject to Rili-BÄK |
|---|---|
| **Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Antibodies against Echinococcus<br>Antibodies against Entamoeba histolytica | **Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>diagnostic comment of an echinococcus infection |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Oct. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | | 27-08-06<br>27-10-05<br>27-10-22 |

## Parasite Serology - Malaria and Schistosomiasis 454

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples variable volumes<br>**Sample Properties:** Serum / Plasma<br>**Additional Information:**<br>For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.<br>A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics. | Prof. Dr. Marc Hübner<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. med. Achim Hörauf |

| Requirement for EQAS/PT according to Rili-BÄK: yearly | Not subject to Rili-BÄK |
|---|---|
| **Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Antibodies against Plasmodium<br>Antibodies against Schistosoma | **Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Comprehensive Diagnostic Evaluation of a Plasmodium Infection<br>Comprehensive Diagnostic Evaluation of a Schistosoma Infection |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | 27-02-26<br>27-04-27<br>27-05-14 | | | |

## Parasite Serology - Toxoplasmosis 452

**EQAS/PT Properties**
**Samples:** 2 samples variable volumes
**Sample Properties:** Serum / Plasma
**Additional Information:**
- For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested.
- A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.

**EQAS/PT Experts:**
Prof. Dr. Marc Hübner

**Deputy EQAS/PT Experts:**
Prof. Dr. med. Achim Hörauf

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Antibodies against Toxoplasma gondii

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Comprehensive diagnostic evaluation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | May | | | Oct. |
| Registration Deadline: | | | 27-02-26 | | | 27-08-06 |
| Sample Shipment: | | | 27-04-27 | | | 27-10-05 |
| Closing Date: | | | 27-05-14 | | | 27-10-22 |

## Virtual Parasite Microscopy (Blood) 906

**EQAS/PT Properties**
**Samples:** Images of at least 2 clinical cases
**Sample Properties:** Digital slides
**Max. number of sample sets:** 1

**EQAS/PT Experts:**
Prof. Dr. med. Egbert Tannich

**Deputy EQAS/PT Experts:**
Prof. Dr. Iris Bruchhaus
Prof. Dr. med. Achim Hörauf
Prof. Dr. Marc Hübner

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Blood parasites - specification

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
- Available online in digital microscopy! - No shipment!
- In March and September: Prof. Hübner, Bonn; in May and October: Prof. Tannich, Hamburg

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | May | | Aug. | Oct. |
| Registration Deadline: | | 26-12-18 | 27-02-26 | | 27-06-11 | 27-08-06 |
| Sample Shipment: | | 27-02-23 | 27-04-27 | | 27-08-10 | 27-10-05 |
| Closing Date: | | 27-03-12 | 27-05-14 | | 27-08-27 | 27-10-22 |

## Virtual Parasite Detection (Stool) 907

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** Images of slides with feacal smears of at least 2 clinical cases<br>**Sample Properties:** Digital slides<br>**Max. number of sample sets:** 1 | **EQAS/PT Experts:**<br>Prof. Dr. med. Egbert Tannich<br><br>**Deputy EQAS/PT Experts:**<br>Prof. Dr. Iris Bruchhaus |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Stool parasites - specification | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Available online in digital microscopy! - No shipment! | **Safety Information:**<br>Process as patient sample material |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | **May** | | | **Oct.** |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | 27-02-26<br>27-04-27<br>27-05-14 | | | 27-08-06<br>27-10-05<br>27-10-22 |

# VIRUS DIAGNOSTICS

## Virus Genome Detection

### Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag) 410

**EQAS/PT Properties**
**Samples:** 5 samples of 0.5 ml
**Sample Properties:** Liquid cell culture material (inactivated)
**Additional Information:**

- Note: When performing tests using your own swab, please note that the provided sample volume of 0.5 ml is generally sufficient for performing one SARS-CoV-2 test, one influenza virus test, and one RSV test. However, depending on the absorbency of the swab used, a second tube may be necessary.
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** entfällt

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
The samples are suitable to detect influenza A/B antigen, RSV A/B antigen, and SARS-CoV-2 antigen.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

**Information will be updated at the end of autumn.**

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses 370

**EQAS/PT Properties**

**Samples:** 6 samples of 1.5 ml

**Sample Properties:** Lyophilised cell culture material or allantoic fluid

**Additional Information:**

- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
  Note for laboratories from non-EU countries:
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Referenzzentrum für Influenza, Robert Koch-Institut, Berlin; Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Nationales Referenzlabor für Aviäre Influenza, Insel Riems

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual

**Validity Certificate:** 12 months

**Parameter / Analytes:**

- This program may be completed with currently circulating influenza viruses.
- Please note: these EQA samples are not suitable for virus propagation and immune fluorescence tests for antigen detection. Some of the samples can contain chemically inactivated avian influenza A viruses.
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for influenza A and B viruses and antigen testing
- Option for typing of seasonal and avian influenza A viruses

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Nov. |
| **Registration Deadline:** | | 27-01-08 | | | | 27-09-03 |
| **Sample Shipment:** | | 27-03-09 | | | | 27-11-02 |
| **Closing Date:** | | 27-03-26 | | | | 27-11-19 |

## Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus 359

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: Institut für Virologie und Immunbiologie, Universität Würzburg; Institut für Virologie, Universitätsklinikum Düsseldorf; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for RSV RNA and RSV antigen testing

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Adenoviruses 371

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material

**EQAS/PT Experts:**
PD Dr. med. Albert Heim

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for adenovirus DNA
- Determination of species of adenovirus
- Typing of adenovirus

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - BK Polyomavirus (BKPyV / BKV) 364

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or suspension of urine
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln

**EQAS/PT Experts:**
Dr. Steffi Silling

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for BK-Polyomavirus DNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Borna Viruses 404

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml* or 0.5 ml**
**Sample Properties:** *Lyophilised cell culture material (inactivated) or ** lyophilised RNA eluate
**Additional Information:**
Cooperation with: Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Institut für Virusdiagnostik, Insel Riems

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Bornaviruses - RNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Chikungunya Virus 392

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma and cell culture material (inactivated)
**Additional Information:**
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:**
**Validity Certificate:** not applicable
**Parameter / Analytes:**

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CHIKV RNA

**Shipping Information:**
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| **Registration Deadline:** | | 27-01-08 | | | 27-06-25 | |
| **Sample Shipment:** | | 27-03-09 | | | 27-08-24 | |
| **Closing Date:** | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Coronaviruses incl. SARS-CoV-2 340

**EQAS/PT Properties**
**Samples:** 6 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2-RNA, MERS-CoV-RNA and other human coronavirus RNA
- Option for differentiaton between SARS-CoV-2, MERS-CoV and other human coronaviruses (samples which contain SARS-CoV-2 and MERS-CoV, repectively, are inactivated)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Cytomegalovirus Program 1 365

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or cell culture material

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CMV DNA

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Cytomegalovirus Program 2 - additional Training Program (can only be ordered with program 365) 368

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma
**Additional Information:**

- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (368) can only be ordered together with the corresponding main EQA scheme (365) for March.
- Separate certificates will be issued for the training program (368) and the main EQA scheme (365, subject to Rili-BÄK-B3).
- Cooperation with: Nationale Konsiliarlabore für Cytomegalievirus (CMV): Institut für Virologie, Universitätsklinikum Ulm; Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CMV DNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| Registration Deadline: | | 27-01-08 | | | | |
| Sample Shipment: | | 27-03-09 | | | | |
| Closing Date: | | 27-03-26 | | | | |

## Virus Genome Detection - Cytomegalovirus Resistance Determination 349

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or cell culture material
**Additional Information:**
Cooperation with: Nationale Konsiliarlabore für Cytomegalievirus (CMV): Institut für Virologie, Universitätsklinikum Ulm; Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for CMV resistance determination

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Oct. | |
| Registration Deadline: | | | | | 27-06-25 | |
| Sample Shipment: | | | | | 27-08-24 | |
| Closing Date: | | | | | 27-10-01 | |

## Virus Genome Detection - Dengue Viruses 369

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or cell culture material (inactivated)
**Additional Information:**
Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for denguevirus RNA
- Typing of denguevirus

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Enteroviruses 372

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised cell culture material | **EQAS/PT Experts:**<br>Dr. med. Martin Obermeier<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for enterovirus RNA<br>• Typing of enterovirus | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | 27-04-09<br>27-06-08<br>27-06-25 | | 27-09-03<br>27-11-02<br>27-11-19 |

## Virus Genome Detection - Epstein Barr Virus 376

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised cell culture material | **EQAS/PT Experts:**<br>Prof. Dr. Holger F. Rabenau<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for EBV DNA | **Not subject to Rili-BÄK** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | 27-04-09<br>27-06-08<br>27-06-25 | | 27-09-03<br>27-11-02<br>27-11-19 |

## Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests 430

**EQAS/PT Properties**
**Samples:** 3 samples of 1.5 ml
**Sample Properties:** Lyophilised suspension of feces or cell culture material
**Additional Information:**

- The RiliBÄK requirements (Guidelines of the German Medical Association on quality assurance in medical laboratory testing / Bundesärztekammer) will be used to detect the pathogens listed below. This EQA scheme will include each of the pathogens mentioned below at least once a year. Participation in both EQA scheme terms is recommended.
- **Please note: Only results of multiplex tests will be accepted for EQA scheme 430**
- This multiplex EQA scheme is not suitable for (i) ´singleplex´ PCRs, (ii) tests for antigen detection, (iii) testing of sensitivity and (iv) typing. For this purpose, we refer to the INSTAND EQA schemes for the corresponding viruses.
- This program will be completed with currently circulating virus variants.

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of gastrointestinal adeno, astro, entero, noro, parecho, rota and sapoviruses, respectively.

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of gastrointestinal adeno, astro, entero, noro, parecho, rota and sapoviruses, respectively.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Hepatitis A Virus 377

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HAV RNA

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Hepatitis B Virus Genotyping 396

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised plasma<br>**Additional Information:**<br>Cooperation with: WHO Collaborating Centre for Blood Products and IVD-Devices, Paul-Ehrlich-Institut, Langen | **EQAS/PT Experts:**<br>Dr. med. Martin Obermeier<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) incl. sequencing for HBV genotyping |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | | Nov. |
| **Registration Deadline:** | | | | | | 27-09-03 |
| **Sample Shipment:** | | | | | | 27-11-02 |
| **Closing Date:** | | | | | | 27-11-19 |

## Virus Genome Detection - Hepatitis B Virus Program 1 361

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised plasma | **EQAS/PT Experts:**<br>Dr. med. Martin Obermeier<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** bi-annual<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HBV DNA | **Not subject to Rili-BÄK:** not applicable |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| **Registration Deadline:** | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| **Sample Shipment:** | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| **Closing Date:** | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Hepatitis B Virus Program 2 - additional Training Program (can only be ordered with program 361) 378

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma
**Additional Information:**
- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (378) can only be ordered together with the corresponding main EQA scheme (361) for March.
- Separate certificates will be issued for the training program (378) and the main EQA scheme (361, subject to Rili-BÄK-B3).

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HBV DNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-08<br>27-03-09<br>27-03-26 | | | | |

## Virus Genome Detection - Hepatitis B Virus Resistance Determination 397

**EQAS/PT Properties**
**Samples:** 4 samples à 0.1 ml* or à 1.5 ml**
**Sample Properties:** *Plasmids in water or **lyophilised plasma

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HBV resistance determination

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Oct. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | 27-06-25<br>27-08-24<br>27-10-01 | |

## Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping 375

**EQAS/PT Properties**
**Samples:** 3-4 samples of 1.5 ml
**Sample Properties:** Lyophilised serum/plasma
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf; Medizinisches Infektiologiezentrum Berlin

**EQAS/PT Experts:**
Prof. Dr. med. Jörg Timm

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** yearly
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV geno- and subtype differentiation

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Sep. | |
| Registration Deadline: | | | | | 27-06-25 | |
| Sample Shipment: | | | | | 27-08-24 | |
| Closing Date: | | | | | 27-09-10 | |

## Virus Genome Detection - Hepatitis C Virus Program 1 362

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Prof. Dr. med. Jörg Timm

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV RNA

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Hepatitis C Virus Program 2 - additional Training Program (can only be ordered with program 362) 379

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma
**Additional Information:**
- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (379) can only be ordered together with the corresponding main EQA scheme (362) for March.
- Separate certificates will be issued for the training program (379) and the main EQA scheme (362, subject to Rili-BÄK-B3).
- Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf

**EQAS/PT Experts:**
Prof. Dr. med. Jörg Timm

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV RNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-08<br>27-03-09<br>27-03-26 | | | | |

## Virus Genome Detection - Hepatitis C Virus Resistance Determination 399

**EQAS/PT Properties**
**Samples:** 2-3 samples of 0.5 ml
**Sample Properties:** Serum/plasma (non-lyohilised)
**Additional Information:**
- Please note: Only tests in the gene region NS5A will be offered in this EQA scheme. Resistance tests in the gene region NS3 will no longer be offered due to lack of clinical relevance.
- Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf; Medizinisches Infektiologiezentrum Berlin

**EQAS/PT Experts:**
Prof. Dr. med. Jörg Timm

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HCV resistance determination

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Oct. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | 27-06-25<br>27-08-24<br>27-10-01 | |

## Virus Genome Detection - Hepatitis D Virus 400

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma
**Additional Information:**
Cooperation with: WHO Collaborating Centre for Blood Products and IVD-Devices, Paul-Ehrlich-Institut, Langen

**EQAS/PT Experts:**
Prof. Dr. Holger F. Rabenau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HDV RNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Hepatitis E Virus 380

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised serum/plasma or suspension of feces
**Additional Information:**
Cooperation with: Nationales Konsiliarlabor für Hepatitis-A-Virus (HAV) und Hepatitis-E-Virus (HEV), Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HEV RNA

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2 363

**EQAS/PT Properties**
**Samples:** 6 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or cell culture material

**EQAS/PT Experts:**
Prof. Dr. Holger F. Rabenau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for differentiation of HSV 1 and HSV 2 DNA

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | 27-04-09<br>27-06-08<br>27-06-25 | | 27-09-03<br>27-11-02<br>27-11-19 |

## Virus Genome Detection - HIV-1 (RNA) Program 2 - additional Training Program (can only be ordered with program 360) 382

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma
**Additional Information:**
- The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3.
- The training program (382) can only be ordered together with the corresponding main EQA scheme (360) for March.
- Separate certificates will be issued for the training program (382) and the main EQA scheme (360, subject to Rili-BÄK-B3).
- Cooperation with: Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-1 (RNA)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-08<br>27-03-09<br>27-03-26 | | | | |

## Virus Genome Detection - HIV-1 (RNA) Program 1 360

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-1 (RNA)

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - HIV-1 Drug Resistance Determination - Standard Program for Protease and Reverse Transcriptase Inhibitors 383

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml* or 0.1 ml**
**Sample Properties:** *Plasma or **Plasmids in water (non-lyophilised)
**Additional Information:**
Cooperation with IMD Labor Frankfurt; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
- Please note: The samples will contain plasmids and heat-inactivated cell culture supernatant viruses respectively!
- Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of protease inhibitors and reverse transcriptase inhibitors

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Oct. | |
| Registration Deadline: | | | | | 27-06-25 | |
| Sample Shipment: | | | | | 27-08-24 | |
| Closing Date: | | | | | 27-10-01 | |

## Virus Genome Detection - HIV-1 Drug Resistance Determination - additional Program for Integrase Inhibitors and Tropism Determination 384

**EQAS/PT Properties**
**Samples:** 2 samples of 1.5 ml
**Sample Properties:** Plasma (non-lyophilised)
**Additional Information:**
Cooperation with IMD Labor Frankfurt; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
- Please note: The samples will contain heat-inactivated cell culture supernatant viruses!
- Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of integrase inhibitors and determination of tropism

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Oct. | |
| Registration Deadline: | | | | | 27-06-25 | |
| Sample Shipment: | | | | | 27-08-24 | |
| Closing Date: | | | | | 27-10-01 | |

## Virus Genome Detection - HIV-2 (RNA) 395

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised serum/plasma
**Additional Information:**
Cooperation with: Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-2 (RNA)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Human Herpesvirus 6 (HHV-6) 405

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised cell culture material<br>**Additional Information:**<br>Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf | **EQAS/PT Experts:**<br>Prof. Dr. med. Jörg Timm<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human herpesvirus 6 (HHV-6) - DNA |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| **Registration Deadline:** | | 27-01-08 | | | 27-06-25 | |
| **Sample Shipment:** | | 27-03-09 | | | 27-08-24 | |
| **Closing Date:** | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Human Herpesvirus 8 (HHV-8) 406

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised cell culture material<br>**Additional Information:**<br>Cooperation with: Institut für Virologie, Medizinische Hochschule Hannover | **EQAS/PT Experts:**<br>Dr. med. Martin Obermeier<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human herpesvirus 8 (HHV-8) - DNA |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | |
| **Registration Deadline:** | | 27-01-08 | | | | |
| **Sample Shipment:** | | 27-03-09 | | | | |
| **Closing Date:** | | 27-03-26 | | | | |

## Virus Genome Detection - Human Metapneumovirus 385

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. rer. nat. Kerstin Knies

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human metapneumovirus RNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Human Papillomaviruses (HPV) 373

**EQAS/PT Properties**
**Samples:** 5 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material or biopsy material
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln

**EQAS/PT Experts:**
Dr. Steffi Silling

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and hybridization for HPV DNA
- Differentiation of ‚high risk' and ‚low risk' types, and typing of ‚high risk' HPV and ‚low risk' HPV

**Not subject to Rili-BÄK** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Human Rhinoviruses 393

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. rer. nat. Kerstin Knies

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HRV RNA
- Typing of human rhinovirus

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - JC Polyomavirus (JCPyV / JCV) 394

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material or suspension of urine
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln

**EQAS/PT Experts:**
Dr. Steffi Silling

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for JC-Polyomavirus DNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Measles Virus 386

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 4 samples of 1.5 ml<br>**Sample Properties:** Lyophilised cell culture material<br>**Additional Information:**<br>Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin | Prof. Dr. med. Martin Enders<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |

| Requirement for EQAS/PT according to Rili-BÄK: bi-annual | Not subject to Rili-BÄK: not applicable |
|---|---|
| **Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>• Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for measles virus RNA<br>• Typing of measles virus | |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | July | | Dec. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-07-09 | | 27-12-03 |

## Virus Genome Detection - MPXV / Orthopoxviruses 418

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material (MPXV inactivated)
**Additional Information:**
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Konsiliarlabor für Pockenviren, Robert Koch-Institut, Zentrum für Biologische Gefahren und Spezielle Pathogene, ZBS 1 - Hochpathogene Viren, Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
MPXV (DNA) - quantitative
MPXV (DNA) - qualitative
MPXV (DNA) - clade identification
Orthopoxviruses (DNA) – quantitative
Orthopoxviruses (DNA) – qualitative
Orthopoxviruses (DNA) – type identification

**Shipping Information:**
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Mumps Virus 387

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for mumps virus RNA
- Typing of mumps virus

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | July | | Dec. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-07-09 | | 27-12-03 |

## Virus Genome Detection - Norovirus 381

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised suspension of feces
**Additional Information:**
Cooperation with: Nationales Konsiliarlabor für Noroviren, Robert Koch-Institut, Berlin; Nationales Konsiliarlabor für Hepatitis-A-Virus (HAV) und Hepatitis-E-Virus (HEV), Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg; Institut für Virologie, Medizinische Hochschule Hannover

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for norovirus RNA with the option for differentiation in genogroup I and II

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | | Nov. |
| **Registration Deadline:** | | 27-01-08 | | | | 27-09-03 |
| **Sample Shipment:** | | 27-03-09 | | | | 27-11-02 |
| **Closing Date:** | | 27-03-26 | | | | 27-11-19 |

## Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens NEW! 435

**EQAS/PT Properties**
**Samples:** 5 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
N.N

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for qualitative detection of Zika-, Dengue-, Chikungunya-, Japanese encephalitis- and Oropouche virus-RNA and Plasmodium spp.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests 433

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
- We will include the listed pathogens in this EQAS/PT program at least once a year. We therefore recommend participating in both rounds of the EQAS/PT program.
- We will accept only results from multiplex tests for this proficiency testing program.
- This multiplex proficiency testing program is not suitable for (i) “singleplex” PCRs, (ii) antigen detection tests, (iii) sensitivity assessments, and (iv) typing. For these purposes, please refer to the corresponding INSTAND proficiency testing programs for the respective viruses.
- The program includes currently circulating virus variants.

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** not applicable
**Parameter / Analytes:**
Polymerase Chain Reaction (PCR) and other nucleic acid amplification techniques (NAT) for the simultaneous qualitative detection of cytomegalovirus, enteroviruses, Epstein-Barr virus, herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus.

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase Chain Reaction (PCR) and other nucleic acid amplification techniques (NAT) for the simultaneous qualitative detection of adenoviruses, human herpesvirus 6, and parechovirus.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Parainfluenza Viruses 388

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. rer. nat. Kerstin Knies

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for parainfluenza virus RNA
- Typing of parainfluenza virus

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Parechovirus 407

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Parechovirus (RNA)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Genome Detection - Parvovirus B19 367

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for parvovirus B19 DNA

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Rabies Virus (Tollwutvirus) 390

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised samples (inactivated, vaccine)
**Additional Information:**
INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rabies virus RNA

**Shipping Information:**
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Sep. | |
| Registration Deadline: | | | | | 27-06-25 | |
| Sample Shipment: | | | | | 27-08-24 | |
| Closing Date: | | | | | 27-09-10 | |

## Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests 431

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
- The pathogens listed will be included in this EQAS/PT at least once a year. We therefore recommend participating in both EQAS/PT rounds.
- **For this EQAS/PT (No. 431), only results from multiplex tests will be accepted.**
- This multiplex EQA scheme is not suitable for (i) ´singleplex´ PCRs, (ii) tests for antigen detection, (iii) testing of sensitivity and (iv) typing. For this purpose, we refer to the INSTAND EQA schemes for the corresponding viruses.
- The program is rounded out with virus variants currently in circulation
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of respiratory adeno, entero, influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively.
- Some of the samples can contain chemically inactivated avian influenza A viruses.

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of respiratory boca, corona, human metapneumo, human rhino, parecho, parainfluenza.

**Shipping Information:**
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Respiratory Virus Panel 2 432

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
- This EQAS/PT program is not suitable for (I) antigen detection tests, (II) sensitivity testing, and (III) typing. For these purposes, please refer to the corresponding INSTAND proficiency testing programs for the respective viruses.
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- The program is rounded out with virus variants currently in circulation.

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated).
- Some of the samples can contain chemically inactivated avian influenza A viruses.

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Rotaviruses 401

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised suspension of feces
**Additional Information:**
Cooperation with: Nationales Konsiliarlabor für Rotaviren, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rotavirus RNA
- Typing of rotavirus

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Genome Detection - Rubella Virus 389

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rubella virus RNA
- Typing of rubella virus

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | July | | Dec. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-07-09 | | 27-12-03 |

## Virus Genome Detection - SARS-CoV-2 409

**EQAS/PT Properties**
**Samples:** 5 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material
**Additional Information:**
Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

**Information will be updated at the end of autumn.**

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - SARS-CoV-2 sequence analysis 417

**EQAS/PT Properties**
**Samples:** 3-5 samples of 1.5 ml
**Sample Properties:** Lyophilised cell culture material (inactivated)
**Additional Information:**
Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité – Universitätsmedizin Berlin; Medizinisches Infektiologiezentrum Berlin;
Abt. Methodenentwicklung und Forschungsinfrastruktur, Robert Koch-Institut, Berlin

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing
  Please note:
- Submitted sequences are evaluated for sequence quality both in the S gene and separately in the whole genome.

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Apr. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-04-09 | | | 27-09-24 | |

## Virus Genome Detection - Torque Teno Virus (TTV) 408

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma
**Additional Information:**
Cooperation with: Institut für Virologie, Uniklinik Köln

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 24 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Torque teno virus (TTV) DNA

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Sep. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | | 27-06-25<br>27-08-24<br>27-09-10 | |

## Virus Genome Detection - Varicella Zoster Virus 366

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or cell culture material

**EQAS/PT Experts:**
Prof. Dr. Holger F. Rabenau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for VZV DNA

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | 27-04-09<br>27-06-08<br>27-06-25 | | 27-09-03<br>27-11-02<br>27-11-19 |

## Virus Genome Detection - West Nile Virus 391

**EQAS/PT Properties**
**Samples:** 6 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma and cell culture material (inactivated)
**Additional Information:**
Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for West Nile virus RNA
- Typing of West Nile virus (Lineage determination)

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

**Information will be updated at the end of autumn.**

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Genome Detection - Zika Virus 403

**EQAS/PT Properties**
**Samples:** 4 samples of 1.5 ml
**Sample Properties:** Lyophilised plasma or cell culture material (inactivated)
**Additional Information:**
Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Zika virus RNA
- Typing of Zika virus (Lineage determination)

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Immunology

### Virus Immunology - Borna Viruses (Ab) 415

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 10 samples of 100 µl<br>**Sample Properties:** Liquid serum/plasma<br>**Additional Information:**<br>Cooperation with WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg | **EQAS/PT Experts:**<br>Prof. Dr. med. Jonas Schmidt-Chanasit<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Anti-borna virus IgG |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | 27-04-09<br>27-06-08<br>27-06-25 | | |

### Virus Immunology - Chikungunya Virus (Ab) 402

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.3 ml<br>**Sample Properties:** Liquid serum (inactivated in case of chikungunya virus RNA positive samples)<br>**Additional Information:**<br>Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg | **EQAS/PT Experts:**<br>Prof. Dr. med. Jonas Schmidt-Chanasit<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Anti-CHIKV IgG<br>Anti-CHIKV IgG - avidity<br>Anti-CHIKV IgM |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| **Dates** | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Sep. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | 27-06-25<br>27-08-24<br>27-09-10 | |

## Virus Immunology - Cytomegalovirus (Ab) 351

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-CMV IgG, Anti-CMV IgG - avidity, Anti-CMV IgM

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) 350

**EQAS/PT Properties**
**Samples:** 4 samples of 0.3 ml
**Sample Properties:** Liquid serum (inactivated in case of dengue virus RNA positive ples)
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg

**EQAS/PT Experts:**
Prof. Dr. med. Jonas Schmidt-Chanasit

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-dengue virus IgG, Anti-dengue virus IgM, dengue virus-NS1 Ag, clinical interpretation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline: | | 27-01-08 | | | 27-06-25 | |
| Sample Shipment: | | 27-03-09 | | | 27-08-24 | |
| Closing Date: | | 27-03-26 | | | 27-09-10 | |

## Virus Immunology - Epstein Barr Virus (Ab) 352

**EQAS/PT Properties**
**Samples:** 2 samples of 0.6 ml
**Sample Properties:** Liquid serum
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- The following parameters are not considered for the ´certificate´ (only stated in the ´certificate of participation´): anti-EA IgG, anti-EA IgA, anti-EA IgM, anti-EA, anti-VCA IgA, anti-EBV IgA and strip-immunoblot anti-EBV IgA

**EQAS/PT Experts:**
Prof. Dr. Holger F. Rabenau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Antibodies against EBV with and without differentiation of antigen specificity (incl. avidity) and heterophilic antibodies clinical interpretation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | | | 27-04-09<br>27-06-08<br>27-06-25 | | 27-09-03<br>27-11-02<br>27-11-19 |

## Virus Immunology - Hantaviruses (Ab) 355

**EQAS/PT Properties**
**Samples:** 4 samples of 0.5 ml
**Sample Properties:** Liquid serum (inactivated in case of Hantavirus RNA positive samples)
**Additional Information:**
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Cooperation with: Labor Berlin, Charite-Vivantes GmbH

**EQAS/PT Experts:**
Prof. Dr. Jörg Hofmann

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
- Antibodies against hantaviruses (IgG and IgM) and differentiation of serotype specific antibodies
- Status of hantavirus infection

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | | Sep. | |
| Registration Deadline:<br>Sample Shipment:<br>Closing Date: | | 27-01-08<br>27-03-09<br>27-03-26 | | | 27-06-25<br>27-08-24<br>27-09-10 | |

## Virus Immunology - Hepatitis A Virus (Ab) 343

**EQAS/PT Properties**
**Samples:** 4 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-HAV IgG / Anti-HAV total
Anti-HAV IgM

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, Anti-HBe) 344

**EQAS/PT Properties**
**Samples:** 5 samples of 1.5 mL
**Sample Properties:** Liquid serum
**Additional Information:**

- Please note: Note: The EQA schemes for hepatitis B virus immunology have been restructured to incorporate diagnostic scenarios. Instead of individual samples for each parameter, samples with simulated diagnostic scenarios will be sent out in the future. Since only a few laboratories perform testing for anti-HBc-IgM, this parameter has been moved to the separate Program 345. All other parameters of HBV serology are grouped together in this Program 344.
- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HBsAg
Confirmation test HBsAg
Anti-HBs
Anti-HBc
HBeAg
Anti-HBe

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Diagnostic interpretation

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM) 345

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-HBc IgM

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) 346

**EQAS/PT Properties**
**Samples:** 4 samples of 0.5 ml
**Sample Properties:** Liquid serum/plasma
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Prof. Dr. med. Jörg Timm

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Screening test anti-HCV and combined detection anti-HCV and HCV antigen
HCV antigen
Complementary test (blot) anti-HCV

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - Hepatitis D Virus (Ab) 347

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Liquid serum/plasma | **EQAS/PT Experts:**<br>Prof. Dr. Holger F. Rabenau<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Anti-HDV IgG / Anti-HDV total Anti-HDV IgM |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | | **June** | | **Nov.** |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Hepatitis E Virus (Ab) 348

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.4 ml<br>**Sample Properties:** Liquid serum | **EQAS/PT Experts:**<br>Dr. Axel Schubert<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Anti-HEV IgG Anti-HEV IgM |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| **Dates** | **Q1** | | **Q2** | **Q3** | | **Q4** |
|---|---|---|---|---|---|---|
| | | | | **June** | | **Nov.** |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Herpes Simplex Viruses (Ab) 354

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Prof. Dr. Holger F. Rabenau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-HSV 1/2 IgG
Anti-HSV 1/2 IgG - avidity
Anti-HSV 1 IgG
Anti-HSV 1 IgG - avidity
Anti-HSV 2 IgG
Anti-HSV 2 IgG - avidity
Anti-HSV 1/2 IgM
Anti-HSV 1 IgM
Anti-HSV 2 IgM

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - HIV-1 p24 Antigen 337

**EQAS/PT Properties**
**Samples:** 2 samples of 0.75 ml
**Sample Properties:** Liquid serum
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
HIV-1 p24 Ag
HIV-1 p24 Ag Confirmation test

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - HIV-1/HIV-2 (Ab) 335

**EQAS/PT Properties**
**Samples:** 4 samples of 0.75 ml
**Sample Properties:** Liquid serum/plasma
**Additional Information:**
For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**
Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Screening test anti-HIV-1 / anti-HIV-2 (3rd and 4th Generation)
Confirmation test (blot and other confirmatory test) anti-HIV-1 / anti-HIV-2
Confirmation test (blot and other confirmatory test) anti-HIV-1
Confirmation test (blot and other confirmatory test) anti-HIV-2

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - HTLV-1/HTLV-2 (Ab) 339

**EQAS/PT Properties**
**Samples:** 4 samples of 0.5 ml
**Sample Properties:** Liquid serum/plasma
**Additional Information:**
Cooperation with: Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Screening test anti-HTLV-1 / anti-HTLV-2
Confirmation test (Blot and other confirmation test) anti-HTLV-1 / anti-HTLV-2

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Measles Virus (Ab) 357

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-measles virus IgG
Anti-measles virus IgG - avidity
Anti-measles virus IgM

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Mumps Virus (Ab) 356

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-mumps virus IgG
Anti-mumps virus IgG - avidity
Anti-mumps virus IgM

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Parvovirus B19 (Ab) 342

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 4 samples of 0.5 ml<br>**Sample Properties:** Liquid serum/plasma | **EQAS/PT Experts:**<br>Prof. Dr. med. Martin Enders<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 12 months<br>**Parameter / Analytes:**<br>Anti-parvovirus B19 IgG<br>Anti-parvovirus B19 IgG - avidity<br>Anti-parvovirus B19 IgM |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens. |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| **Registration Deadline:** | | | | 27-04-09 | | 27-09-03 |
| **Sample Shipment:** | | | | 27-06-08 | | 27-11-02 |
| **Closing Date:** | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Rabies Virus (Tollwutvirus) (Ab) 336

| | |
|---|---|
| **EQAS/PT Properties**<br>**Samples:** 2 samples of 0.5 ml<br>**Sample Properties:** Liquid serum/plasma (vaccinee) | **EQAS/PT Experts:**<br>Dr. med. Martin Obermeier<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |
| **Requirement for EQAS/PT according to Rili-BÄK:** not applicable | **Not subject to Rili-BÄK**<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Anti-rabies Virus |
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Sep. | |
| **Registration Deadline:** | | | | | 27-06-25 | |
| **Sample Shipment:** | | | | | 27-08-24 | |
| **Closing Date:** | | | | | 27-09-10 | |

## Virus Immunology - Rubella Virus (Ab) 341

**EQAS/PT Properties**
**Samples:** 2 samples of 0.8 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Prof. Dr. med. Martin Enders

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-rubella virus IgG
Anti-rubella virus IgG - avidity
Anti-rubella virus IgM

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - SARS-CoV-2 (Ab) 416

**EQAS/PT Properties**
**Samples:** 4 samples of 0.5 ml
**Sample Properties:** Liquid serum/plasma

**EQAS/PT Experts:**
Dr. med. Martin Obermeier

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-SARS-CoV-2 total (without differentiation of IgG, IgA and IgM)
Anti-SARS-CoV-2 IgG
Anti-SARS-CoV-2 IgG avidity (not certified)
Anti-SARS-CoV-2 IgA (not certified)
Anti-SARS-CoV-2 IgM (not certified)
Anti-SARS-CoV-2 Surrogate neutralizing antibodies

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | Mar. | | June | Sep. | Nov. |
| Registration Deadline: | | 27-01-08 | | 27-04-09 | 27-06-25 | 27-09-03 |
| Sample Shipment: | | 27-03-09 | | 27-06-08 | 27-08-24 | 27-11-02 |
| Closing Date: | | 27-03-26 | | 27-06-25 | 27-09-10 | 27-11-19 |

## Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab) 358

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Dr. Axel Schubert

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable

**Not subject to Rili-BÄK**
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-TBE/FSME virus IgG
Anti-TBE/FSME virus IgG - avidity
Anti-TBE/FSME virus IgM

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Varicella Zoster Virus (Ab) 353

**EQAS/PT Properties**
**Samples:** 2 samples of 0.5 ml
**Sample Properties:** Liquid serum

**EQAS/PT Experts:**
Prof. Dr. Holger F. Rabenau

**Deputy EQAS/PT Experts:**
Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual
**Validity Certificate:** 12 months
**Parameter / Analytes:**
Anti-VZV IgG Anti-VZV IgG - avidity Anti-VZV IgM

**Not subject to Rili-BÄK:** not applicable

**Shipping Information:**
Shipping not cooled

**Safety Information:**
Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | June | | Nov. |
| Registration Deadline: | | | | 27-04-09 | | 27-09-03 |
| Sample Shipment: | | | | 27-06-08 | | 27-11-02 |
| Closing Date: | | | | 27-06-25 | | 27-11-19 |

## Virus Immunology - Zika Virus (Ab) 338

| EQAS/PT Properties | EQAS/PT Experts: |
|---|---|
| **Samples:** 2 samples of 0.3 ml<br>**Sample Properties:** Liquid serum (inactivated in case of Zika virus RNA positive samples)<br>**Additional Information:**<br>Cooperation with:WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg | Prof. Dr. med. Jonas Schmidt-Chanasit<br><br>**Deputy EQAS/PT Experts:**<br>Dr. rer. nat. Martin Kammel |

| Requirement for EQAS/PT according to Rili-BÄK: not applicable | Not subject to Rili-BÄK<br>**Validity Certificate:** 24 months<br>**Parameter / Analytes:**<br>Anti-ZIKV IgG Anti-ZIKV IgG - avidity Anti-ZIKV IgM |
|---|---|
| **Shipping Information:**<br>Shipping not cooled | **Safety Information:**<br>Process as patient sample material |

| Dates | Q1 | | Q2 | Q3 | | Q4 |
|---|---|---|---|---|---|---|
| | | | | | Sep. | |
| **Registration Deadline:**<br>**Sample Shipment:**<br>**Closing Date:** | | | | | 27-06-25<br>27-08-24<br>27-09-10 | |

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Prof. Dr. med. Nicolas Ahsen, von

Zentrallaboratorien der Kliniken Bremen-Mitte, Bremen-Nord, Bremen-Ost und Links der Weser
Gesundheit Nord Klinikverbund Bremen gGmbH
Klinikum Links der Weser
Senator-Weßling-Straße 1, Bremen

**T** +49 421 879 4557
**E** nicolas.vonahsen@gesundheitnord.de

### Frau MSc. Simone Ahting

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

**T** +49 341 97 20596
**E** simone.ahting@medizin.uni-leipzig.de

### Herr Dr. Sönke Andres

Forschungszentrum Borstel
Nationales Referenzzentrum für Mykobakterien
Parkallee 38, Borstel

**T** +49 4537 188 6480
**E** sandres@fz-borstel.de

### Herr PD Dr. rer. nat. Oliver Bader

Institut für Medizinische Mikrobiologie und Virologie
Universitätsmedizin Göttingen
Kreuzbergring 57, Göttingen

**T** +49 551 3965403
**E** obader@gwdg.de

### Herr Dr. med. Harald Bartsch

Gemeinschaftspraxis für Pathologie Traunstein

Cuno-Niggl-Str. 3, Traunstein

**T** +49 211-1592 13 0
**E** harald.bartsch@instand-ringversuch.de

### Herr Prof. Dr. med. Hannsjörg Baum

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 0
**E** hannsjoerg.baum@instand-ringversuch.de

### Herr Dr. rer. nat. Martin Blüthner

MVZ Labor PD Dr. Volkmann und Kollegen SE & Co. eGbR

Gerwigstrasse 67, Karlsruhe

**T** +49 721 85000 225
**E** bluethner@laborvolkmann.de

### Herr Dr. Gernot Brauers

Uniklinikum Düsseldorf

Moorenstr. 5, Düsseldorf

**T** +49 211-1592 13 0
**E** gernot.brauers@med.uni-duesseldorf.de

### Frau Prof. Dr. Iris Bruchhaus

Bernhard-Nocht-Institiut für Tropenmedizin

Bernhard-Nocht-Straße 74, Hamburg

**T** +49 40 285380-472
**E** bruchhaus@bnitm.de

### Herr Dr. med. vet. Heiner Buttlar, von

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

**T** +49 992692 3894
**E** heinervonbuttlar@bundeswehr.org

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Dr. rer. nat. Morten O. Christensen

Gerinnungszentrum Rhein-Ruhr
Ambulanz und Fachlaboratorium für
Gerinnungserkrankungen/Hämophilie
Königstraße 13, Duisburg

**T** +49 203 348 336 24
**E** morten.christensen@gzrr.de

### Frau Dr. rer. biol. hum. Andrea Dick

LMU Klinikum
Abteilung für Transfusionsmedizin, Zelltherapeutika und
Hämostaseologie
Elisabeth-Winterhalter-Weg 15, München

**T** +49 89 44007 7403
**E** andrea.dick@med.uni-muenchen.de

### Herr Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Labor Becker MVZ GbR

Führichstr. 70, München

**T** +49 89 450 917 349
**E** j.durner@labor-becker.de

### Herr Prof. Dr. med. Martin Enders

Labor Prof. G. Enders & Kollegen, MVZ
Medizinische Diagnostik
Rosenbergstr. 85, Stuttgart

**T** +49 711-6357 120
**E** martin.enders@instand-ringversuch.de

### Frau Dr. ssa Rosanna Falbo

University Department of Laboratory Medicine
University Milano Bicocca
Piazza dell'Ateneo Nuovo, 1, Milano
Italien
**T** +39 362-385312
**E** rosanna.falbo@asst-brianza.it

### Herr Dr. rer. nat. Manfred Falck

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211 178 355 20
**E** manfred.falck@instand-ringversuch.de

### Herr Dr. med. Volker Fingerle

Nationales Referenzzentrum für Borrelien
Bayerisches Landesamt für Gesundheit und
Lebensmittelsicherheit (LGL)
Veterinärstraße 2, Oberschleißheim

**T** +49 9131 6808 5870
**E** volker.fingerle@lgl.bayern.de

### Herr Prof. Dr. med. Willy A. Flegel

Chief, Laboratory Services Section
DTM/CC/NIH
, Bethesda MD 20892-1184
USA
**T** +1 301 5947 401
**E** willy.flegel@instand-ringversuch.de

### Herr Dr. rer. nat. Ralf-Rüdiger Flörke

Am Lindenbruch 48, Essen

**T** +49 160 2131 052
**E** ralf.floerke@instand-ringversuch.de

### Herr PD Dr. med. Dimitrios Frangoulidis

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

**T** +49 89 992692 3869
**E** dimitriosfrangoulidis@bundeswehr.org

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

### Herr Dr. Roman Fried

MQ Zürich, Universitätsspital Zürich
Institut für Klinische Chemie
Rämistrasse 100, Zürich
Schweiz
**T** +41 44 255 3518
**E** roman.fried@usz.ch

### Frau Dr. med. Claudia Frömmel

MDI Limbach Berlin GmbH

Aroser Allee 84, Berlin

**T** +49 30 443364 535
**E** claudia.froemmel@instand-ringversuch.de

### Herr Prof. Dr. med. Winfried Gassmann

St. Marienkrankenhaus
Medizinische Klinik III
Kampenstr. 51, Siegen

**T** +49 271 231 1300
**E** w.gassmann@mariengesellschaft.de

### Herr Dr. rer. nat. Walter Geißdörfer

Mikrobiologisches Institut - Klinische Mikrobiologie,
Immunologie und Hygiene
Universitätsklinikum Erlangen
Wasserturmstraße 3-5, Erlangen

**T** +49 9131 85 22668
**E** walter.geissdoerfer@uk-erlangen.de

### Herr Prof. Dr. Dr. med. André Gessner

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

**T** +49 941 944 6400
**E** andre.gessner@ukr.de

### Frau Ulyana Gräf

Krankenhaus Nordwest
Zentralinstitut für Labormedizin, Mikrobiologie &
Krankenhaushygiene
Steinbacher Hohl 2-26, Frankfurt

**T** +49 69-7601 3646
**E** graef.ulyana@khnw.de

### Herr PD Dr. rer. nat. Gregor Grass

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

**T** +49 992692 2806
**E** gregorgrass@bundeswehr.org

### Herr Prof. Dr. med. Kai Gutensohn

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 160 1549548
**E** kai.gutensohn@instand-ringversuch.de

### Herr Prof. Dr. med. Gerhard Haase

Labordiagnostisches Zentrum - Bereich Mikrobiologie
Universitätsklinikum RWTH Aachen
Pauwelsstraße 30, Aachen

**T** +49 241 8089 515/510
**E** ghaase@ukaachen.de

### Herr Prof. Dr. med. Dr. rer. nat. Ekkehard Haen

Klinische Pharmakologie am Lehrstuhl für Psychiatrie
und Psychotherapie
und am Lehrstuhl für Pharmakologie und Toxikologie der
Universität und am Institut AGATE gGmbH
Nelkenweg 10, Pentling

**T** +49 178 204 3288
**E** ekkehard.haen@klinik.uni-regensburg.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Prof. Dr. med. Dr. phil. Torsten Haferlach

MLL Münchner Leukämielabor GmbH

Max-Lebsche-Platz 31, München

**T** +49 89 99017 100
**E** torsten.haferlach@mll.com

### Herr Dr. Gerulf Hänel

Klinikum der Universität München
Labor für Leukämiediagnostik
Marchioninistr. 15, München

**T** +49 89 - 2180 76835
**E** haenel@genzentrum.lmu.de

### Herr Prof. Dr. Dr. med. Fabian Hauck

LMU Klinikum
Dr. von Haunersches Kinderspital
Lindwurmstr. 4, München

**T** +49 89 4400-53931
**E** fabian.hauck@med.uni-muenchen.de

### Herr PD Dr. med. Albert Heim

Institut für Virologie
Medizinische Hochschule Hannover
, Hannover

**T** +49 511-5324311
**E** adenovirus@gmx.de

### Frau PD Dr. rer.nat. Julia Hentschel

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

**T** +49 341 97 11349
**E** julia.hentschel@instand-ringversuch.de

### Herr PD Dr. Andreas Hiergeist

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

**T** +49 941 944 16465
**E** andreas.hiergeist@ukr.de

### Frau Dr. med. Britta Höchsmann

Institut für Klinische Transfusionsmedizin und
Immungenetik Ulm (IKT)

Helmholtzstraße 10, Ulm

**T** +49 731 150 560
**E** b.hoechsmann@blutspende.de

### Herr Prof. Dr. Jörg Hofmann

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 30 8105 4300
**E** joerg.hofmann@instand-ringversuch.de

### Herr Prof. Dr. med. Stefan Holdenrieder

Institut für Laboratoriumsmedizin
TUM Universitätsklinikum - Deutsches Herzzentrum
München
Lazarettstraße 36, München

**T** +49 89 1218 1011
**E** stefan.holdenrieder@instand-ringversuch.de

### Herr Prof. Dr. med. Achim Hörauf

Institut für Medizinische Mikrobiologie, Immunologie und
Parasitologie
Universitätsklinikum Bonn
Sigmund-Freud-Straße 25, Bonn

**T** +49 228 287 15675
**E** immip.office@ukbonn.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

### Herr Prof. Dr. Marc Hübner

Universitätsklinikum Bonn
Institut für Medizinische Mikrobiologie, Immunologie und Parasitologie (IMMIP)
Venusberg-Campus 1, Bonn

**T** +49-228-287-19177
**E** huebner@uni-bonn.de

### Herr Prof. Dr. med. Andreas Humpe

Klinikum der Universität München, Campus Großhadern
Abteilung für Transfusionsmedizin, Zelltherapeutika und Hämostaseologie
Marchioninistraße 15, München

**T** +49 89 4400 7 3701
**E** andreas.humpe@med.uni-muenchen.de

### Herr Prof. Dr. med. Klaus-Peter Hunfeld

Zentralinstitut für Labormedizin, Mikrobiologie & Krankenhaushygiene
Krankenhaus Nordwest
Steinbacher Hohl 2-26, Frankfurt am Main

**T** +49 69 7601 4349
**E** hunfeld.klaus-peter@khnw.de

### Frau Dr. rer. nat. Eva-Maria Jacobsen

Diagnostische Laboratorien der Universitätsklinik für Kinder- und Jugendmedizin Ulm

Eythstr. 24, Ulm

**T** +49 731 500 57202
**E** eva-maria.jacobsen@uniklinik-ulm.de

### Frau Dr. Patricia KaiserP

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 210
**E** kaiser@instand-ev.de

### Herr Dr. rer. nat. Rolf KaiserR

Institut für Virologie
Universität und Universitätsklinikum zu Köln
Fürst-Pückler-Straße 56, Köln

**T** +49 221 478-85808
**E** rolf.kaiser@uk-koeln.de

### Herr Dr. rer. nat. Martin Kammel

Institut für Qualitätssicherung in der Virusdiagnostik - IQVD

Potsdamer Chaussee 80, Berlin

**T** +49 30 8105 4300
**E** m.kammel@iqvd.de

### Herr Dr. med. Günther Kappert

Gerinnungszentrum Rhein-Ruhr

Königstraße 13, Duisburg

**T** +49 203 348 336 0
**E** guenther.kappert@gzrr.de

### Herr Prof. Dr. med. Wolfgang Kern

MLL Münchner Leukämielabor GmbH

Max-Lebsche-Platz 31, München

**T** +49 89 99017 200
**E** wolfgang.kern@mll.com

### Frau Irina Keßel

MVZ Düsseldorf-Centrum GbR

Immermannstraße 65A, Düsseldorf

**T** +49 162 211 4792
**E** irina.kessel@instand-ringversuch.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Prof. Dr. Michael Kirschfink

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 0
**E** kirschfink@uni-hd.de

### Frau Dr. rer. nat. Kerstin Knies

Universität Würzburg - Institut für Virologie und Immunbiologie
c/o INSTAND e.V.
Ubierstr. 20, Düsseldorf

**T** +49 211-1592 13 0
**E** kerstin.knies@uni-wuerzburg.de

### Herr Dr. Uwe Kölsch

IMD Institut für Medizinische Diagnostik Berlin-Potsdam GbR

Nicolaistraße 22, Berlin-Steglitz

**T** +49 30 77001322
**E** u.koelsch@imd-berlin.de

### Herr Dipl.-Ing. (FH) Udo Kramer

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 220
**E** kramer@instand-ev.de

### Herr Prof. Dr. med. Karl-Anton Kreuzer

Universitätsklinikum Köln
Innere Medizin I
Kerpener Straße 62, Köln

**T** +49 221 478 97626
**E** karl-anton.kreuzer@uni-koeln.de

### Herr Dr. med. Hartmut Kroll

Institut für Transfusionsmedizin Dessau
DRK-Blutspendedienst NSTOB
Altener Damm 50, Dessau

**T** +49 340 54141 110
**E** hartmut.kroll@bsd-nstob.de

### Herr Dr.-Ing. Nils Lachmann

Charité-Universitätsmedizin Berlin, ZTB-Zentrum für Transfusionsmedizin
und Zelltherapie Berlin gGmbH, Gewebetypisierung am Campus Virchow-Klinikum
Augustenburger Platz 1, Berlin

**T** +49 30 450 665 098
**E** nils.lachmann@instand-ringversuch.de

### Herr Dr. med. Marc Lindenberg

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

**T** +49 511 532 19521
**E** lindenberg.marc@mh-hannover.de

### Herr Dr. med. Benedikt Lohr

St. Vincenz-Krankenhaus Limburg

Auf dem Schafsberg, Limburg

**T** +49 6431-292 7620
**E** benedikt.lohr@instand-ringversuch.de

### Frau Dr. rer. nat. Eva Lorsy

Universitätsklinikum Köln

Kerpener Straße 62, Köln

**T** +49 221 478 98828
**E** eva.lorsy@instand-ringversuch.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

### Herr Prof. Dr. med. Peter B. Luppa

Institut für Laboratoriumsmedizin
TUM Universitätsklinikum Rechts der Isar
Ismaninger Straße 22, München

**T** +49 211-1592 13 0
**E** p.luppa@tum.de

### Herr Dr. med. Thomas Lutz

MVZ Düsseldorf-Centrum GbR

Immermannstraße 65A, Düsseldorf

**T** +49 211 27101 1326
**E** lutz@zotzklimas.de

### Frau Dr. Marie Mayrhofer

MVZ Labor PD Dr. Volkmann und Kollegen SE & Co. eGbR

Gerwigstrasse 67, Karlsruhe

**T** +49 721 85000 226
**E** m.mayrhofer@laborvolkmann.de

### Frau Ilka McCormick Smith

Robert Koch-Institut
FG 16 Erreger von Pilz- und Parasiteninfektionen und Mykobakteriosen
Seestraße 10, Berlin

**T** +49 30 18754 2184
**E** mccormick-smithl@rki.de

### Frau Dr. med. Adriana Méndez

Kantonsspital Baden AG

, Baden
Schweiz
**T** +41 56 486 26 41
**E** adriana.mendez@ksb.ch

### Herr Prof. Dr. med. Matthias Nauck

Institut für Klinische Chemie und Laboratoriumsmedizin
Universitätsmedizin Greifswald
Körperschaft des öffentlichen Rechts
Ferdinand-Sauerbruch-Straße, Greifswald

**T** +49 3834 86 5500
**E** matthias.nauck@med.uni-greifswald.de

### Herr Dr. med. Thomas Nebe

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 621 4373 2991
**E** instand@instand-ev.de

### Herr Prof. Dr. med. Pietro Nenoff

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof. Dr. P. Nenoff, T. Löwe, E. von Rein
Mölbiser Hauptstraße 8, Rötha/OT Mölbis

**T** +49 34347 6191-0
**E** p.nenoff@labopart.de

### Herr Dr. rer. nat. Stefan Neubeck

Medizinische Universität Lausitz □ Carl Thiem
Institut für Laboratoriumsmedizin
Thiemstraße 111, Cottbus

**T** +49 355 46 3304
**E** s.neubeck@mul-ct.de

### Herr Dr. med. Christoph Niederau

MVZ Labor Dortmund Leopoldstraße GmbH

Leopoldstraße 10, Dortmund

**T** +49 231 860 27 0
**E** christoph.niederau@labor-dortmund.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Dr. med. Martin Obermeier

MVZ medizinisches Infektiologiezentrum Berlin AG

Oudenarder Strasse 16, Berlin

**T** +49 30-34409104-66
**E** obermeier@mvz-mib.de

### Frau Dr. Michaela Patz

Universitätsklinikum Köln

Kerpener Straße 62, Köln

**T** +49 221 478 32569
**E** michaela.patz@uk-koeln.de

### Frau Prof. Dr. med. Dipl.-Biol. Astrid Petersmann

Universitätsmedizin Oldenburg, Klinikum Oldenburg AöR
Universitätsinstitut für Klinische Chemie und Laboratoriumsmedizin
Rahel-Straus-Str. 10, Oldenburg

**T** +49 441-403-2601
**E** astrid.petersmann@instand-ringversuch.de

### Herr Prof. Dr. Zoltan Prohaszka

Semmelweis University
Department of Internal Medicine and Hematology
Szentkirályi st. 46, Budapest
Ungarn
**T** +361 3251379
**E** prohaszka.zoltan@semmelweis.hu

### Herr Prof. Dr. Holger F. Rabenau

Institut für Medizinische Virologie
Universitätsklinikum Frankfurt
Paul-Ehrlich-Str. 40, Frankfurt

**T** +49 211-1592 13 0
**E** holger.rabenau@instand-ringversuch.de

### Herr Dr. med. Roland Reibke

Klinik Bad Trissl GmbH
Abteilung für Innere Medizin I und Palliativmedizin
Bad-Trissl-Straße 73, Bad Trissl

**T** +49 80 33 20-285
**E** roland.reibke@klinik-bad-trissl.de

### Herr Prof. Dr. rer. nat. Udo Reischl

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

**T** +49 941 944 6450
**E** udo.reischl@instand-ringversuch.de

### Herr Prof. Dr. med. Karl H. Reuner

Medizinische Universität Lausitz □ Carl Thiem
Institut für Laboratoriumsmedizin
Thiemstraße 111, Cottbus

**T** +49 355 46-2480
**E** k.reuner@mul-ct.de

### Herr PD Dr. med. Volker Rickerts

Robert Koch-Institut
FG 16 Erreger von Pilz- und Parasiteninfektionen und Mykobakteriosen
Seestraße 10, Berlin

**T** +49 30 18754 2208
**E** rickertsv@rki.de

### Herr Florian Ridders

Klinische Pharmakologie am Lehrstuhl für Pharmakologie und Toxikologie der Universität

Universitätsstr. 31, Regensburg

**T** +49 941 943 4766
**E** florian.ridders@klinik.uni-regensburg.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Dr. med Martin Roskos

MVZ SYNLAB Leverkusen GmbH

Paracelsus Straße 13, Leverkusen

**T** +49 214 374 - 24892
**E** martin.roskos@synlab.com

### Herr Prof. Dr. med. Ulrich Sachs

Justus-Liebig-Universität Gießen
Institut für Klinische Immunologie und Transfusionsmedizin
Langhansstraße 7, Gießen

**T** +49 641 985 41514
**E** ulrich.sachs@instand-ringversuch.de

### Herr Prof. Dr. med. Ulrich Sack

Universitätsklinikum Leipzig AöR
Institut für Klinische Immunologie
Johannisallee 30, Leipzig

**T** +49 341 972 5500
**E** ulrich.sack@instand-ringversuch.de

### Herr Dr. med. Richard Schabath

Praxis für Hämatologie und Onkologie Berlin Mitte

Friedrichstraße 113A, Berlin

**T**
**E** richard@schabath.de

### Herr Prof. Dr. rer. nat. Ingo Schellenberg

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 120
**E** schellenberg@instand-ev.de

### Herr Prof. Dr. med. Dirk Schlüter

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

**T** +49 511 532 0
**E** dirk.schlueter@instand-ringversuch.de

### Herr Prof. Dr. med. Jonas Schmidt-Chanasit

Bernhard-Nocht-Institut für Tropenmedizin
Nationales Referenzzentrum für tropische Infektionserreger Kooperationszentrum der WHO für Arboviren
Bernhard-Nocht-Strasse 74, Hamburg

**T** +49 40 285380 271
**E** schmidt-chanasit@bnitm.de

### Frau Dr. rer. nat. Heike Schneider

Institut für Klinische Chemie und Pathobiochemie
TUM-Klinikum Rechts der Isar AöR
Ismaninger Straße 22, München

**T** +49 89 4140 5252
**E** heike.schneider@instand-ringversuch.de

### Herr Prof. Dr. rer. nat. Holger C. Scholz

Robert Koch-Institut
Abteilung ZBS 2
Nordufer 20, Berlin

**T** +49 211-1592 13 0
**E** scholzh@rki.de

### Frau Dr. rer. nat. Susanna Schubert

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

**T**
**E** susanna.schubert@instand-ringversuch.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts


### Herr Dr. Axel Schubert

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-15 92 13 720
**E** schubert@instand-ev.de

### Herr Dr. Torsten J. Schulze

Institut Springe
Eldagsener Straße 38, Springe

**T** +49 5041 772 □ 533
**E** torsten.schulze@bsd-nstob.de

### Frau Dr. Steffi Silling

Nationales Referenzzentrum für Papillom- und Polyomaviren
Institut für Virologie Uniklinik Köln
Fürst-Pückler-Straße 56, Köln

**T** +49 221-47885811
**E** steffi.silling@instand-ringversuch.de

### Herr Prof. Dr. med. Michael Spannagl

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 125
**E** m.spannagl@instand-ev.de

### Herr Prof. Dr. med. Werner Steimer

Institut für Laboratoriumsmedizin
TUM Klinikum Rechts der Isar
Ismaningerstraße 22, München

**T** +49 89 30659957
**E** werner.steimer@instand-ringversuch.de

### Frau Prof. Dr. Marion Subklewe

Ludwig-Maximilians-Universität München
Gene Center Laboratory for Translational Cancer Immunology
Feodor-Lynen-Straße 25, München

**T** +49 89 - 4400 73133
**E** marion.subklewe@med.uni-muenchen.de

### Herr Prof. Dr. med. Egbert Tannich

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 0
**E** egbert.tannich@hamburg.de

### Herr Prof. Dr. med. Jörg Timm

Universitätsklinikum Düsseldorf
Heinrich-Heine-Universität
Moorenstr. 5, Düsseldorf

**T** +49 211-81-12225
**E** joerg.timm@med.uni-duesseldorf.de

### Frau M.Sc. Luisa Toll

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 380
**E** toll@instand-ev.de

### Herr Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Max-Planck-Institut für Psychiatrie

Kraepelinstraße 2-10, München

**T** +49 89 30622 8035
**E** manfred.uhr@instand-ringversuch.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

### Frau Dr. rer. med. Silke Uhrlaß

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof. Dr. P. Nenoff, T. Löwe, E. von Rein
Mölbiser Hauptstraße 8, Rötha/OT Mölbis

**T** +49 34347 6191-259
**E** s.uhrlass@labopart.de

### Herr PD Dr. med. Franz F. Wagner

DRK-Blutspendedienst NSTOB

Eldagsener Straße 38, Springe

**T** +49 5041 772 172
**E** fwagner@bsd-nstob.de

### Herr Prof. Dr. med. Michael S. Weig

Institut für Medizinische Mikrobiologie
Universitätsmedizin Göttingen
Kreuzbergring 57, Göttingen

**T** +49 551 39 67099
**E** mweig@gwdg.de

### Herr Dr. med. Christof Weinstock

DRK-Blutspendedienst Baden-Württemberg
Hessen gemeinnützige GmbH
Helmholtzstraße 10, Ulm

**T** +49 731 150 600
**E** c.weinstock@blutspende.de

### Frau Dr. Nathalie Weiss

INSTAND e.V.

Ubierstraße 20, Düsseldorf

**T** +49 211-1592 13 430
**E** weiss@instand-ev.de

### Herr Prof. Dr. med. Folker Wenzel

Fakultät Medical and Life Sciences
Campus Villingen-Schwenningen
Jakob-Kienzle-Str. 17, Villingen-Schwenningen

**T** +49 7720 307 4358
**E** wenzel@instand-ev.de

### Frau PD Dr. rer. nat. et med. habil Cornelia Wiegand

Klinik für Hautkrankheiten Universitätsklinikum Jena
Dermatologisches Forschungslabor
Am Klinikum 1, Jena

**T** +49 3641 9328878
**E** c.wiegand@med.uni-jena.de

### Herr Dr. med. Georg Wittmann

Labor Becker MVZ eGbR

Führichstr. 70, München

**T** +49 89 450917-395
**E** g.wittmann@labor-becker.de

### Frau Sükran Zaralioglu

Charité-Universitätsmedizin Berlin, ZTB-Zentrum für Transfusionsmedizin
und Zelltherapie Berlin gGmbH, Gewebetypisierung am Campus Virchow-Klinikum
Augustenburger Platz 1, Berlin

**T** +49 30 450 665 098
**E** suekran.zaralioglu@charite.de

### Frau Prof. Dr. med. Inga Zerr

Nationales Referenzzentrum für TSE
Klinik für Neurologie Universitätsmedizin Göttingen
Robert-Koch-Straße 40, Göttingen

**T** +49 551 39 61805
**E** ingazerr@med.uni-goettingen.de

## Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

**Herr Dr. med. Stefan Ziesing**

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

**T** +49 511 532 4344
**E** ziesing.stefan@mh-hannover.de

**Herr Dr. rer. nat. Thomas Zimmermann**

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof. Dr. P. Nenoff, T. Löwe, E. von Rein
Wurzener Straße 5, Dresden

**T** +49 351 210799 211
**E** th.zimmermann@labopart.de

## INDEX

### SYMBOL


(d-)Methamphetamine (urine) (176) 151


### 1


1,25 dihydroxy vitamin D (290) 159
1,25-OH Cholecalciferol (serum) (290) 159
1-39 ACTH (298) 105
1-84 PTH (301) 106
10-OH-Carbamazepine (192, 860) 128, 136
17-beta-Estradiol (302) 109
17-Hydroxyprogesterone (dried blood spots) (785) 125
17-Hydroxyprogesterone (serum / plasma) (309) 111


### 2


21-hydroxylase deficiency (DNA) (773) 33
25-Hydroxy-Cholecalciferol (290) 159
25-Hydroxy-Vitamin-D (290) 159
25-OH CCF (Vitamin D) (290) 159


### 3


3-Methoxytyramine (175) 155


### 4


4-Hydroxyproline (710) 113


### 5


5-HIAA (175) 155
5-Hydroxyindolea acid (175) 155


### 9


9-OH-Risperidone (862) 137


### A


A - Subtyping (Machine-based, whole blood) (237, 83, 83
A - Subtyping (serum / erythrocytes suspension) (231, 232) 81, 81
A B 0 - system (DNA ) (235) 26
A B 0 characteristics, Rhesus type (Machine-based, whole blood) (237, 238) 83, 83
A B 0 characteristics, Rhesus type (serum / erythrocytes suspension) (231, 232) 81, 81
a1-Antitrypsine (241) 143
a1-AT S-Locus (743) 28
a1-AT Z-Locus (743) 28
a1-Globulins (141) 120
a1-Globulins (electrophoresis, Serum) (102) 115
a1-Glycoprotein (241) 143
A1298C (DNA ) (747) 42
A1298C (whole blood, Dna) (732) 42
A149P (793) 27
A174D (793) 27
a1PI (743) 28
a2-Globulins (141) 120
a2-Globulins (electrophoresis, Serum) (102) 115
a2-Makroglobulin (241) 143
A20 (plasma) (509) 103
AAT (743) 28
ACE (630) 113
ACE INS/DEL (DNA) (763) 28
acetaminophen (194) 135
Acid phosphatase (100) 115
Acid-fast bacilli (Slide) (421) 188
ACT (286) 102
activated clotting time (286) 102
Activated partial thromboplastin time (221, 230, 280, 94, 95, 102,
Acute myeloid leukemia (798) 57
Adenoviruses (cell culture lysate) (371, 431, 433) 199, 221, 224
Adenoviruses (suspensions of feces) (430) 206
ADHS-Treatment (879) 135
aDNase (321) 181
Adrenal Gland (298) 105
Aeromonas spp (548) 168
AFP (Pregnancy) (306) 107
AFP (tumor marker) (292) 149
Alanine (710) 113
ALAT (100, 810) 115, 145
Albumin (CSF) (460) 124
Albumin (electrophoresis, Serum) (102) 115
Albumin (POCT: Abaxis Piccolo) (810) 145
Albumin (serum) (100, 141) 115, 120
Albumin (urine) (171, 182) 156, 158
Albumin quotient (CSF / serum) (460) 124
Alcohol (750, 751) 119, 152
ALDOB (793) 27
Aldolase (serum) (100) 115
Aldolase B (A149P, A174D, N334K) (DNA) (793) 27
Aldolase B (DNA ) (793) 27
Aldosterone (serum) (304) 105
Aldosterone (urine) (179) 155
Alkaline Phosphatase (100, 810) 115, 145
Allergy Diagnostic (basophils, EDTA-whole blood) (653) 70
Allergy Diagnostic (IgE, serum) (720) 62
allo-Isoleucine (710) 113
alpha-1-Microglobulin (urine) (182) 158
alpha-2-macroglobulin (urine) (182) 158
alpha-Aminoadipic acid (710) 113
alpha-Amylase (POCT: Abaxis Piccolo) (810) 145
alpha-Amylase (serum) (100) 115
alpha-Amylase (urine) (173) 157
Alpha-Fetoprotein (306) 107

## INDEX


alpha-Globin (DNA ) (794) 27
alpha1-Antitrypsin (743) 28
alpha1-proteinase-Inhibitor (743) 28
Alprazolam (876) 133
ALT (100, 810) 115, 145
Alternative pathway (246) 80
Aluminium (plasma) (206) 147
Aluminium (urine) (205) 153
AMH (297) 106
Amicacin (197) 138
Amino Acid Analysis (710) 113
Aminolaevulinic acid (urine) (180) 154
Amiodarone (190) 126
Amisulpride (861, 873) 131, 136
Amitriptyline (serum) (199, 203, 863) 137, 140, 141
Amitriptyline (urine) (204) 153
AML-Panel (NGS) (798) 57
Ammonia (118) 114
Amoebiasis (455) 194
Amphetamine (urine) (174) 150
Ampicillin (890) 127
AMR (544) 162
Amyloid ß Peptid 40 (Aß40) (466) 121
Amyloid ß Peptid 42 (Aß42) (466) 121
Amyloid ß Peptid Ratio (Aß 42/40) (466) 121
ANA (251) 64
ANCR (DNA) (786) 45
Androstendion (309) 111
Angelmann syndrome (AS) (DNA) (786) 45
Angiotensin Converting Enzym Apolipoprotein (DNA) (763) 28
Angiotensin-Converting-Enzyme (630) 113
Anthrax (542) 164
Anti -P450 C17 -Hydroxylase (263) 63
Anti - Acetylcholin Receptors (269) 66
Anti - Actin (253) 66
Anti - Adrenal Cortex (263) 63
Anti - Amphiphysin 1 (265) 67
Anti - Asialoganglioside (AGA1) (267) 68
Anti - Borna virus (415) 230
Anti - BPAg-1 (259) 63
Anti - BPAg-2 (259) 63
Anti - C1 inhibitor (250) 77
Anti - Cardiolipin (IgG) (275) 62
Anti - Cardiolipin (IgM) (275) 62
Anti - CCP (cyclic citrulline peptide) (273) 69
Anti - CHIKV (cell culture lysate) (402) 230
Anti - CMV (serum) (351) 231
Anti - deamidated Gliadin (271) 65
Anti - dengue virus (serum) (350) 231
Anti - Desmoglein-1 (259) 63
Anti - Desmoglein-3 (259) 63
Anti - Desmoplakin I/II (259) 63
Anti - Desmosomes (serum) (259) 63
Anti - DFS70/LEDGF (251) 64
Anti - Disialoganglioside (GD1a) (267) 68
Anti - Disialoganglioside (GD1b) (267) 68
Anti - ds-DNA (251) 64
Anti - Endomysium (271) 65
Anti - Glia Cell Nuclear Antibody (AGNA) (265) 67
Anti - Gliadin (271) 65
Anti - glomerular basement membrane (GBM) (serum) (257) 69
Anti - Glutamic Acid Decarboxylase (GAD) (261) 65
Anti - H+/K+-ATPase (253) 66
Anti - HAV (serum) (343) 233
Anti - HBc (serum) (344) 233
Anti - HBc-IgM (serum) (345) 234
Anti - HBe (serum) (345) 234
Anti - HBs (serum) (344) 233
Anti - HCV (serum) (346) 234
Anti - HDV (serum) (347) 235
Anti - Hemidesmosomes (259) 63
Anti - HEV (serum) (348) 235
Anti - HIV-1 (serum) (335) 237
Anti - HIV-2 (serum) (335) 237
Anti - HSV (serum) (354) 236
Anti - HTLV-1 (serum) (339) 237
Anti - HTLV-2 (serum) (339) 237
Anti - HuD (serum) (265) 67
Anti - Insulin (IAA) (261) 65
Anti - Islet Cells (ICA) (261) 65
Anti - Jo 1 (Histidyl-tRNA-Synthetase) (255) 64
Anti - MCV (mutated citrullinated Vimentin) (273) 69
Anti - measles virus (serum) (357) 238
Anti - Microsomes (LKM 1) (253) 66
Anti - Mikrosomen (295) 110
Anti - Mitochondria (253) 66
Anti - Monosialoganglioside (GM1) (267) 68
Anti - Monosialoganglioside (GM2) (267) 68
Anti - Monosialoganglioside (GM3) (267) 68
Anti - MPO (257) 69
Anti - Mullerian hormone (297) 106
Anti - mumps virus (serum) (358) 241
Anti - Musclespecific Receptor Tyrosinkinase (MuSK) (269) 66
Anti - Myelin-associated Glycoprotein (MAG) (267) 68
Anti - Neuronal Nuclei (265) 67
Anti - P450 C21 -Hydroxylase (263) 63
Anti - P450 ssc -Hydroxylase (263) 63
Anti - Parietal Cells (253) 66
Anti - parvovirus B19 (serum) (342) 239
Anti - PM / Scl (255) 64
Anti - PR3 (257) 69
Anti - Purkinje Cells (265) 67
Anti - Quadrosialoganglioside (GQ1b) (267) 68
Anti - rabies Virus (serum) (336) 239
Anti - Ri / Nova 1 (265) 67
Anti - rubella virus (serum) (341) 240
Anti - Skeletal Muscle (269) 66
Anti - Sm (255) 64
Anti - Sm (D) (255) 64
Anti - Smooth Muscle (253) 66
Anti - SOX1 (265) 67
Anti - SSA / Ro (255) 64
Anti - SSA / Ro (52kD - Proteins) (255) 64

## INDEX


| | |
|---|---|
| Anti - SSA / Ro (60kD - Proteins) (255) | 64 |
| Anti - SSB / La (255) | 64 |
| Anti - streptodornase (serum) (321) | 181 |
| Anti - streptolysin O (serum) (321) | 181 |
| Anti - Ta (Ma 2) (265) | 67 |
| Anti - TBE/FSME (serum) (358) | 241 |
| Anti - Titin (269) | 66 |
| Anti - Topoisomerase-1 (Scl 70) (255) | 64 |
| Anti - TPO (295) | 110 |
| Anti - Transglutaminase IgA (271) | 65 |
| Anti - Trisialoganglioside (GT1b) (267) | 68 |
| Anti - Tyreoglobulin (295) | 110 |
| Anti - Tyrosine Phosphatase (IA2) (261) | 65 |
| Anti - U1 -snRNP (Anti - U1 -70K) (255) | 64 |
| Anti - VZV (serum) (353) | 241 |
| Anti - Yo (CDR62) (265) | 67 |
| Anti - ZIKV (serum) (338) | 242 |
| Anti - Zinc Transporter 8 (ZnT8A) (261) | 65 |
| Anti - ß2-Glycoprotein (IgG) (275) | 62 |
| Anti - ß2-Glycoprotein (IgM) (275) | 62 |
| anti nuclear antibodies (251) | 64 |
| Anti- DNA double stranded (251) | 64 |
| Anti-DGP (271) | 65 |
| anti-Microsome (295) | 110 |
| anti-Thyroglobulin (295) | 110 |
| anti-TPO (295) | 110 |
| Antiarrhytmics (190) | 126 |
| Antibacterials (193, 890) | 126, 127 |
| antibiotic resistance (544) | 162 |
| Antibiotics (193) | 126 |
| Antibodies (452) | 195 |
| Antibodies against Bartonella henselae (serum) (326) | 170 |
| Antibodies against Bordetella pertussis (serum) (317) | 171 |
| Antibodies against Borrelia (serum) (332) | 171 |
| Antibodies against Brucella (serum) (327) | 172 |
| Antibodies against campylobacter (serum) (319) | 172 |
| Antibodies against Chlamydia pneumoniae (serum) (314) | 173 |
| Antibodies against Chlamydia trachomatis (serum) (312) | 173 |
| Antibodies against Coxiella burnetii (serum) (325) | 175 |
| Antibodies against diphtheria toxoid (serum) (318) | 175 |
| Antibodies against EBV (serum) (352) | 232 |
| Antibodies against Echinococcus (455) | 194 |
| Antibodies against Entamoeba histolytica (455) | 194 |
| Antibodies against Francisella (serum) (328) | 176 |
| Antibodies against hantaviruses (serum) (355) | 232 |
| Antibodies against Helicobacter pylori (serum) (334) | 176 |
| Antibodies against Leptospira (serum) (329) | 177 |
| Antibodies against mycoplasma pneumoniae (serum) (324) | 177 |
| Antibodies against Plasmodium (454) | 194 |
| Antibodies against Rickettsia (serum) (330) | 179 |
| Antibodies against salmonella (serum) (331) | 180 |
| Antibodies against Schistosoma (454) | 194 |
| Antibodies against tetanus toxoid (serum) (310) | 181 |
| Antibodies against Toxoplasma gondii (452) | 195 |
| Antibodies against Treponema pallidum (serum) (311) | 182 |
| Antibodies against Yersinia (serum) (315) | 183 |
| Antibody ID (Machine-based, whole blood) (237, 238) | 83, 83 |
| Antibody ID (serum / erythrocytes suspension) (232) | 81 |
| Antibody Identification (232, 237, 238) | 81, 83, 83 |
| Antibody quantitation (Machine-based, whole blood) (238) | 83 |
| Antibody quantitation (serum / erythrocytes suspension) (232) | 81 |
| Antibody Screening (Machine-based, whole blood) (237, 238) | 83, 83 |
| Antibody Screening (serum / erythrocytes suspension) (231, 232) | 81, 81 |
| Antibody titer (232) | 81 |
| anticoagulant (230, 282, 501, 502, 503, 504, 505) | 94, 94, 96, 97, |
| Anticonvulsants (191, 192, 871, 872) | 127, 128, 128, |
| Antifungals (198, 602) | 129, 130 |
| Antimon (lyophilized whole blood) (208) | 146 |
| Antimon (serum) (207) | 147 |
| Antiphospholipid Syndrome (275) | 62 |
| Antipsychotic Drugs (200, 200, 873, 873, 874, 874, 875, 875) | 130, 130, 131, 131, 131, 131, 132, 132 |
| Antithrombin (225, 285) | 95, 95 |
| Antithrombin (DNA ) (792) | 29 |
| Antivirals (850) | 132 |
| AP (100) | 115 |
| AP (POCT: Abaxis Piccolo) (810) | 145 |
| APC resistance (288) | 100 |
| Apixaban (504) | 94 |
| Apo B (DNA ) (771) | 30 |
| Apo E (Genotyp 2, 3, 4) (DNA) (744) | 30 |
| Apo-E (734) | 29 |
| ApoB (151, 771) | 30, 119 |
| ApoB (DNA) (771) | 30 |
| ApoE (151) | 119 |
| ApoE (genotype 2, 3, 4) (DNA) (744) | 30 |
| ApoE (genotype 2, 3, 4) (whole blood) (734) | 29 |
| Apolipoprotein A1 (151) | 119 |
| Apolipoprotein B (151) | 119 |
| Apolipoprotein E (744) | 30 |
| Apolipoprotein E (DNA) (744) | 30 |
| Apolipoprotein E (serum / plasma) (151) | 119 |
| Apolipoprotein E (whole blood) (734) | 29 |
| Apolipoprotein E (whole blood, Dna) (734) | 29 |
| APS (275) | 62 |
| aPTT (Argatroban) (230) | 94 |
| aPTT (Plasma) (221, 280, 285) | 95, 102, 104 |
| aPTT (whole blood) (286) | 102 |
| Argatroban (Argatroban) (230) | 94 |
| Arginine (710) | 113 |
| Argininosuccinic acid (710) | 113 |
| Aripiprazole (860) | 136 |
| Arsenic (lyophilized whole blood) (208) | 146 |
| Arsenic (plasma) (206) | 147 |
| Arsenic (urine) (205) | 153 |
| ASAT (100, 810) | 115, 145 |
| Ascorbic acid (urine) (171) | 156 |

## INDEX


| | |
|---|---|
| Ascorbic acid (Vitamin C) (plasma) (296) | 159 |
| Asialotransferrin (750) | 119 |
| ASO (serum) (321) | 181 |
| Asparagine (710) | 113 |
| Aspartic acid (710) | 113 |
| AST (100, 810) | 115, 145 |
| Astroviruses (suspensions of feces) (430) | 206 |
| ASXL1 Nomenclature (798) | 57 |
| AT (plasma) (225) | 95 |
| AT3 (DNA ) (792) | 29 |
| Atazanavir (850) | 132 |
| Atomoxetine (879) | 135 |
| ATP 7 B: H 1069 Q (DNA) (745) | 34 |
| Auto-anti C1q (245) | 78 |
| Auto-anti FH (249) | 78 |
| auto-anti-C1 inhibitor (250) | 77 |
| Autoantibodies against nuclei (251, 251) | 64, 64 |
| Autoimmune Dermatitis (259) | 63 |
| Autoimmune Diseases 01 - Connective Tissue Diseases (ANA) (251) | 64 |
| Autoimmune Diseases 02 - Hepatic Syndromes (253) | 66 |
| Autoimmune Diseases 03 - Connective Tissue Diseases (ENA) (255) | 64 |
| Autoimmune Diseases 04 - Vasculitis/Glomerulopathies (257) | 69 |
| Autoimmune Diseases 05 - Autoimmune Dermatitis (259) | 63 |
| Autoimmune Diseases 06 - Diabetes mellitus (261) | 65 |
| Autoimmune Diseases 07 - Autoimmune Endocrinopathies (263) | 63 |
| Autoimmune Diseases 08 - Paraneoplastic Neuropathies (265) | 67 |
| Autoimmune Diseases 09 - Peripheral Neuropathies (267) | 68 |
| Autoimmune Diseases 10 - Myasthenia gravis (269) | 66 |
| Autoimmune Diseases 11 - Gluten-Sensitive Enteropathies (271) | 65 |
| Autoimmune Diseases 12 - Rheumatoid Arthritis (273) | 69 |
| Autoimmune Diseases 13 - Antiphospholipid Syndrome (275) | 62 |
| Autoimmune Endocrinopathies (263) | 63 |
| autoprothrombin IIA (788) | 31 |
| Avian Influenza (cell culture lysate) (370) | 198 |
| Avidity - Anti-CHIKV IgG (cell culture lysate) (402) | 230 |
| Avidity - Anti-CMV IgG (serum) (351) | 231 |
| Avidity - Anti-HSV IgG (serum) (354) | 236 |
| Avidity - Anti-measles virus IgG (serum) (357) | 238 |
| Avidity - Anti-mumps virus IgG (serum) (356) | 238 |
| Avidity - Anti-parvovirus B19 IgG (serum) (342) | 239 |
| Avidity - Anti-rubella virus IgG (serum) (341) | 240 |
| Avidity - Anti-TBE/FSME virus IgG (serum) (358) | 241 |
| Avidity - Anti-VZV IgG (serum) (353) | 241 |
| Avidity - Anti-ZIKV IgG (serum) (338) | 242 |
| AZF (DNA) (788) | 31 |
| Azoospermia factor (788) | 31 |


## B


| | |
|---|---|
| b-Alanine (710) | 113 |
| B-cells (cellular products) (617) | 93 |
| B-Cells (EDTA-Vollblut) (651) | 74 |
| B-Lymphocytes (213) | 90 |
| Bacillary angiomatosi (326) | 170 |
| Bacillus anthracis (Bacterial genome) (542) | 164 |
| Bacterial Genome Detection (548) | 168 |
| Bacterial identification (412) | 185 |
| Bacteriology (411, 412) | 184, 185 |
| Bacteriology (Slide (fixed)) (413) | 185 |
| Bacteriology - Gram Stain (Slide (fixed)) (413) | 185 |
| Barbiturate-phenobarbiturate (urine) (174) | 150 |
| Bartonella henselae (antibody, serum) (326) | 170 |
| Basidiomycetes (living cultures) (490) | 191 |
| Basophil Activation Test (653) | 70 |
| Basophilic Granulocytes (whole blood) (612) | 88 |
| Bb (247) | 79 |
| Becker muscular dystrophy (BMD) (DNA) (780) | 37 |
| Benzodiazepine Lorazepam (urine) (177) | 151 |
| Benzodiazepines (serum) (876, 877, 878) | 133, 133, 134 |
| Benzoylecgonine (urine) (174) | 150 |
| Beryllium (serum) (207) | 147 |
| beta-2-Microglobulin (serum) (292) | 149 |
| beta-2-Microglobulin (urine) (182) | 158 |
| beta-Globin (DNA ) (794) | 27 |
| beta-Globulins (electrophoresis, Serum) (102) | 115 |
| beta-Globulins (Serum) (141) | 120 |
| Bilirubin (newborn, serum) (110) | 125 |
| Bilirubin (POCT: Abaxis Piccolo) (810) | 145 |
| Bilirubin (serum) (100) | 115 |
| Bilirubin (urine) (171) | 156 |
| Biochemistry (100) | 115 |
| Biogene Amines (plasma) (185) | 114 |
| Biogene Amines (urine) (175) | 155 |
| Biotin (Vitamin H) (290) | 159 |
| Bismuth (207) | 147 |
| BK polyomavirus (BKPyV or BKV) (plasma / urine) (364) | 200 |
| BK Virus (plasma / urine) (364) | 200 |
| BK virus-associated nephropathy (364) | 200 |
| bleeding tendency (670, 671, 672, 673, 674, 675, 676, 677, 678) | 49, 49, 50, 50, 51, 51, 52, 52, 54 |
| Blood Cell Count (QBC systems) (209) | 87 |
| Blood Cell Count (stabilized control blood) (211) | 86 |
| blood coagulation factor XIV (788) | 31 |
| Blood Gas Analysis (POCT OPTI Systems) (163) | 145 |
| Blood Gas Analysis (POCT) (161, 162) | 144, 144 |
| blood grouping (231, 232, 237) | 81, 81, 83 |
| Blood parasites (blood smear) (456) | 193 |
| Blood parasites (pictures) (906) | 195 |
| Blood Smear Analysis (blood smear) (212) | 87 |
| BNP (761) | 112 |
| Bocaviruses (cell culture lysate) (431) | 224 |
| BoDV (404, 415) | 200, 230 |

## INDEX


| | |
|---|---|
| Bone Marrow Cytology (bone marrow aspirate (digital image)) (218) | 88 |
| Bordetella pertussis (antibody, serum) (317) | 171 |
| Bordetella pertussis (Bacterial genome) (532) | 161 |
| Borna Viruses (cell culture lysate) (404) | 200 |
| Borna Viruses (serum) (415) | 230 |
| Borrelia burgdorferi (Ab) (antibody, serum) (332) | 171 |
| Borrelia burgdorferi (Bacterial genome) (535) | 161 |
| Borrelia IgG Antibody Index (AI) calculation (CSF) (465) | 123 |
| Borrelia IgG Antibody Index (CSF) (465) | 123 |
| Borrelia specific quotient (CSF) (465) | 123 |
| BRAF (795) | 57 |
| BRAF Nomenclature (795) | 57 |
| BRAF p.V600 (795, 795) | 57, 57 |
| BRAF V600 (liquid biopsy) (752) | 35 |
| BRCA1 (DNA ) (779) | 31 |
| BRCA2 (DNA ) (779) | 31 |
| breast and ovarian cancer (DNA) (779) | 31 |
| Brivaracetam (871) | 128 |
| Bromazepam (878) | 134 |
| Brucella (antibody, serum) (327) | 172 |
| Brucella spp. (Bacterial genome) (543) | 165 |
| Brucellosis (543) | 165 |
| Bruton tyrosine kinase (796) | 58 |
| BTK (796) | 58 |
| BTK Nomenclature (796) | 58 |
| BTK p.C481 (796) | 58 |
| Buprenorphine (urine) (176) | 151 |


## C


| | |
|---|---|
| c-ANCA (serum) (257) | 69 |
| C-Peptide (serum / plasma) (300) | 108 |
| C-Reactive Protein (241) | 143 |
| C-Reactive Protein (antibody, serum) (322) | 143 |
| C. difficile (545) | 164 |
| C1 inhibitor: activity (246) | 80 |
| C1 inhibitor: proteine (246) | 80 |
| C1-Inhibitor (plasma) (225) | 95 |
| C1q proteine (246) | 80 |
| C282Y (DNA ) (741) | 39 |
| C282Y (whole blood, Dna) (733) | 40 |
| C3 - nephritic factor (248) | 79 |
| C3-Complement (246) | 80 |
| C3-Complement (plasma) (241) | 143 |
| C3a (247) | 79 |
| C3d (247) | 79 |
| C4-Complement (246) | 80 |
| C4-Complement (plasma) (241) | 143 |
| CA 125 (292) | 149 |
| CA 15-3 (292) | 149 |
| CA 19-9 (292) | 149 |
| CA 72-4 (292) | 149 |
| Cadmium (lyophilized whole blood) (208) | 146 |
| Cadmium (plasma) (206) | 147 |
| Cadmium (urine) (205) | 153 |
| Caffeine (870) | 138 |
| CAH (DNA) (773) | 33 |
| Calcitonin (Calcium metabolism) (301) | 106 |
| Calcitonin (Tumor marker) (299) | 149 |
| Calcium (POCT: Abaxis Piccolo) (810) | 145 |
| Calcium (serum) (100) | 115 |
| Calcium (urine) (173) | 157 |
| Calcium Metabolism (301) | 106 |
| Calprotectin (130) | 148 |
| CALR (DNA ) (768) | 59 |
| Campylobacter (548) | 168 |
| Campylobacter (antibody, serum) (319) | 172 |
| Candida antibodies (480) | 191 |
| Candida antigen (serum) (480) | 191 |
| Candidiasis (480) | 191 |
| Capillary Zone Electrophoresis (102) | 115 |
| CAR-T-Cells (822) | 85 |
| Carbamacepine (195) | 139 |
| Carbamazepine-epoxide (192) | 128 |
| carbamezepine (195) | 139 |
| Carbapenemase genes (microbiological samples) (544) | 162 |
| Carbapenemase-Genes (Bacterial genome) (544) | 162 |
| Cardiac markers (760) | 112 |
| Cariprazine (875) | 132 |
| Cat-scratch disease (326) | 170 |
| CCR5-Gene (DNA) (764) | 32 |
| CD107a expression (NK and T cell blasts) (657) | 76 |
| CD16+ (651) | 74 |
| CD19+ (651) | 74 |
| CD21low/CD38low B cells (651) | 74 |
| CD3+ (651) | 74 |
| CD34 (whole blood) (217, 660) | 92, 93 |
| CD34+ events (whole blood) (217) | 92 |
| CD4 (213) | 90 |
| CD4+ (651) | 74 |
| CD45+ (cellular products) (617) | 93 |
| CD45+ events (whole blood) (217) | 92 |
| CD56+ (651) | 74 |
| CD8 (213) | 90 |
| CDI (545) | 164 |
| CEA (292) | 149 |
| CEBPA (CDS) Mutation(s) (798) | 57 |
| CEBPA Nomenclature (798) | 57 |
| Cefepime (890) | 127 |
| Ceftazidime (890) | 127 |
| Celiac disease (271) | 65 |
| Cellular Immunodeficiency Diagnostic (EDTA-whole blood) (651) | 74 |
| Cerebrospinal Fluid Analysis (467, 468) | 121, 122 |
| Cerebrospinal Fluid Analysis (CSF + serum) (460, 462, 463) | 123, 124, 124 |
| Cerebrospinal Fluid Analysis (CSF) (464, 465, 466) | 121, 122, 123 |
| Cerebrospinal Fluid Analysis 01 - Protein Analysis (CSF + serum) (460) | 124 |

## INDEX


| | |
|---|---|
| Cerebrospinal Fluid Analysis 02 - Oligoclonal IgG (CSF + serum) (462) | 124 |
| Cerebrospinal Fluid Analysis 03 - MRZ Reaction (CSF + serum) (463) | 123 |
| Cerebrospinal Fluid Analysis 04 - Lactate/ Glucose (CSF) (464) | 122 |
| Cerebrospinal Fluid Analysis 05 - Neuroborreliosis (CSF + serum) (465) | 123 |
| Cerebrospinal Fluid Analysis 06 - Dementia Markers (CSF) (466) | 121 |
| CFTR Common Mutations (DNA ) (778) | 32 |
| CFTR gene (DNA) (778) | 32 |
| CGG-Repeat (DNA) (781) | 39 |
| CHE (100) | 115 |
| chemokine receptor (764) | 32 |
| Chikungunya Virus (cell culture lysate) (402) | 230 |
| Chikungunya Virus (plasma) (392) | 201 |
| Chimerism Diagnostics (618) | 26 |
| Chlamydia (312, 313, 314, 316, 530, 531) | 163, 163, 173, 173, 174, 174 |
| Chlamydia pneumoniae (antibody, serum) (314) | 173 |
| Chlamydia pneumoniae (Bacterial genome) (540) | 162 |
| Chlamydia trachomatis (antibody, serum) (312, 313) | 173, 174 |
| Chlamydia trachomatis (Bacterial genome) (530, 531) | 163, 163 |
| Chlamydia trachomatis (Slide (fixed)) (316) | 174 |
| Chloramphenicol (198) | 130 |
| Chlordiazepoxide (876) | 133 |
| Chloride (POCT OPTI Systems) (163) | 145 |
| Chloride (POCT) (161) | 144 |
| Chloride (POCT: Abaxis Piccolo) (810) | 145 |
| Chloride (serum) (100) | 115 |
| Chloride (urine) (173) | 157 |
| Chlorprotixene (875) | 132 |
| Cholesterol (100, 151) | 115, 119 |
| Cholesterol (POCT: Abaxis Piccolo) (810) | 145 |
| Cholinesterase (100) | 115 |
| Chromatographic analysis (188) | 152 |
| Chromium (lyophilized whole blood) (208) | 146 |
| Chromium (plasma) (206) | 147 |
| Chromium (urine) (205) | 153 |
| Chromium release assay (657) | 76 |
| chronic lymphocytic leukemia (820) | 86 |
| Citalopram (860) | 136 |
| Citrulline (710) | 113 |
| CK (100) | 115 |
| CK (POCT: Abaxis Piccolo) (810) | 145 |
| CK-MB (760) | 112 |
| Classical pathway (246) | 80 |
| CLL-MRD Immunophenotyping (820) | 86 |
| Clobazam (878) | 134 |
| Clobazepam (878) | 134 |
| Clomipramine (serum) (199, 203, 863) | 137, 140, 141 |
| Clomipramine (urine) (204) | 153 |
| Clonazepam (877) | 133 |
| Clostridium difficile (Bacterial genome) (545) | 164 |
| Clostridium difficile (microbiological samples) (545) | 164 |
| Clostridium difficile (toxinogen) (548) | 168 |
| clotting factor (670, 671, 672, 673, 674, 675, 676, 677, 678, 790, 791, 792) | 29, 45, 46, 49, 49, 50, 50, 51, 51, 52, 52, 54 |
| Clozapine (200, 862, 863) | 130, 137, 137 |
| cMRSA (Bacterial genome) (539) | 167 |
| CMV (349, 351) | 204, 231 |
| CMV (cell culture lysate) (433) | 221 |
| CMV (plasma) (349, 365, 368) | 203, 203, 204 |
| coagulation (223, 224, 225, 226, 227, 670, 671, 672, 673, 674, 675, 676, 677, 678) | 49, 49, 50, 50, 51, 51, 52, 52, 54, 95, 96, 98, 98, 99 |
| coagulation (DNA) (790, 791) | 45, 46 |
| Cobalamin (Vitamin B12) (290) | 159 |
| Cobalt (lyophilized whole blood) (208) | 146 |
| Cobalt (plasma) (206) | 147 |
| Cobalt (urine) (205) | 153 |
| Coeliac Disease (772) | 73 |
| Coeliac disease diagnostics (serum) (271) | 65 |
| Coelomycetes (living cultures) (490) | 191 |
| Coeruloplasmin (241) | 143 |
| Collagen Receptor C807T (739) | 33 |
| Collagen receptor C807T (DNA) (739) | 33 |
| Collagen receptor GP Ia/IIa (C 807 T) (739) | 33 |
| Collagen receptor GP Ia/IIa (DNA) (739) | 33 |
| Collagenosis Screening (ANA) (serum) (251) | 64 |
| Colton system [CO] (DNA) (235) | 26 |
| Complement activation products (247) | 79 |
| Complement Analysis (245, 246, 247, 248, 249, 250) | 77, 78, 78, 79, 79, 80 |
| Complement Analysis 01 (Auto-anti-C1q) (245) | 78 |
| Complement Analysis 02 (Functions and proteins) (246) | 80 |
| Complement Analysis 03 (Complement activation products) (247) | 79 |
| Complement Analysis 04 (C3 - nephritic factor) (248) | 79 |
| Complement Analysis 05 (Auto-anti FH) (249) | 78 |
| Complement Analysis 06 (anti - C1 inhibitor) (250) | 77 |
| Complement factor H (246) | 80 |
| Complement factor I (246) | 80 |
| Concentration of Hb in reticulocytes (216) | 91 |
| congenital adrenal hyperplasia (DNA) (773) | 33 |
| Connective Tissue Diseases (ANA) (serum) (251) | 64 |
| Connective Tissue Diseases (ENA) (255) | 64 |
| Connexin 26 (DNA) (782) | 34 |
| Copper (plasma) (206) | 147 |
| Copper (serum) (100) | 115 |
| Copper (urine) (205) | 153 |
| Coproporphyrin (178) | 156 |
| Coronaviruses (409) | 227 |
| Coronaviruses (cell culture lysate) (340, 417, 431, 432) | 202, 224, 225, 227 |
| Coronaviruses (cell culture supernatants) (410, 410) | 197, 197 |
| Coronaviruses (serum) (416) | 240 |
| Cortisol (serum) (302) | 109 |
| Cortisol free (urine) (179) | 155 |
| COVID (409, 410, 416) | 197, 227, 240 |

## INDEX


| | |
|---|---|
| Coxiella burnetii (antibody, serum) (325) | 175 |
| Coxiella burnetii (Bacterial genome) (542) | 164 |
| Creatine Kinase (100) | 115 |
| Creatinine (POCT) (161) | 144 |
| Creatinine (POCT: Abaxis Piccolo) (810) | 145 |
| Creatinine (serum) (100) | 115 |
| Creatinine (urine) (173, 182) | 157, 158 |
| Creatinine kinase (810) | 145 |
| CRP (810) | 145 |
| Cryptococcosis (481) | 192 |
| Cryptococcus gattii (serum or liquor) (481) | 192 |
| Cryptococcus neoformans (serum or liquor) (481) | 192 |
| Cryptosporidium spp. (458) | 193 |
| CSF (460, 462, 463, 464, 465, 466, 467, 468) | 121, 121, 122, 122, 123, 123, 124, 124 |
| ctDNA (liquid biopsy) (752) | 35 |
| Cultivation of mycobacteria (sputum) (422) | 186 |
| Cultivation, identification and sensitivity testing of bacteria (3 Samples) (411) | 184 |
| Cultivation, identification and sensitivity testing of bacteria (5 Samples) (412) | 185 |
| Cx26 (782) | 34 |
| Cyclosporine A (601) | 134 |
| CYFRA 21-1 (292) | 149 |
| Cyp21A2 (DNA) (773) | 33 |
| CYP21A2 gene (DNA) (773) | 33 |
| CYP2C19 (DNA) (775) | 35 |
| CYP2C9 (DNA) (775) | 35 |
| CYP2D6 (DNA) (777) | 36 |
| Cystathionine (710) | 113 |
| Cystatin-C (242) | 142 |
| Cysteine-Homocysteine-disulfide (710) | 113 |
| Cystic fibrosis (778) | 32 |
| Cystine (710) | 113 |
| Cytomegalovirus (cell culture lysate) (433) | 221 |
| Cytomegalovirus (plasma) (349, 365, 368) | 203, 203, 204 |
| Cytomegalovirus (serum) (351) | 231 |


## D


| | |
|---|---|
| D-Dimer (226, 285) | 95, 96 |
| Dabigatran (502) | 96 |
| Darunavir (850) | 132 |
| DAT (231, 232, 237, 238) | 81, 81, 83, 83 |
| delta-9-THC-COOH (urine) (177) | 151 |
| Dementia Markers (CSF) (466) | 121 |
| Dengue fever (350, 369) | 204, 231 |
| Dengue Viruses (plasma) (369) | 204 |
| Dengue Viruses (serum) (350) | 231 |
| Dermatophytes (living cultures) (491) | 190 |
| Dermatophytes Genome Detection (Lyophilized spore suspension) (492) | 190 |
| Desalkylflurazepam (876) | 133 |
| Desethylamiodarone (190) | 126 |
| Desipramine (863) | 137 |
| Desipramine (serum) (202, 203) | 139, 141 |
| Desipramine (urine) (204) | 153 |
| Desmethyl fluoxetine (874) | 131 |
| Desmethyl olanzapine (875) | 132 |
| Desmethyl sertraline (873) | 131 |
| Desmethyldiazepam (876) | 133 |
| DFNB1 (DNA) (782) | 34 |
| DHEA (298) | 105 |
| DHEA sulfate (298) | 105 |
| DHEA-S (298) | 105 |
| Diabetes mellitus (261) | 65 |
| Diazepam (876) | 133 |
| Diego system [DI] (DNA) (235) | 26 |
| Differential Blood Count (whole blood) (612) | 88 |
| Differentiation of tuberculosis bacteria (sputum) (422) | 186 |
| Digitoxin (197) | 138 |
| Digoxin (195) | 139 |
| Dihydropyrimidin Dehydrogenase (DNA) (762) | 36 |
| Diphtheria Toxoid (antibody, serum) (318) | 175 |
| Dipstick (171) | 156 |
| Direct Antiglobulin Test (Machine-based, whole blood) (237, 238) | 83, 83 |
| Direct Antiglobulin Test (serum / erythrocytes suspension) (231, 232) | 81, 81 |
| Direct detection of Chlamydia trachomatis antigen (antigen, serum) (313) | 174 |
| Direct detection of Chlamydia trachomatis antigen (Slide (fixed)) (316) | 174 |
| Disialotransferrin (serum) (750) | 119 |
| DMD (DNA) (780) | 37 |
| Dolutegravir (serum) (850) | 132 |
| Dombrock system [DO] (DNA) (235) | 26 |
| Dopamine (plasma) (185) | 114 |
| Dopamine (urine) (175) | 155 |
| Doxepin (serum) (201, 203, 863) | 137, 140, 141 |
| Doxepin (urine) (204) | 153 |
| DPA1 (444) | 70 |
| DPB1 (444) | 70 |
| DPD (777) | 36 |
| DPYD (DNA) (762) | 36 |
| DQA1 (444) | 70 |
| DQB1 (444) | 70 |
| DRB1 (444) | 70 |
| DRB3 (444) | 70 |
| DRB4 (444) | 70 |
| DRB5 (444) | 70 |
| Drug Resistance Determination (plasma) (349, 383, 384, 397, 399) | 204, 208, 210, 213, 214 |
| Drugs of Abuse (174, 176, 177) | 150, 151, 151 |
| Duchenne muscular dystrophy (DMD) (DNA) (780) | 37 |
| Duffy system [FY] (DNA) (235) | 26 |
| Duloxetine (862) | 137 |
| Dysfibrinogenemia (676) | 52 |
| Dystrophin (DNA ) (780) | 37 |

## INDEX

### E


E. coli (534) 165
EBV (352, 376, 433) 205, 221, 232
Echinococcosis (serum/plasma) (455) 194
EDDP (urine) (177) 151
Edoxaban (505) 97
educational program (378, 379, 382) 208, 210, 212
Efavirenz (850) 132
Effector memory T cells (651) 74
Effector T cells (651) 74
EGFR T790M (liquid biopsy) (752) 35
EHEC (Bacterial genome) (534) 165
Elvitegravir (850) 132
Emicizumab (plasma) (506) 97
ENA (255) 64
Endocrinopathies (263) 63
Engraftment Diagnostics (618) 26
Entamoeba histolytica (458) 193
Enterohemorrhagic E. coli (EHEC / STEC) (548) 168
Enteroinvasive E. coli (EIEC) (548) 168
Enteropathogenic E. coli (EPEC) (548) 168
Enterotoxigenic E. coli (ETEC) (548) 168
Enteroviruses (cell culture lysate) (372, 431, 433) 205, 221, 224
Enteroviruses (suspensions of feces) (430) 206
Eosinophilic Granulocytes (whole blood) (612) 88
Epinephrine (175) 155
Epinephrine (plasma) (185) 114
Epinephrine (urine) (175) 155
Epstein Barr Virus (cell culture lysate) (433) 221
Epstein Barr Virus (plasma) (376) 205
Epstein Barr Virus (serum) (352) 232
Erythocyte - alleles (DNA ) (235) 26
Erythrocytes (stabilized control blood) (211) 86
Erythrocytes (urine) (171) 156
Erythrocytes (whole blood) (612) 88
Erythropoiesis (bone marrow aspirate (digital image)) (218) 88
Erythropoietin (626) 108
Escherichia coli (534) 165
Escherichia coli O157 (548) 168
Escitalopram (861) 136
Eslicarbazepine (871) 128
ESR1 (liquid biopsy) (752) 35
ESR1 (DNA) (590) 55
Ethanol (700) 116
Ethosuximid (195) 139
Ethylglucuronid (751) 152
Etravirine (850) 132
Everolimus (601) 134
Expansion of trinucleotide CAG repeats (DNA) (784) 40


### F


F10 (DNA ) (674) 51
F11 (DNA ) (675) 51
F13A1 (DNA ) (677) 52
F13B (DNA ) (677) 52
F5 (DNA ) (670) 49
F7 (DNA ) (671) 50
F8 (DNA ) (672) 50
F9 (DNA ) (673) 49
Factor II (223) 98
Factor IX (224) 98
Factor IX (DNA ) (673) 49
Factor V (223) 98
Factor V (DNA ) (670) 49
Factor V-Leiden (DNA ) (740) 37
Factor V-Leiden (DNA) (740) 37
Factor V-Leiden (whole blood) (730) 38
Factor VII (223) 98
Factor VII (DNA ) (671) 50
Factor VIII (227) 99
Factor VIII (DNA ) (672) 50
Factor X (223) 98
Factor X (DNA ) (674) 51
Factor XI (224) 98
Factor XI (DNA ) (675) 51
Factor XII (224) 98
Factor XIII (224) 98
Factor XIII (DNA ) (677) 52
FDP screening (222) 99
Fecal Diagnostics (130, 131) 148, 148
Fecal elastase (130) 148
Felbamate (871) 128
Ferritin (241) 143
Ferritin (CSF) (467) 121
Fertility (297) 106
fetal haemoglobin (210) 89
Fetoprotein (306) 107
FGA (DNA ) (676) 52
FGB (DNA ) (676) 52
FGG (DNA ) (676) 52
Fibrinogen (222, 285) 95, 99
Fibrinogen (DNA ) (676) 52
Fibrinogen degradation products (222) 99
Fibrinogen Receptor (749) 38
Fifth disease (342, 367) 223, 239
Flavine Adenine Dinucleotide (FAD) (291) 160
Flavine mononucleotid (FMN) (291) 160
Flowcytometry (217, 617) 92, 93
FLT3 (internal tandem duplication) (DNA) (701) 53
FLT3 (TKD) Mutation(s) (798) 57
FLT3 Nomenclature (798) 57
FLT3-ITD (DNA) (701) 53
Fluconazole (198) 130
Flucytosine (198) 130
Flunitrazepam (877) 133
Fluoride (plasma) (206) 147
Fluoride (urine) (205) 153
Fluoxetine (874) 131
Flurazepam (877) 133
Fluvoxamine (873) 131
FMR1 (DNA) (781) 39
Folate (290) 159

## INDEX


| | |
|---|---|
| Folic acid (serum) (290) | 159 |
| Follicle-stimulating hormone (297) | 106 |
| Fondaparinux (plasma) (501) | 100 |
| Food allergens (IgE against) (720) | 62 |
| Fraction CO-Hb (POCT) (162) | 144 |
| Fraction Met-Hb (POCT) (162) | 144 |
| Fraction O2-Hb (POCT) (162) | 144 |
| Fragile X (DNA ) (781) | 39 |
| Fragile X syndrom (DNA) (781) | 39 |
| Francisella (antibody, serum) (328) | 176 |
| Francisella tularensis (Bacterial genome) (543) | 165 |
| Free beta-chain hCG (serum / plasma) (305) | 107 |
| Free Haemoglobin (236) | 89 |
| Free Hemoglobin (236) | 89 |
| Free light chains (243) | 117 |
| Fructosamine (146) | 116 |
| FSH (297) | 106 |
| Fungal Genome Detection (Fungal genome) (560) | 189 |
| fungal infection (480, 481) | 191, 192 |
| FXPOI (DNA) (781) | 39 |
| FXS (DNA) (781) | 39 |
| FXTAS (DNA) (781) | 39 |


## G


| | |
|---|---|
| G6PDH (279) | 117 |
| Gabapentin (872) | 129 |
| gamma-Globulins (100, 141) | 115, 120 |
| gamma-Globulins (electrophoresis, Serum) (102) | 115 |
| Gammopathies (243) | 117 |
| Gap junction beta-2 protein (782) | 34 |
| Gardnerella (547) | 169 |
| Gastrin (300) | 108 |
| Gastrointestinal disease (381, 430) | 206, 220 |
| Gastrointestinal Virus Panel (suspensions of feces) (430) | 206 |
| Gastrointestinale Pathogene (548) | 168 |
| genome detection (424) | 189 |
| Gentamicin (197) | 138 |
| GGT (POCT: Abaxis Piccolo) (810) | 145 |
| GGT (serum) (100) | 115 |
| Giardia duodenalis (458) | 193 |
| GJB2 (782) | 34 |
| GJB2 (DNA) (782) | 34 |
| GJB2 gene (DNA) (782) | 34 |
| GJB6 (DNA) (782) | 34 |
| GJB6 gene (DNA) (782) | 34 |
| Glandular fever (352, 376) | 205, 232 |
| GLDH (100) | 115 |
| Glomerulopathies (serum) (257) | 69 |
| Glucagon (300) | 108 |
| Glucose (CSF) (464) | 122 |
| Glucose (POCT) (161, 800) | 144, 146 |
| Glucose (POCT: Abaxis Piccolo) (810) | 145 |
| Glucose (serum) (100, 111) | 115, 118 |
| Glucose (urine) (171, 173) | 156, 157 |
| Glucose quotient (CSF/Serum) (CSF) (464) | 122 |
| Glucose-6 Phosphat-Dehydrogenase (279) | 117 |
| Glutamic acid (710) | 113 |
| Glutamine (710) | 113 |
| Gluten-Sensitive Enteropathies (serum) (271) | 65 |
| Glycine (710) | 113 |
| Gold (plasma) (206) | 147 |
| GOT (POCT: Abaxis Piccolo) (810) | 145 |
| GOT (serum) (100) | 115 |
| GP Ia/IIa (DNA) (739) | 33 |
| GPI deficient cells (616) | 91 |
| GPT (POCT: Abaxis Piccolo) (810) | 145 |
| GPT (serum) (100) | 115 |
| Gram Stain (Lyophilisate) (411, 412) | 184, 185 |
| Gram Stain (Slide (fixed)) (413) | 185 |
| Granulocyte (neutrophil) antigens (234) | 82 |
| Granulocyte - alleles (DNA ) (235) | 26 |
| Granulocyte antibodies (234) | 82 |
| Granulocyte Function (Oxidative Burst) (654) | 77 |
| Granulocyte Function (Phagocytosis Test) (655) | 68 |
| Granulocyte Immunology (234) | 82 |
| Granulopoiesis (bone marrow aspirate (digital image)) (218) | 88 |
| Growth Hormone (GH) (298) | 105 |


## H


| | |
|---|---|
| H. pylori (334, 533) | 166, 176 |
| H63D (741) | 39 |
| Haematocrit (QBC systems) (209) | 87 |
| Haematocrit (stabilized control blood) (211) | 86 |
| Haematocrit (whole blood) (612) | 88 |
| Haematology 07 - Blood Smear Analysis (blood smear) (212) | 87 |
| Haematology 09 - Bone Marrow Cytology (bone marrow aspirate (digital image)) (218) | 88 |
| Haemoglobin (POCT OPTI Systems) (163) | 145 |
| Haemoglobin (POCT) (162) | 144 |
| Haemoglobin (QBC systems) (209) | 87 |
| Haemoglobin (stabilized control blood) (211) | 86 |
| Haemoglobin (whole blood) (612) | 88 |
| Haemoglobin-Haptoglobin-Complex (stool) (131) | 148 |
| Haemoglobinopathies (whole blood) (210) | 89 |
| Haloperidol (862) | 137 |
| Hantaviruses (serum) (355) | 232 |
| Haptoglobin (plasma) (241) | 143 |
| Haptoglobin (stool) (131) | 148 |
| HAV (344, 377) | 206, 233 |
| Hb-A (210) | 89 |
| Hb-A2 (210) | 89 |
| Hb-F (210) | 89 |
| Hb-S (210) | 89 |
| HBA (794) | 27 |
| HbA1c (EDTA Vollblut) (145) | 118 |

## INDEX


| | |
|---|---|
| HBB (794) | 27 |
| HBDH (100) | 115 |
| HBeAg (serum) (345) | 234 |
| HBOC (DNA) (779) | 31 |
| HBsAg (serum) (344) | 233 |
| HBV (345, 361, 378, 396, 397) | 207, 207, 208, 208, 234 |
| hCG (urine) (171) | 156 |
| hCG intact (Pregnancy) (306) | 107 |
| hCG intact (Tumor marker) (292) | 149 |
| hCG intact (urine) (179) | 155 |
| HCT (209, 211, 612) | 86, 87, 88 |
| HCV (346, 362, 375, 379, 399) | 209, 209, 210, 210, 234 |
| HCV Antigen (serum) (346) | 234 |
| HD (784) | 40 |
| HDL-cholesterol (151) | 119 |
| HDL-cholesterol (POCT: Abaxis Piccolo) (810) | 145 |
| HDV (347, 400) | 211, 235 |
| HE4 (292) | 149 |
| Helicobacter pylori (antibody, serum) (334) | 176 |
| Helicobacter pylori (Bacterial genome) (533) | 166 |
| hematocrit (209, 211, 612) | 86, 87, 88 |
| Hematopoetic Growth Factors (626) | 108 |
| Hemoglobin (162, 163, 209, 211, 612) | 86, 87, 88, 144, 145 |
| Hemoglobin-Haptoglobin-Complex (131) | 148 |
| Hemoglobinopathies (210) | 89 |
| hemolytic anemia (279) | 117 |
| Hemopexin (241) | 143 |
| Hemophilia A (672) | 50 |
| Hemophilia B (673) | 49 |
| Hemophilia C (675) | 51 |
| hemostasis (670, 671, 672, 673, 674, 675, 676, 677, 678, 790, 791, 792) | 29, 45, 46, 49, 49, 50, 50, 51, 51, 52, 52, 54 |
| Hepatic Syndromes (serum) (253) | 66 |
| Hepatitis A Virus (plasma) (377) | 206 |
| Hepatitis A Virus (serum) (343) | 233 |
| Hepatitis B Virus (plasma) (361, 378, 396, 397) | 207, 207, 208, 208 |
| Hepatitis B Virus (serum) (344, 345) | 233, 234 |
| Hepatitis C Virus (plasma) (362, 375, 379, 399) | 209, 209, 210, 210 |
| Hepatitis C Virus (serum) (346) | 234 |
| Hepatitis D Virus (plasma) (400) | 211 |
| Hepatitis D Virus (serum) (347) | 235 |
| Hepatitis E Virus (plasma) (380) | 211 |
| Hepatitis E Virus (serum) (348) | 235 |
| Heptaprorphyrin (178) | 156 |
| HER2/new (292) | 149 |
| hereditary hemochromatosis (733, 741) | 39, 40 |
| Hereditary nonpolyposis colorectal cancer (783) | 41 |
| Herpes simplex specific quotient (CSF / serum) (463) | 123 |
| Herpes simplex virus IgG Antibody Index (CSF / serum) (463) | 123 |
| Herpes Simplex Viruses (cell culture lysate) (433) | 221 |
| Herpes Simplex Viruses (plasma) (363) | 212 |
| Herpes Simplex Viruses (serum) (354) | 236 |
| HEV (348, 380) | 211, 235 |
| Hexaporphyrin (178) | 156 |
| HFE (741) | 39 |
| HFE (C282Y, H63D, S65C) (DNA) (741) | 39 |
| HFE (C282Y, H63D, S65C) (whole blood) (733) | 40 |
| HFE: C 282 Y (733) | 40 |
| HFE: H 63 D (733) | 40 |
| HFE: S 65 C (733) | 40 |
| HGH (298) | 105 |
| HHV-6 (cell culture lysate) (405) | 215 |
| HHV-8 (cell culture lysate) (406) | 215 |
| high resolution (444) | 70 |
| Histidine (710) | 113 |
| HIV (850) | 132 |
| HIV-1 (plasma) (360, 382, 383, 384) | 212, 213, 213, 214 |
| HIV-1 (serum) (335) | 237 |
| HIV-1 Drug Susceptibility Determination (plasma) (384) | 214 |
| HIV-1 p24 Antigen (serum) (337) | 236 |
| HIV-2 (plasma) (395) | 214 |
| HIV-2 (serum) (335) | 237 |
| HLA A (441, 442, 444) | 70, 72, 73 |
| HLA Antibody Screening and Specification (445) | 71 |
| HLA B (441, 442, 444) | 70, 72, 73 |
| HLA B 57 (444) | 70 |
| HLA C (442, 444) | 70, 73 |
| HLA Crossmatching (443) | 71 |
| HLA Typing (blood samples) (441, 442) | 72, 73 |
| HLA Typing (buffy coat) (444) | 70 |
| HLA-B27 Determination (440) | 72 |
| HLA-DQ (441, 772) | 72, 73 |
| HLA-DR (441) | 72 |
| HMPV (385) | 216 |
| HNA (234) | 82 |
| HNA - system (DNA ) (235) | 26 |
| HNPCC (DNA) (783) | 41 |
| Holotranscobalamine (290) | 159 |
| Homocystein (151) | 119 |
| Homovanillic acid (175) | 155 |
| HPA (749) | 38 |
| HPA - system (DNA ) (235) | 26 |
| HPA 1a/1b (DNA) (749) | 38 |
| HPV (373) | 216 |
| HPV (cell culture lysate) (373) | 216 |
| hsCRP (240) | 142 |
| HSV (354, 363, 433, 463) | 123, 212, 221, 236 |
| HTLV-1 (serum) (339) | 237 |
| HTLV-2 (serum) (339) | 237 |
| HTT (DNA) (784) | 40 |
| HTT gene (DNA) (784) | 40 |
| HTT Huntingtin (DNA) (784) | 40 |
| Human brucellosis (327) | 172 |
| Human Herpesvirus (cell culture lysate) (405, 406) | 215, 215 |
| Human immunodeficiency virus (360, 382, 383, 384, 850) | 132, 212, 213, 213, 214 |
| Human immunodeficiency virus 2 (395) | 214 |
| Human immunodeficiency viruses (335, 337) | 236, 237 |

## INDEX


| | |
|---|---|
| Human Metapneumovirus (cell culture lysate) (385) | 216 |
| Human neutrophil antigens (234) | 82 |
| Human Papilloma Viruses (cell culture lysate) (373) | 216 |
| Human Rhinoviruses (cell culture lysate) (393) | 217 |
| Human T-lymphotropic virus (339) | 237 |
| Huntingtin (DNA) (784) | 40 |
| Huntington disease (HD) (DNA) (784) | 40 |
| HVA (175) | 155 |
| Hydatid (455) | 194 |
| Hydroxy-Itraconazole (602) | 129 |
| Hydroxycarbamazepine (860) | 136 |
| Hydroxycarbazepine (192) | 128 |
| hypercholesterolemia (771) | 30 |
| Hyphomycetes (living cultures) (490) | 191 |
| Hypodysfibrinogenemia (676) | 52 |
| Hypofibrinogenemia (676) | 52 |

### I

| | |
|---|---|
| Identification of mycobacteria (suspensions of mycobacterial strains) (423) | 187 |
| IDH1 Exon 4 Mutation(s) (798) | 57 |
| IDH1 Nomenclature (798) | 57 |
| IDH2 Exon 4 Mutation(s) (798) | 57 |
| IDH2 Nomenclature (798) | 57 |
| IgA (CSF) (460) | 124 |
| IgA (plasma) (241, 243) | 117, 143 |
| IgA (serum) (100) | 115 |
| IgA Quotient (CSF / serum) (460) | 124 |
| IgE (food allergens) (720) | 62 |
| IgE (inhaled allergens) (720) | 62 |
| IgE (insect poison allergens) (720) | 62 |
| IgE (plasma) (241) | 143 |
| IgE (serum) (720) | 62 |
| IgE (specific) (720) | 62 |
| IgG (CSF) (460) | 124 |
| IgG (plasma) (241, 243) | 117, 143 |
| IgG (serum) (100) | 115 |
| IgG (urine) (182) | 158 |
| IgG Quotient (CSF / serum) (460) | 124 |
| IgG Subclasses (serum) (244) | 111 |
| IgM (CSF) (460) | 124 |
| IgM (plasma) (241, 243) | 117, 143 |
| IgM (serum) (100) | 115 |
| IgM Quotient (CSF + serum) (460) | 124 |
| IGRA (Heparin-whole blood) (650) | 75 |
| IL28B (777) | 36 |
| Imipramine (serum) (202, 203, 863) | 137, 139, 141 |
| Imipramine (urine) (204) | 153 |
| Immature reticulocytes (216) | 91 |
| Immunogenetics (blood samples) (440, 441, 442) | 72, 72, 73 |
| Immunogenetics (buffy coat) (444) | 70 |
| Immunogenetics (serum) (443, 445) | 71, 71 |
| Immunohaematology 01 (manual performance) (231) | 81 |
| Immunohaematology 02 (manual perfomance and titer determination) (232) | 81 |
| Immunohaematology 05 (Machine-Based Analysis) (Machine-based, whole blood) (237) | 83 |
| Immunohaematology 06 - Molecular Diagnostic (DNA ) (235) | 26 |
| Immunohaematology 07 (Machine-Based Analysis and titer determination) (Machine-based, whole blood) (238) | 83 |
| Immunophenotyping (bone marrow or blood smears and leukaemia or lymphoma cells) (214) | 90 |
| Immunophenotyping (cellular products) (617) | 93 |
| Immunophenotyping (whole blood) (213) | 90 |
| Immunosuppressants (lyophilized whole blood) (601) | 134 |
| Immunosuppressants (serum / plasma) (602) | 129 |
| Infectious Mononucleosis (352, 376) | 205, 232 |
| Influenza Viruses (cell culture lysate) (370, 431, 432) | 198, 224, 225 |
| Inhaled allergens (IgE against) (720) | 62 |
| INR (plasma) (221, 285) | 95, 102 |
| INR (whole blood) (286) | 102 |
| insect poison allergens (IgE against) (720) | 62 |
| Insulin (300) | 108 |
| Integrase Inhibitors (plasma) (384) | 214 |
| Interferon Gamma Release Assay (650) | 75 |
| International Normalized Ratio (221, 285) | 95, 102 |
| Iodine (plasma) (206) | 147 |
| Iodine (urine) (205) | 153 |
| ionized Calcium (POCT OPTI Systems) (163) | 145 |
| ionized Calcium (POCT) (161) | 144 |
| Iron (plasma) (206) | 147 |
| Iron (serum) (100) | 115 |
| Iron (urine) (205) | 153 |
| Iron binding capacity (100) | 115 |
| IRT (785) | 125 |
| Isoleucine (710) | 113 |
| IT15 (784) | 40 |
| Itraconazole (602) | 129 |

### J

| | |
|---|---|
| JAK2 (768) | 59 |
| JC polyomavirus (JCPyV / JCV) (plasma / urine) (394) | 217 |
| JC Virus (plasma / urine) (394) | 217 |

### K

| | |
|---|---|
| kappa (243) | 117 |
| Kappa Free Light Chains (CSF) (468) | 122 |
| Kell antigen (Machine-based, whole blood) (237, 238) | 83, 83 |
| Kell antigen (serum / erythrocytes suspension) (231, 232) | 81, 81 |
| Kell system [KEL] (DNA) (235) | 26 |
| Ketone bodies (urine) (171) | 156 |
| Kidd system [JK] (DNA) (235) | 26 |
| Kissing disease (352, 376) | 205, 232 |
| KIT (767) | 58 |
| Knops system [KN] (DNA) (235) | 26 |
| KRAS Codon 12 (liquid biopsy) (752) | 35 |
| KRAS Codon 13 (liquid biopsy) (752) | 35 |
| KRAS Codon 61 (liquid biopsy) (752) | 35 |

## INDEX

### L


Lacosamide (871) 128
Lactase gene (DNA) (770) 41
Lactase-gene (DNA) (770) 41
Lactate (CSF) (464) 122
Lactate (POCT OPTI Systems) (163) 145
Lactate (POCT) (161) 144
Lactate (POCT: Abaxis Piccolo) (810) 145
Lactate (serum) (100) 115
Lactate Dehydrogenase (100, 810) 115, 145
Lactose (DNA) (770) 41
lactose intolerance (770) 41
Lactose intollerance (DNA) (770) 41
lambda (243) 117
Lamotrigine (191, 860) 127, 136
Landsteiner Wiener system [LW] (DNA) (235) 26
LCT (DNA) (770) 41
LDH (100) 115
LDH (POCT: Abaxis Piccolo) (810) 145
LDL-cholesterol (151) 119
LDL-cholesterol (POCT: Abaxis Piccolo) (810) 145
Lead (lyophilized whole blood) (208) 146
Lead (urine) (205) 153
Lectin pathway (246) 80
Legionella pneumophila (Bacterial genome) (536) 166
Legionellosis (536) 166
Legionnaires disease (536) 166
Leptospira (329) 177
Leptospira (antibody, serum) (329) 177
Leptospirosis (329) 177
Leucine (710) 113
Leucocytes (cellular products) (617) 93
Leucocytes (QBC systems) (209) 87
Leucocytes (stabilized control blood) (211) 86
Leucocytes (urine) (171) 156
Leucocytes (whole blood) (213, 217, 612) 88, 90, 92
leukozyte antigen (440, 441, 442, 443, 444, 445) 70, 71, 71, 72, 72, 73
Levetiracetam (191) 127
Levomepromazine (873) 131
LH (297) 106
Lime borreliosis (535) 161
Linezolid (890) 127
Lipase (100) 115
Lipids (151) 119
Lipoproteins (151) 119
Liquid Biopsy (752) 35
Listeria (538) 167
Listeria spp. (Bacterial genome) (538) 167
Listeriosis (538) 167
Lithium (100, 195) 115, 139
Liver disease (253) 66
LMW Heparin (281) 101
Lopinavir (850) 132
Lorazepam (878) 134
low molecular weight heparin (281) 101
low resolution (442) 73
Lp (a) (151) 119
LSD (urine) (176) 151
Luteinizing hormone (297) 106
Lutheran system [Lu] (DNA) (235) 26
Lyme disease (332, 535) 161, 171
Lymphocyte Proliferation Assay (656) 76
lymphocytes (651) 74
Lymphocytes (whole blood) (213, 612) 88, 90
Lymphozyte Transformation Test (LTT) (656) 76
Lynch syndrome (783) 41
Lysine (710) 113


### M


Magnesium (lyophilized whole blood) (208) 146
Magnesium (POCT) (161) 144
Magnesium (POCT: Abaxis Piccolo) (810) 145
Magnesium (serum) (100) 115
Magnesium (urine) (173) 157
Malaria (serum/plasma) (454) 194
Manganese (lyophilized whole blood) (208) 146
Manganese (plasma) (206) 147
Manganese (urine) (205) 153
Maproptiline (202, 863) 137, 139
Maraviroc (850) 132
Markers of Ethanol Abuse (serum) (750) 119
Markers of Ethanol Abuse (urine) (751) 152
MCV (stabilized control blood) (211) 86
MCV (whole blood) (612) 88
MDMA (urine) (177) 151
mean cell volume (211, 612) 86, 88
mean corpuscular volume (211, 612) 86, 88
Measles specific quotient (CSF + serum) (463) 123
Measles Virus (cell culture lysate) (386) 218
Measles Virus (serum) (357) 238
Measles virus IgG Antibody Index (CSF + serum) (463) 123
mecA (539) 167
Megakaryopoiesis (bone marrow aspirate (digital image)) (218) 88
Memory T cells (651) 74
MEN2 Syndrome (DNA) (738) 56
MEN2A (DNA ) (738) 56
Mercury (lyophilized whole blood) (208) 146
Mercury (urine) (205) 153
Meropenem (890) 127
MERS (cell culture lysate) (340) 202
Metanephrines (175) 155
Methadone (urine) (176) 151
Methicillin-resistant Staphylococcus aureus (539) 167
Methionine (710) 113
Methotrexate (197) 138
Methylmalonic Acid (187) 158
Methylphenidate (879) 135

## INDEX


| | |
|---|---|
| Mianserine (874) | 131 |
| Microalbumin (173) | 157 |
| Microbiome (stool) (580) | 183 |
| Microscopic detection of mycobacteria (Slide) (421) | 188 |
| Minimal residual disease (820, 821) | 86, 120 |
| Mirtazapine (861) | 136 |
| MLH1 (DNA) (783) | 41 |
| MMF (602) | 129 |
| MNS - system (DNA ) (235) | 26 |
| MNS system [GYP] (DNA) (235) | 26 |
| molecular susceptibility testing of tuberculosis bacteria (suspensions of mycobacterial strains) (426) | 188 |
| Molybdaen (207) | 147 |
| Molybdenum (207) | 147 |
| Monkeypox virus / Orthopoxviruses (418) | 219 |
| Monocytes (whole blood) (612) | 88 |
| Morphology (Slide (fixed)) (413) | 185 |
| Morphology of erythrocytes (blood smear) (212) | 87 |
| Morphology of leukocytes (blood smear) (212) | 87 |
| Morphology of platelets (blood smear) (212) | 87 |
| Mould Fungus (living cultures) (491) | 190 |
| MPA (602) | 129 |
| MPL (768) | 59 |
| MPN (768) | 59 |
| MPOX (418) | 219 |
| MPXV (418) | 219 |
| MRSA (Bacterial genome) (539) | 167 |
| MSH2 (DNA) (783) | 41 |
| MSH6 (DNA) (783) | 41 |
| MTHFR (C677T, A1298C) (DNA) (747) | 42 |
| MTHFR (C677T, A1298C) (whole blood) (732) | 42 |
| MTHFR (whole blood, Dna) (732) | 42 |
| MTHFR C677T (DNA ) (747) | 42 |
| MTHFR C677T (whole blood, Dna) (732) | 42 |
| Mucorales (living cultures) (490) | 191 |
| Multiple Endocrine Neoplasia Type 2A (DNA ) (738) | 56 |
| Multiplex Test (cell culture lysate) (431, 432, 433) | 221, 224, 225 |
| Multiplex Test (suspensions of feces) (430) | 206 |
| Mumps Virus (cell culture lysate) (387) | 220 |
| Mumps Virus (serum) (356) | 238 |
| muscular dystrophy (780) | 37 |
| Myasthenia gravis (serum) (269) | 66 |
| Mycobacteria (Slide) (421) | 188 |
| Mycobacteria (sputum) (422, 424) | 186, 189 |
| Mycobacteria (suspensions of mycobacterial | 186, 187, 187, 188 |
| Mycobacterial diagnostics - Cultivation (sputum) (422) | 186 |
| Mycobacterial diagnostics - Drug Susceptibility Testing of nontuberculous mycobacteria (suspensions of non-mycobacterial strains) (427) | 187 |
| Mycobacterial diagnostics - Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (425) | 186 |
| Mycobacterial diagnostics - Identification (suspensions of mycobacterial strains) (423) | 187 |
| Mycobacterial diagnostics - Microscopy (Slide) (421) | 188 |
| Mycobacterial diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (426) | 188 |
| Mycobacterial diagnostics - NAT tuberculosis bacteria (sputum) (424) | 189 |
| Mycobacterial diagnostics 01 - Microscopy (Slide) (421) | 188 |
| Mycobacterial diagnostics 02 - Cultivation (sputum) (422) | 186 |
| Mycobacterial diagnostics 03 - Identification (suspensions of mycobacterial strains) (423) | 187 |
| Mycobacterial diagnostics 05 - Drug Susceptibility Testing of tuberculosis bacteria (suspensions of | 186 |
| Mycobacterial diagnostics 06 - Molecular Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (426) | 188 |
| Mycobacterial diagnostics 07 - Drug Susceptibility Testing of nontuberculous mycobacteria (suspensions of non-mycobacterial strains) (427) | 187 |
| Mycology (living cultures) (490, 490, 491) | 190, 191, 191 |
| Mycophenolic acid (602) | 129 |
| Mycoplasma (547) | 169 |
| Mycoplasma pneumoniae (antibody, serum) (324) | 177 |
| Mycoplasma pneumoniae (Bacterial genome) (541) | 168 |
| Mycoserology (serum or liquor) (481) | 192 |
| Mycoserology (serum) (480) | 191 |
| MYD88 (766) | 59 |
| Myeloproliferative Neoplasia (768) | 59 |
| Myocardial Markers (760, 761) | 112, 112 |
| Myoglobin (760) | 112 |


## N


| | |
|---|---|
| N-Desmethylclozapine (200, 862, 863) | 130, 137, 137 |
| N-Desmethylmethsuximide (192) | 128 |
| N334K (793) | 27 |
| Naive B cells (651) | 74 |
| Naive T cells (651) | 74 |
| Neisseria gonorrhoeae (Bacterial genome) (530) | 163 |
| Neonatal Bilirubin (110) | 125 |
| Neuroborreliosis (CSF) (465) | 123 |
| Neutrophilic Granulocytes (whole blood) (612) | 88 |
| Nevirapine (850) | 132 |
| Newborn screening (785, 785) | 125, 125 |
| Next Generation Sequencing (798) | 57 |
| Next Generation Sequencing (stool) (580) | 183 |
| NGS-Analysis (stool) (580) | 183 |
| Nickel (lyophilized whole blood) (208) | 146 |
| Nickel (plasma) (206) | 147 |
| Nickel (urine) (205) | 153 |
| Nitrazepam (877) | 133 |
| Nitrite (urine) (171) | 156 |
| NK and cytotoxic T cells function (657) | 76 |
| NK cell activation assay (CD107a) (657) | 76 |
| NK cell subpopulations (651) | 74 |
| NK cytotoxicity assay (CD107a or lysis) (657) | 76 |
| NK-cells (cellular products) (617) | 93 |
| NK-Cells (EDTA-whole blood) (651) | 74 |
| NK-cells (whole blood) (213) | 90 |
| Non-switched B cells (651) | 74 |
| non-syndromic hearing inpairment (DNA) (782) | 34 |
| Nontuberculous mycobacteria (suspensions of mycobacterial strains) (427) | 187 |

## INDEX


Norclomipramine (serum) (199, 203, 863) 137, 140, 141
Norclomipramine (urine) (204) 153
Norclozapine (862, 863) 137, 137
Nordiazepam (876) 133
Nordoxepin (serum) (201, 203, 863) 137, 140, 141
Nordoxepin (urine) (204) 153
Norepinephrine (plasma) (185) 114
Norepinephrine (urine) (175) 155
Normaproptiline (202) 139
Normetanephrine (175) 155
Noroviruses (suspensions of feces) (381, 430) 206, 220
Nortrimipramine (serum) (201, 203) 140, 141
Nortrimipramine (urine) (204) 153
Nortriptyline (serum) (199, 203, 863) 137, 140, 141
Nortriptyline (urine) (204) 153
NPM1 Exon 11 Mutation(s) (798) 57
NPM1 Nomenclature (798) 57
NSAIDs (194) 135
NSE (292) 149
NT-pro BNP (760) 112

### O

O-Desmethylvenlafaxine (860, 861) 136, 136
Olanzapine (862, 875) 132, 137
Oligoclonal IgG (CSF / serum) (462) 124
Opiate (urine) (174) 150
Orgaran (282) 101
Ornithine (710) 113
Osmolality (serum) (100) 115
Osmolality (urine) (173) 157
Oxazepam (876) 133

### P

p-ANCA (serum) (257) 69
P. jirovecii (560) 189
p.D816V (767) 58
p.L265P (766) 59
PAI-1 (4G/5G) (DNA ) (748) 44
PAI-1 (4G/5G) (whole blood) (735) 44
PAI-1 (4G/5G) (whole blood, Dna) (735) 44
Paliperidone (862) 137
Pancreas (300) 108
Pancreas amylase (serum) (100) 115
Panel for Viral Meningitis (cell culture lysate) (433) 221
Pantothenic acid (Vitamin B5) (290) 159
PAP (785) 125
PAPP-A (serum / plasma) (305) 107
Paracetamol (194) 135
Parainfluenza Viruses (cell culture lysate) (388, 431) 222, 224
Paraneoplastic Neuropathies (serum) (265) 67
Parasite Microscopy (blood smear) (456) 193
Parasite Microscopy (stool) (451) 145
Parasites (blood smear) (456) 193
Parasites (pictures) (906, 907) 195, 196
Parasites (serum/plasma) (452, 454, 455) 194, 194, 195
Parasites (stool) (451) 145
Parechovirus (cell culture lysate) (407, 431, 433) 221, 222, 224
Parechovirus (suspensions of feces) (430) 206
Paroxetine (875) 132
Paroxysmal Nocturnal Hemoglobinuria (616) 91
Parvovirus B19 (plasma) (367) 223
Parvovirus B19 (serum) (342) 239
pCO2 (POCT OPTI Systems) (163) 145
pCO2 (POCT) (161) 144
PCR/NAT Multiplex (548) 168
Peliosis hepatis (326) 170
Pentaporphyrin (178) 156
Perampanel (871) 128
Perazine (860, 874) 131, 136
Peripheral Neuropathies (serum) (267) 68
pH (POCT OPTI Systems) (163) 145
pH (POCT) (161) 144
pH (urine) (171) 156
Pharmacogenetics (775) 35
Phenobarbital (195) 139
Phenylalanine (710) 113
Phenytoin (195) 139
Phosphate (POCT: Abaxis Piccolo) (810) 145
Phosphate (serum) (100) 115
Phosphate (urine) (173) 157
Phosphoethanolamine (710) 113
Phospholipids (151) 119
PhosphoTau Protein (pTau) (CSF) (466) 121
Photometer Controls (181) 141
PIGF (625) 109
PIK3CA (liquid biopsy) (752) 35
PIK3CA (DNA) (752, 590) 35, 55
Pipamperone (873) 131
Piperacilline (890) 127
Pituitary (298) 105
Placental growth factor (625) 109
Plasma Cell Neoplasia-MRD Immunophenotyping (821) 120
Plasmaprotein (240, 241, 242) 142, 142, 143
Plasminogenactivator inhibitor (PAI): 4G, 5G (whole blood) (735) 44
Plasminogenactivator-Inhibitor (PAI): 4G, 5G (DNA ) (748) 44
Plasminogenactivator-Inhibitor (PAI): 4G, 5G (whole blood, Dna) (735) 44
Plasmodia (454) 194
Platelet antibodies (233) 82
Platelet antigens (233) 82
Platelet Immunology (233) 82
Platelets (209, 211, 612) 86, 87, 88
Platin (206) 147
PLGF (625) 109
PML::RARA gene fusion (cDNA) (702) 54
PML::RARA qualitative (cDNA) (702) 54
PMS2 (DNA) (783) 41
Pneumocystis jirovecii (Fungal genome) (560) 189
PNH (EDTA-whole blood) (616) 91

## INDEX


| | |
|---|---|
| pO2 (POCT OPTI Systems) (163) | 145 |
| pO2 (POCT) (161) | 144 |
| POCT (100, 131, 145, 151, 171, 173, 174, 176, 177, 179, 203, 204, 209, 211, 226, 240, 286, 292, 293, 311, 321, 322, 324, 334, 337, 344, 346, 350, 352, 355, 359, 370, 410, 481, 539, 545, 546, 612, 760, 761, 800, 810) | 86, 87, 88, 96, 102, 112, 112, 115, 118, 119, 141, 142, 143, 145, 146, 148, 149, 150, 150, 151, 151, 153, 155, 156, 157, 164, 167, 170, 176, 177, 181, 182, 192, 197, 198, 199, 231, 232, 232, 233, 234, 236 |
| Porphobilinogen (urine) (180) | 154 |
| Porphyrins (178) | 156 |
| Posaconazole (198) | 130 |
| Potassium (POCT OPTI Systems) (163) | 145 |
| Potassium (POCT) (161) | 144 |
| Potassium (POCT: Abaxis Piccolo) (810) | 145 |
| Potassium (serum) (100) | 115 |
| Potassium (urine) (173) | 157 |
| Prader-Willi syndrome (PWS) (DNA) (786) | 45 |
| Prader□Labhart□Willi-Fanconi syndrome (786) | 45 |
| Preeclampsia Marker (625) | 109 |
| Pregabalin (872) | 129 |
| Pregnancy (305, 306) | 107, 107 |
| Primidon (195) | 139 |
| Pro-Gastrin-Releasing Peptide (299) | 149 |
| Pro-insuline (300) | 108 |
| PROC (DNA) (790, 791) | 45, 46 |
| PROC gene (DNA) (790) | 45 |
| Procalcitonin (serum) (320) | 178 |
| Progenitor Cells (whole blood) (217) | 92 |
| Progesterone (302) | 109 |
| Prolactin (298) | 105 |
| Proline (710) | 113 |
| PROS (791) | 46 |
| PROS1 gene (DNA) (791) | 46 |
| Prostatic acid Posphatase (100) | 115 |
| Protease Inhibitors (plasma) (384) | 214 |
| Protein (CSF) (460) | 124 |
| Protein (POCT: Abaxis Piccolo) (810) | 145 |
| Protein (serum) (100, 141) | 115, 120 |
| Protein (urine) (171, 173) | 156, 157 |
| Protein Analysis (CSF + serum) (460) | 124 |
| Protein C (DNA ) (790) | 45 |
| Protein C (plasma) (225) | 95 |
| Protein S (DNA ) (791) | 46 |
| Protein S (plasma) (225) | 95 |
| Prothrombin G20210A (DNA ) (746) | 46 |
| Prothrombin G20210A (whole blood) (731) | 47 |
| Prothrombin G20210A (whole blood, Dna) (731) | 47 |
| Prothrombin Time (221) | 102 |
| PSA (292, 293) | 149, 150 |
| Psychostimulants (879) | 135 |
| Psychotherapeutic Drugs (860, 861, 862, 863) | 136, 136, 137, 137 |
| Pyridoxal-5-phosphate (Vitamin B6) (lyophilized whole blood) (291) | 160 |
| Pyridoxal-5-phosphate (Vitamin B6) (serum) (290) | 159 |


## Q


| | |
|---|---|
| Q fever (325, 542) | 164, 175 |
| Querry fever (325, 542) | 164, 175 |
| Quetiapine (860, 861, 862) | 136, 136, 137 |
| Quick (plasma) (221, 285) | 95, 102 |
| Quick (whole blood) (286) | 102 |


## R


| | |
|---|---|
| RA (273) | 69 |
| Rabies Virus (lyophilised) (390) | 223 |
| Rabies Virus (serum) (336) | 239 |
| Raltegravir (850) | 132 |
| rare erythrocyte blood group systems (DNA) (235) | 26 |
| Reboxetine (873) | 131 |
| red blood cell (RBC) morphology (212) | 87 |
| red blood cells (RBC) (171, 211, 612) | 86, 88, 156 |
| Respiratory burst (granulocytes) (654) | 77 |
| respiratory diseases (431, 432) | 224, 225 |
| respiratory infection (314) | 173 |
| Respiratory Stimulants (870, 870) | 138, 138 |
| Respiratory Syncytial Virus (cell culture lysate) (359, 432) | 199, 225 |
| Respiratory Virus Panel (cell culture lysate) (431, 432) | 224, 225 |
| RET (DNA) (738) | 56 |
| Ret Proto-Oncogene (DNA ) (738) | 56 |
| Reticulated Platelets (216) | 91 |
| Reticulocyte (blood smears) (215) | 92 |
| Reticulocyte production Index (RPI) (216) | 91 |
| Reticulocytes (blood smears) (215) | 92 |
| Reticulocytes (whole blood) (216) | 91 |
| Retinol (Vitamin A) (290) | 159 |
| Retinol binding protein (urine) (182) | 158 |
| Reverse Transcriptase Inhibitors (plasma) (384) | 214 |
| RF (273, 323) | 69, 178 |
| Rh (D) Factor (Machine-based, whole blood) (237, 238) | 83, 83 |
| Rh (D) Factor (serum / erythrocytes suspension) (231, 232) | 81, 81 |
| Rh - Subtyping (Machine-based, whole blood) (237) | 83 |
| Rh - Subtyping (serum / erythrocytes suspension) (231, 232) | 81, 81 |
| Rh - Subtyping (without Cw) (Machine-based, whole blood) (238) | 83 |
| RHCE (DNA ) (235) | 26 |
| RHD (DNA ) (235) | 26 |
| RHD - Deletion (DNA ) (235) | 26 |
| Rheumatoid Arthritis (serum) (273) | 69 |
| Rheumatoid Factor (IgA) (serum) (273) | 69 |
| Rheumatoid Factor (IgG) (serum) (273) | 69 |
| Rheumatoid Factor (IgM) (serum) (273) | 69 |
| Rheumatoid Factor (serum) (273, 323) | 69, 178 |

## INDEX


| | |
|---|---|
| Ribavirine (850) | 132 |
| Riboflavin (Vitamin B2) (lyophilized whole blood) (291) | 160 |
| Riboflavin (Vitamin B2) (serum) (290) | 159 |
| Rickettsia (antibody, serum) (330) | 179 |
| rickettsioses (330) | 179 |
| Rilpivirin (850) | 132 |
| Risperidone (862) | 137 |
| Ritalinic acid (879) | 135 |
| Ritonavir (850) | 132 |
| Rivaroxaban (503) | 103 |
| ROMA-Score (292) | 149 |
| Rotaviruses (suspensions of feces) (401, 430, 430) | 206, 206, 226 |
| ROTEM Sigma (plasma) (509) | 103 |
| RSV (359) | 199 |
| Rubella specific quotient (CSF + serum) (463) | 123 |
| Rubella Virus (cell culture lysate) (389) | 226 |
| Rubella Virus (serum) (341) | 240 |
| Rubella virus IgG Antibody Index (CSF + serum) (463) | 123 |
| Rufinamide (871) | 128 |
| RUNX1 (CDS) Mutation(s) (798) | 57 |
| RUNX1 Nomenclature (798) | 57 |


## S


| | |
|---|---|
| S100 (292) | 149 |
| S65C (741) | 39 |
| Salicylate (194) | 135 |
| Salicylic acid (194) | 135 |
| Salmonella (537) | 169 |
| Salmonella (antibody, serum) (331) | 180 |
| Salmonella enterica (Bacterial genome) (537) | 169 |
| Salmonellosis (331, 537) | 169, 180 |
| Sapoviruses (suspensions of feces) (430, 430) | 206, 206 |
| Sarcosine (710) | 113 |
| SARS-CoV-2 (Ag) (cell culture supernatants) (410) | 197 |
| SARS-CoV-2 (cell culture lysate) (340, 409, 417, 431) | 202, 224, 227, 227 |
| SARS-CoV-2 (cell culture supernatants) (410) | 197 |
| SARS-CoV-2 (RNA) (cell culture lysate) (409) | 227 |
| SARS-CoV-2 (serum) (416) | 240 |
| sC5b-9 (247) | 79 |
| SCC (292) | 149 |
| Schistosomiasis (serum/plasma) (454) | 194 |
| Sediment Pictures (pictures) (172) | 157 |
| Selenium (lyophilized whole blood) (208) | 146 |
| Selenium (plasma) (206) | 147 |
| Selenium (urine) (205) | 153 |
| Sepsis (320, 322) | 143, 178 |
| Serine (710) | 113 |
| Serotonin (plasma) (185) | 114 |
| Serotonin (urine) (175) | 155 |
| SERPINC1 (792) | 29 |
| SERPINC1 gene (DNA) (792) | 29 |
| Sertraline (serum) (873) | 131 |
| Serum Proteins (141) | 120 |
| sexually transmitted disease (STI) (311, 312, 313, 316, 530, 531, 547) | 163, 163, 169, 173, 174, 174, 182 |
| sexually transmitted diseases (STI) (373) | 216 |
| sexuell übertragbare Krankheiten (STI) (480) | 191 |
| SF3B1 (DNA ) (797) | 60 |
| SF3B1 Exon 14-15 (DNA ) (797) | 60 |
| SF3B1 Nomenclature (DNA ) (797) | 60 |
| sFLT-1 (soluble fms-like tyrosine kinase-1) (625) | 109 |
| Shiga toxin-producing Escherichia coli (534) | 165 |
| Shigella spp (548) | 168 |
| sickle cells (210) | 89 |
| Sipple syndrome (738) | 56 |
| Sirolimus (601) | 134 |
| Skin antibodies (259) | 63 |
| SMA (DNA) (787) | 47 |
| SMN (DNA) (787) | 47 |
| SMN1 (DNA) (787) | 47 |
| SMN1 and SMN2 genes (DNA) (787) | 47 |
| SMN2 (DNA) (787) | 47 |
| SNRPN (DNA ) (786) | 45 |
| sO2 (POCT OPTI Systems) (163) | 145 |
| Sodium (POCT OPTI Systems) (163) | 145 |
| Sodium (POCT) (161) | 144 |
| Sodium (POCT: Abaxis Piccolo) (810) | 145 |
| Sodium (serum) (100) | 115 |
| Sodium (urine) (173) | 157 |
| soluble transferrin receptor (241) | 143 |
| specific gravity (urine) (171) | 156 |
| spinal muscular atropy (DNA) (787) | 47 |
| Staining characteristics (411) | 184 |
| Staining characteristics (Slide (fixed)) (413) | 185 |
| STAT3 (DNA ) (769) | 60 |
| Status of hantavirus infection (serum) (355) | 232 |
| STEC (Bacterial genome) (534) | 165 |
| Stem Cells (whole blood) (217) | 92 |
| Steroid Homones (302) | 109 |
| sTfR (241) | 143 |
| Stool parasites (pictures) (907) | 196 |
| Stool parasites (stool) (451) | 145 |
| Streptococcal AB (antibody, serum) (321) | 181 |
| Sulbactam (890) | 127 |
| Sulthiame (191) | 127 |
| Survival of motor neuron (787) | 47 |
| Susceptibility Testing of nontuberculous mycobacteria (427) | 187 |
| Susceptibility Testing of tuberculosis bacteria (425) | 186 |
| Susceptibility tests (3 Samples) (drying process) (411) | 184 |
| Susceptibility tests (5 samples) (Lyophilisate) (412) | 185 |
| Switched B cells (651) | 74 |
| Syphilis (311) | 182 |
| Systematic Toxicological Analysis (STA) (188) | 152 |

## INDEX

### T


T cell subpopulations (651) 74
T cytotoxicity assay (CD107a or lysis) (657) 76
T-cells (cellular products) (617) 93
T-Cells (EDTA-whole blood) (651) 74
T-Helper Cells (EDTA-whole blood) (651) 74
T-lymphocytes (whole blood) (213) 90
T3 (294, 302) 109, 110
T4 (294, 302) 109, 110
Tacrolimus (601) 134
Taurine (710) 113
Tazobactam (890) 127
tCO2 (POCT: Abaxis Piccolo) (810) 145
TEG/ROTEM (283) 104
Teicoplanin (193) 126
Temazepam (877) 133
Testosterone (293, 302) 109, 150
Tetanus Toxoid (antibody, serum) (310) 181
Tetracyclic Antidepressants (202) 139
TgAB (295) 110
thalassemia (210) 89
Theophylline (195) 139
Thiamine total (Vitamin B1) (291) 160
Thiaminpyrophosphat (TPP) (291) 160
Threonine (710) 113
Thrombin time (222, 280, 285) 95, 99, 104
Thrombin time (Argatroban) (230) 94
Thrombocyte - alleles (DNA ) (235) 26
Thrombocytes (QBC systems) (209) 87
Thrombocytes (stabilized control blood) (211) 86
Thrombocytes (whole blood) (612) 88
thromboembolism (501) 100
thrombophilia (275, 730, 731, 740, 746) 37, 38, 46, 47, 62
thrombophilia (DNA) (790, 791, 792) 29, 45, 46
Thromboplastin time (221) 102
Thrombopoietin (626) 108
thrombosis (730, 731, 740, 746) 37, 38, 46, 47
thrombosis (DNA) (790, 791, 792) 29, 45, 46
Thyreoglobulin (Special Thyroid) (301) 106
Thyreoglobulin (Tumor marker) (292) 149
Thyroglobulin (301) 106
Thyroid Gland Antibodies (295) 110
Thyroid Hormones (294, 301, 302) 106, 109, 110
thyroid-stimulating hormone (294) 110
Thyroxine (294, 302) 109, 110
Tiagabine (872) 129
TIBC (100) 115
Tick-Borne Encephalitis (serum) (358) 241
Tin (serum) (207) 147
Tobramycin (197) 138
Tocopherol (Vitamin E) (290) 159
Topiramate (872) 129
Torque Teno Virus (TTV) (plasma) (408) 228
Total Protein C (plasma) (225, 225) 95, 95
Total Tau Protein (Tau) (CSF) (466) 121
Toxin Gene (Bacterial genome) (545) 164
Toxin genes (microbiological samples) (545) 164
Toxoplasm gondii (EDTA whole blood) (457) 192
toxoplasmosis (457) 192
Toxoplasmosis (serum/plasma) (452) 195
TP53 (CDS) Mutation(s) (798) 57
TP53 (DNA ) (765) 61
TP53 Nomenclature (798) 57
TPA (292) 149
TPMT (775) 35
TPS (292) 149
TPT (221) 102
TPZ (plasma) (221, 285) 95, 102
TPZ (whole blood) (286) 102
TRAb (295) 110
Trace Elements (lyophilized whole blood) (208) 146
Trace Elements (plasma) (206) 147
Trace Elements (serum) (207) 147
Trace Elements (urine) (205) 153
Training Program (plasma) (368, 378, 379, 382) 203, 208, 210, 212
TRAK/THYBIA (295) 110
transcription factor (769) 60
Transferrine (plasma) (241) 143
Transferrine (serum) (100) 115
Transferrine (urine) (182) 158
Trazodone (876) 133
Treponema (547) 169
Treponema pallidum (antibody, serum) (311) 182
Trichomonas (547) 169
Tricyclic Antidepressants (serum) (199, 201, 202, 203) 139, 140, 140, 141
Tricyclic Antidepressants (urine) (204) 153
Triglycerides (100, 151) 115, 119
Triglycerides (POCT: Abaxis Piccolo) (810) 145
Triioddotyronine (294) 110
Trijodthyronin (294, 302) 109, 110
Trimipramine (serum) (201, 203, 863) 137, 140, 141
Trimipramine (urine) (204) 153
Trockenchemie (POCT) (800) 146
Trockenchemie (POCT: Abaxis Piccolo) (810) 145
Tropism Determination (plasma) (384) 214
Troponin I (760) 112
Troponin T (760) 112
Tryptophan (710) 113
TSH (dried blood spots) (785) 125
TSH (serum / plasma) (294) 110
TSH (serum) (302) 109
Tuberculosis (Slide) (421) 188
Tuberculosis (sputum) (422) 186
Tuberculosis (suspensions of mycobacterial strains) (423, 425, 426, 427) 186, 187, 187, 188
Tuberculosis bacteria (sputum) (424) 189
Tuberculosis bacteria, genome detection (sputum) (424) 189

## INDEX


| | |
|---|---|
| Tularemia (328, 543) | 165, 176 |
| Tumor Markers (292, 293, 299) | 149, 149, 150 |
| Tumor Panel (liquid biopsy) (752) | 35 |
| tumor suppressor (765) | 61 |
| Typing of adenovirus (cell culture lysate) (371) | 199 |
| Typing of Dengue Viruses (plasma) (369) | 204 |
| Typing of enterovirus (cell culture lysate) (372) | 205 |
| Typing of human rhinovirus (cell culture lysate) (393) | 217 |
| Typing of measles virus (cell culture lysate) (386) | 218 |
| Typing of mumps virus (cell culture lysate) (387) | 220 |
| Typing of parainfluenza virus (cell culture lysate) (388) | 222 |
| Typing of rotavirus (suspensions of feces) (401) | 226 |
| Typing of rubella virus (cell culture lysate) (389) | 226 |
| Typing of seasonal and avian influenza A viruses (cell culture lysate) (370) | 198 |
| Typing of West Nile virus (cell culture lysate) (391) | 229 |
| Typing of Zika virus (cell culture lysate) (403) | 229 |
| Tyrosine (710) | 113 |
| tyrosine kinase (767) | 58 |


## U


| | |
|---|---|
| UDP-glucuronyltransferase 1 (*28, *6) (DNA) (742) | 48 |
| UDP-glucuronyltransferase 1 (*28, *6) (whole blood) (726) | 48 |
| UDP-Glucuronyltransferase 1 (DNA ) (742) | 48 |
| UDP-GT1 (742) | 48 |
| UDPG1 (*28, *6) (DNA) (742) | 48 |
| UDPG1 (*28, *6) (whole blood) (726) | 48 |
| UF Heparin (280) | 104 |
| unfractionated heparin (280) | 104 |
| Unit-Use (800) | 146 |
| Urate (100, 810) | 115, 145 |
| Urea (POCT OPTI Systems) (163) | 145 |
| Urea (POCT) (161) | 144 |
| Urea (POCT: Abaxis Piccolo) (810) | 145 |
| Urea (serum) (100) | 115 |
| Urea (urine) (173) | 157 |
| Ureaplasma (547) | 169 |
| Uric Acid (POCT: Abaxis Piccolo) (810) | 145 |
| Uric Acid (serum) (100) | 115 |
| Uric Acid (urine) (173) | 157 |
| Urinary Stone (500) | 154 |
| Urinary Stone Analyses (500) | 154 |
| Urine Chemistry (171, 173, 175, 178, 182) | 155, 156, 156, 157, 158 |
| Urine Chemistry (pictures) (172) | 157 |
| Urine Chemistry (urine) (179) | 155 |
| Urine Chemistry 06 (urine) (180) | 154 |
| Urine Protein Differentiation (171) | 156 |
| Urine Sediment Pictures (pictures) (172) | 157 |
| Urobilinogen (171) | 156 |
| Urogenital Panel (Bacterial genome) (547) | 169 |
| Uroporphorin (178) | 156 |


## V


| | |
|---|---|
| Valine (710) | 113 |
| Valproic Acid (195) | 139 |
| Vanadium (207) | 147 |
| Vancomycin (197) | 138 |
| Vancomycin Resistant Enterococci (Bacterial genome) (546) | 170 |
| Vanillylmandelic acid (175) | 155 |
| Varicella Zoster Virus (cell culture lysate) (433) | 221 |
| Varicella Zoster Virus (plasma) (366) | 228 |
| Varicella Zoster Virus (serum) (353) | 241 |
| Varizella zoster specific quotient (CSF + serum) (463) | 123 |
| Varizella zoster virus IgG Antibody Index (CSF + serum) (463) | 123 |
| Vasculitis (serum) (257) | 69 |
| Vel system [VEL] (DNA) (235) | 26 |
| Venlafaxine (860, 861) | 136, 136 |
| Viable CD34+ events (whole blood) (217) | 92 |
| Viable CD45+ events (whole blood) (217) | 92 |
| Vibrio spp. (548) | 168 |
| Vigabatrin (872) | 129 |
| viral hemorrhagic fever (350, 355, 369, 392, 402) | 201, 204, 230, 231, 232 |
| Virilization (serum / plasma) (309) | 111 |
| virtual (172, 218, 906, 907) | 88, 157, 195, 196 |
| Virtual Parasite Microscopy (Blood) (pictures) (906) | 195 |
| Virtual Parasite Microscopy (Stool) (pictures) (907) | 196 |
| Virus Antigen Detection □ SARS-CoV-2 (Ag) (cell culture supernatants) (410) | 197 |
| Virus Detection (cell culture lysate) (370) | 198 |
| Virus Detection (Genome/Antigen) - Influenza Viruses (cell culture lysate) (370) | 198 |
| Virus Genome Detection - Adenoviruses (cell culture lysate) (371) | 199 |
| Virus Genome Detection - BK Virus (plasma / urine) (364) | 200 |
| Virus Genome Detection - Borna Viruses (cell culture lysate) (404) | 200 |
| Virus Genome Detection - Chikungunya Virus (plasma) (392) | 201 |
| Virus Genome Detection - Coronaviruses (cell culture lysate) (340) | 202 |
| Virus Genome Detection - Cytomegalovirus - additional Training Program (plasma) (368) | 203 |
| Virus Genome Detection - Cytomegalovirus Program 1 (plasma) (365) | 203 |
| Virus Genome Detection - Cytomegalovirus Susceptibility Determination (plasma) (349) | 204 |
| Virus Genome Detection - Dengue Viruses (plasma) (369) | 204 |
| Virus Genome Detection - Enteroviruses (cell culture lysate) (372) | 205 |
| Virus Genome Detection - Epstein Barr Virus (plasma) (376) | 205 |
| Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests (suspensions of feces) (430) | 206 |

## INDEX


Virus Genome Detection - Hepatitis A Virus (plasma) (377) 206
Virus Genome Detection - Hepatitis B Virus - additional Training Program (plasma) (378) 208
Virus Genome Detection - Hepatitis B Virus Genotyping (plasma) (396) 207
Virus Genome Detection - Hepatitis B Virus Program 1 (plasma) (361) 207
Virus Genome Detection - Hepatitis B Virus Susceptibility Determination (plasma) (397) 208
Virus Genome Detection - Hepatitis C Virus - additional Training Program (plasma) (379) 210
Virus Genome Detection - Hepatitis C Virus -Susceptibility Determination (plasma) (399) 210
Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping (plasma) (375) 209
Virus Genome Detection - Hepatitis C Virus Program 1 (plasma) (362) 209
Virus Genome Detection - Hepatitis D Virus (plasma) (400) 211
Virus Genome Detection - Hepatitis E Virus (plasma) (380) 211
Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2 (plasma) (363) 212
Virus Genome Detection - HIV-1 (RNA) - additional Training Program (plasma) (382) 212
Virus Genome Detection - HIV-1 (RNA) Program 1 (plasma) (360) 213
Virus Genome Detection - HIV-1 Drug Susceptibility Determination (plasma) (383) 213
Virus Genome Detection - HIV-2 (RNA) (plasma) (395) 214
Virus Genome Detection - Human Herpesvirus 6 (HHV-6) (cell culture lysate) (405) 215
Virus Genome Detection - Human Herpesvirus 8 (HHV-8) (cell culture lysate) (406) 215
Virus Genome Detection - Human Metapneumovirus (cell culture lysate) (385) 216
Virus Genome Detection - Human Papilloma Viruses (cell culture lysate) (373) 216
Virus Genome Detection - Human Rhinoviruses (cell culture lysate) (393) 217
Virus Genome Detection - JC Virus (plasma / urine) (394) 217
Virus Genome Detection - Measles Virus (cell culture lysate) (386) 218
Virus Genome Detection - Mumps Virus (cell culture lysate) (387) 220
Virus Genome Detection - Norovirus (suspensions of feces) (381) 220
Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests (cell culture lysate) (433) 221
Virus Genome Detection - Parainfluenza Viruses (cell culture lysate) (388) 222
Virus Genome Detection - Parechovirus (cell culture lysate) (407) 222
Virus Genome Detection - Parvovirus B19 (plasma) (367) 223
Virus Genome Detection - Rabies Virus (Tollwutvirus) (lyophilised) (390) 223
Virus Genome Detection - Respiratory Syncytial Virus (Antigen/Genome) (cell culture lysate) (359) 199
Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests (cell culture lysate) (431) 224
Virus Genome Detection - Respiratory Virus Panel 2 for Multiplex Tests (cell culture lysate) (432) 225
Virus Genome Detection - Rotaviruses (suspensions of feces) (401) 226
Virus Genome Detection - Rubella Virus (cell culture lysate) (389) 226
Virus Genome Detection - SARS-CoV-2 (cell culture lysate) (409) 227
Virus Genome Detection - Torque Teno Virus (TTV) (plasma) (408) 228
Virus Genome Detection - Varicella Zoster Virus (plasma) (366) 228
Virus Genome Detection - West Nile Virus (cell culture lysate) (391) 229
Virus Genome Detection - Zika Virus (cell culture lysate) (403) 229
Virus Immunology - Borna Viruses (Ab) (serum) (415) 230
Virus Immunology - Chikungunya Virus (Ab) (cell culture lysate) (402) 230
Virus Immunology - Cytomegalovirus (Ab) (serum) (351) 231
Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) (serum) (350) 231
Virus Immunology - Epstein Barr Virus (Ab) (serum) (352) 232
Virus Immunology - Hantaviruses (Ab) (serum) (355) 232
Virus Immunology - Hepatitis A Virus (Ab) (serum) (343) 233
Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc) (serum) (344) 233
Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM, HBeAg, Anti-HBe) (serum) (345) 234
Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) (serum) (346) 234
Virus Immunology - Hepatitis D Virus (Ab) (serum) (347) 235
Virus Immunology - Hepatitis E Virus (Ab) (serum) (348) 235
Virus Immunology - Herpes Simplex Viruses (Ab) (serum) (354) 236
Virus Immunology - HIV-1 p24 Antigen (serum) (337) 236
Virus Immunology - HIV-1/HIV-2 (Ab) (serum) (335) 237
Virus Immunology - HTLV-1/HTLV-2 (Ab) (serum) (339) 237
Virus Immunology - Measles Virus (Ab) (serum) (357) 238
Virus Immunology - Mumps Virus (Ab) (serum) (356) 238
Virus Immunology - Parvovirus B19 (Ab) (serum) (342) 239
Virus Immunology - Rabies Virus (Tollwutvirus) (Ab) (serum) (336) 239
Virus Immunology - Rubella Virus (Ab) (serum) (341) 240
Virus Immunology - SARS-CoV-2 (Ab) (serum) (416) 240
Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab) (serum) (358) 241
Virus Immunology - Varicella Zoster Virus (Ab) (serum) (353) 241
Virus Immunology - Zika Virus (Ab) (serum) (338) 242
Virusgenome-Detection SARS-CoV-2-VOC-Analysis (cell culture lysate) (417) 227
Vitamin C (171) 156
Vitamin C (plasma) (296) 159

## INDEX


| | |
|---|---|
| Vitamins (lyophilized whole blood) (291) | 160 |
| Vitamins (plasma) (187, 296) | 158, 159 |
| Vitamins (serum) (290) | 159 |
| VKORC1 (775) | 35 |
| VLDL-cholesterol (POCT: Abaxis Piccolo) (810) | 145 |
| VOC-Analysis (cell culture lysate) (417) | 227 |
| von Willebrand factor (DNA ) (678) | 54 |
| von Willebrand syndrome (DNA ) (678) | 54 |
| Voriconazole (198) | 130 |
| VRE (Bacterial genome) (546) | 170 |
| VWF (DNA ) (678) | 54 |
| vWS (678) | 54 |
| VZV (366, 433, 463) | 123, 221, 228 |
| West Nile Virus (cell culture lysate) (391) | 229 |
| white blood cell (WBC) morphology (212) | 87 |
| white blood cells (WBC) (171, 209, 211, 213, 217, 612, 617) | 86, 87, 88, 90, 92, 93, 156 |
| Whooping cough (317, 532) | 161, 171 |
| Willebrand Factor (227) | 99 |
| WNV (391) | 229 |
| Yeasts (living cultures) (490, 491) | 190, 191 |
| Yersinia (antibody, serum) (315) | 183 |
| Yersinia enterocolitica (548) | 168 |
| Yersiniosis (315) | 183 |
| Yt system [YT] (DNA) (235) | 26 |
| Zika fever (338) | 242 |
| Zika Virus (cell culture lysate) (403) | 229 |
| Zika Virus (serum) (338) | 242 |
| Zinc (lyophilized whole blood) (208) | 146 |
| Zinc (plasma) (206) | 147 |
| Zinc (urine) (205) | 153 |
| Ziprasidone (862, 873) | 131, 137 |
| Zonisamide (872) | 129 |
| Zoonosis (325, 331, 338, 339, 340, 355, 385, 404, 535, 537, 538, 539, 542, 543) | 161, 164, 165, 167, 167, 169, 175, 180, 200, 202, 216, 232, 237, 242 |

www.instand-international.com

**INSTAND International GMBH** is distributing EQA Schemes globally as a subsidiary of INSTAND e.V. and is based in Germany.

**INSTAND e.V.** is an interdisciplinary, non-profit, scientific-medical professional association. It operates as a reference institution according to the Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations – Rili-BÄK. INSTAND is based in Germany and has more than 300 members worldwide. INSTAND is a member of numerous national and international professional societies and standardization committees, including DIN, CEN, and ISO. INSTAND's excellent global scientific network is a valuable tool to draw upon for research projects for quality assurance. INSTAND is accredited according to DIN EN ISO/IEC 17043.

INSTAND

**INSTAND International GMBH**
**Address:** Ubierstr. 20, 40223 Duesseldorf, Germany
**Telephone:** +49 211 876 3529 0
**E-mail:** info@instand-international.com

RIDACOM

**RIDACOM Ltd.**
**Address:** 1 Koloman Str., 1618, Sofia, Bulgaria
**Telephone:** +359 2/ 955 99 98
**E-mail:** instand@ridacom.com